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Abstract
The AMBER care bundle for hospital inpatients with
uncertain recovery nearing the end of life: the ImproveCare
feasibility cluster RCT
Jonathan Koffman,1* Emel Yorganci,1 Fliss Murtagh,2 Deokhee Yi,1
Wei Gao,1 Stephen Barclay,3 Andrew Pickles,4 Irene Higginson,1
Halle Johnson,1 Rebecca Wilson,1 Sylvia Bailey,5 Colleen Ewart5
and Catherine Evans1,6
1Cicely Saunders Institute, King’s College London, London, UK
2Wolfson Palliative Care Research Centre, University of Hull, Hull, UK
3Primary Care Unit, Department of Public Health and Primary Care, University of Cambridge,
Cambridge, UK
4Clinical Trials Unit, King’s College London, London, UK
5Patient and public representative
6Sussex Community NHS Foundation Trust, Brighton, UK
*Corresponding author jonathan.koffman@kcl.ac.uk
Background: Patients admitted to hospital with a terminal illness and uncertain recovery often receive
inconsistent care and do not have the opportunity to die in their preferred place of death. Previous
end-of-life care packages, such as the Liverpool Care Pathway for the Dying Patient, have sometimes
been badly implemented. The AMBER (Assessment; Management; Best practice; Engagement; Recovery
uncertain) care bundle was developed to remedy this. It has not been evaluated in a randomised trial,
but a definitive trial would face many hurdles.
Objective: To optimise the design of and determine the feasibility of a pragmatic, multicentre, cluster
randomised controlled trial of the AMBER care bundle compared with best standard care.
Design: A feasibility cluster randomised controlled trial including semistructured interviews with patients
and relatives, focus groups with health-care professionals, non-participant observations of multidisciplinary
team meetings, a standard care survey, heat maps and case note reviews. Retrospective data were collected
from the family or close friends of deceased patients via a bereavement survey.
Setting: Four general medical wards at district general hospitals in England.
Participants: There were 65 participants (control, n = 36; intervention, n = 29). There were 24 interviews,
four focus groups, 15 non-participant meeting observations, six case note reviews and three heat maps,
and 15 of out 23 bereavement, standard care surveys were completed.
Intervention: The AMBER care bundle is implemented by a nurse facilitator. It includes the development
and documentation of a medical plan, consideration of outcomes, resuscitation and escalation status and
daily plan revisiting. The AMBER care bundle encourages staff, patients and families to talk openly about
their preferences and priorities should the worst happen.
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Main outcome measures: Two ‘candidate’ primary outcomes were selected to be evaluated for a future
definitive trial: Integrated Palliative care Outcome Scale patient/family anxiety and communication subscale
and ‘howRwe’. The secondary outcome measures were Integrated Palliative care Outcome Scale symptoms,
Australian-modified Karnofsky Performance Status scale, EuroQol-5 Dimensions, five-level version, Client
Service Receipt Inventory, recruitment rate, intervention fidelity and intervention acceptability.
Results: Data were collected for 65 patients. This trial was not powered to measure clinical effectiveness,
but variance and changes observed in the Integrated Palliative care Outcome Scale subscale indicated
that this measure would probably detect differences within a definitive trial. It was feasible to collect
data on health, social and informal care service use and on quality of life at two time points. The AMBER
care bundle was broadly acceptable to all stakeholders and was delivered as planned. The emphasis on
‘clinical uncertainty’ prompted health-care professional awareness of often-overlooked patients. Reviewing
patients’ AMBER care bundle status was integrated into routine practice. Refinements included simplifying
the inclusion criteria and improving health-care professional communication training. Improvements to
trial procedures included extending the time devoted to recruitment and simplifying consent procedures.
There was also a recommendation to reduce data collected from patients and relatives to minimise burden.
Limitations: The recruitment rate was lower than anticipated. The inclusion criteria for the trial were difficult
to interpret. Information sheets and consent procedures were too detailed and lengthy for the target
population. Health-care professionals’ enthusiasm and specialty were not considered while picking trial wards.
Participant recruitment took place later during hospital admission and the majority of participants were lost to
follow-up because they had been discharged. Those who participated may have different characteristics from
those who did not.
Conclusions: This feasibility trial has demonstrated that an evaluation of the AMBER care bundle
among an acutely unwell patient population, although technically possible, is not practical or feasible.
The intervention requires optimisation.
Trial registration: Current Controlled Trials ISRCTN36040085. National Institute for Health Research
(NIHR) Portfolio registration number 32682.
Funding: This project was funded by the NIHR Health Technology Assessment programme and will be
published in full in Health Technology Assessment; Vol. 23, No. 55. See the NIHR Journals Library website
for further project information.
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Plain English summary
Unwell hospital patients who are approaching the end of their lives and may die at any moment receiveinconsistent care and often do not have opportunities to discuss their future care preferences. The AMBER
(Assessment; Management; Best practice; Engagement; Recovery uncertain) care bundle was developed to
help identify such patients, train health-care professionals to better communicate their concerns with them
and their families and, where possible, to realise their preferences for place of care and death. The Liverpool
Care Pathway for the Dying Patient, previously used across England, was designed to provide the best possible
quality of care to those at the end of life. However, an independent review identified that it often was not
used appropriately, leading to poor patient outcomes.
A number of the criticisms of the Liverpool Care Pathway for the Dying Patient, such as reports of quickened
deaths from the withdrawal of hydration/nutrition, as well as poor communication with patients and families,
may have been identified earlier if it had been thoroughly evaluated.
The AMBER care bundle, developed at Guy’s and St Thomas’ Hospital, aims to provide better outcomes for
patients with clinically uncertain recovery and their families. It is important that the AMBER care bundle is
properly investigated before wider use. A bigger study of the AMBER care bundle would be complex and
expensive, so we examined whether or not this would be possible and acceptable to patients cared for
in four wards across four hospitals, before deciding whether or not to go ahead with this bigger study.
Two wards used the care bundle and two did not. We interviewed participants, their families and staff,
and examined participants’ clinical notes.
We found that the AMBER care bundle was largely acceptable to patients, relatives and staff, and generally
delivered as intended. We successfully collected information from 65 unwell patients at the beginning of
the trial and again 3–5 and 10–15 days later. However, a limited number of data were collected at the final
time point (10–15 days) due to many participants being discharged from the hospital. Group discussions
with staff and interviews with participants and relatives identified important changes required to improve
the AMBER care bundle and views on how the trial was conducted. These included simplifying the type of
patients who may be appropriate for the AMBER care bundle and improving communication training for
staff. Although we identified that a further study was technically possible, it is currently impractical. Future
solutions that would require further testing include focusing on clinical need rather than trying to guess
how the patient’s condition will develop to identify potential trial participants and using questions
completed by the patients as part of their routine care as a source of information. In the meantime,
the AMBER care bundle continues to be used in over 40 hospitals in England.
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Scientific summary
Background
Each year, of 500,000 people who die in the UK, more than half of their deaths occur in hospital, despite
an indication that most patients and their families prefer to die at home. Major reasons for dying in
hospital is poor communication about declining health between patients and health-care professionals,
and poor identification and management of patients whose situations are ‘clinically uncertain’.
Clinical uncertainty is a complex concept. Situations of clinical uncertainty usually result from several
inter-related factors. If uncertainty is not explicitly addressed, patient outcomes are worse. Their outcomes
are influenced by the lack of discussions about their situation and preferences for care and death. Clinical
uncertainty also has an impact on clinicians’ confidence and their practice. Clinicians frequently struggle
with uncertainty and feel inadequately trained to deal with these situations, which can result in
overtreatment or overinvestigation.
Increased attention has been given to poor hospital care and inadequate communication, particularly among
the elderly and dying. The Liverpool Care Pathway for the Dying Patient, which was designed to provide those
at the end of life with the best possible quality of care, sparked criticism after an independent review identified
that it often was not implemented appropriately, leading to poor patient outcomes. Such reports highlight
the devastating effect that poor communication and lack of honesty can have on patients and their families
towards the end of life. However, when clinical uncertainty is acknowledged and managed alongside
high-quality care, collaborative decision-making is possible. This empowers patients and carers, and in turn
leads to improved outcomes and increased satisfaction with care. The AMBER (Assessment; Management;
Best practice; Engagement; Recovery uncertain) care bundle has been developed as a potential solution to
caring and supporting patients and their relatives in this situation.
The AMBER care bundle aims to make clinical decision-making explicit in situations of uncertainty by
encouraging the clinical team (1) to develop and document, within 12 hours, a clear medical plan in
conjunction with the patient and relatives, (2) to consider anticipated outcomes and (3) to consider
resuscitation and escalation status.
Aims and objectives
Aim
To determine the feasibility of a pragmatic, multicentre, cluster randomised controlled trial to optimise the
design of the intervention, and to define the outcomes, for a definitive trial of the AMBER care bundle
versus usual care.
Objectives
1. To examine recruitment, retention and follow-up rates at both patient and cluster levels.
2. To test trial data collection measures and determine their optimum timing in a larger trial.
3. To assess the degree of contamination at a ward level due to ‘between-ward’ staff and
patient movements.
4. To provide a preliminary estimate of the effectiveness of the AMBER care bundle compared with
standard care to inform sample size calculation for the full trial.
5. To estimate the intracluster correlation coefficient and likely cluster size.
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6. To examine differences in the use of financial resources between the AMBER care bundle and
standard care.
7. To examine the extent to which the AMBER care bundle requires further refinement or adaptation
(e.g. referral criteria to identify which patients would benefit most) to suit local conditions.
8. To assess the acceptability of the AMBER care bundle to patients, their families and health-care
professionals.
9. To determine the ‘active ingredients’ of the AMBER care bundle that need to be maintained to ensure
fidelity of the intervention for a full trial.
10. To assess compliance with and barriers to the delivery of the AMBER care bundle.
Research design
This was a mixed-methods feasibility cluster randomised controlled trial across four district general
hospitals in England.
Trial setting and participants
The trial took place in one or two medical wards at each of the four district general hospitals. Trial wards were
chosen based on those with the highest numbers of deaths per year, which were derived from heat maps.
The participants included patients or their relatives, when patients met the following criteria: they were
located on one of the intervention or control wards, were aged ≥ 18 years, were deteriorating, were in a
clinically uncertain situation with limited reversibility, were at risk of dying during their current episode of
care despite treatment and were able to provide written informed consent or assent through a personal
consultee. Potential participants were identified by research nurses, in conjunction with health-care
professionals.
Outcome measures and data collection
Two candidate primary outcome measures were tested during the trial: (1) the Integrated Palliative care
Outcome Scale ‘Patient/family anxiety and communication subscale’, which includes items about receipt
of information, practical matters, sharing feelings with family, being at peace, and patients’ and families’
levels of anxiety and depression, and (2) the ‘howRwe’, a patient self-reported experience measure, which
captures changes in patients’ perceptions of their experience of care.
Research nurses conducted face-to-face interviews on each ward with patients, or their relatives, to collect
baseline data including demographic and clinical circumstances. At this time point, the Patient/family anxiety
and communication subscale of the Integrated Palliative care Outcome Scale and the howRwe were measured.
These two measures were reassessed at time point 1 (days 3–5) and time point 2 (days 10–15). In addition,
the Client Service Receipt Inventory was used to collect information on resource utilisation, measuring the
use of health, social and informal care 3 months prior to the hospital admission at baseline and during the
inpatient stay in hospital at 10–15 days. The EuroQol-5 Dimensions, five-level version, was used to measure
health-related quality of life at all time points.
Furthermore, we made use of a modified QUALYCARE postal survey to collect data on the experience and
satisfaction of care, and the quality of information/communication from the perspective of family or close
friends of deceased patients who were cared for on the trial wards at a minimum of 10–12 weeks after
their death.
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We also developed a tool to characterise best standard care across all of the trial sites. This was measured at
baseline, mid patient recruitment and at the end of patient recruitment. Data were collected from different
health-care professionals to obtain a broader understanding of this type of care. Survey questions addressed
care planning, recognising dying, referrals and discharge procedures.
Case note reviews were conducted based on a purposive selection of 20 participants on each ward. These
reviews provided information on the care provided to this participant group prior to implementation of the
AMBER care bundle.
Qualitative components and data collection
The qualitative components included interviews with patients and relatives, non-participant observations of
multidisciplinary team meetings and focus groups with health-care professionals.
Interviews with patients and relatives
Before approaching the patient, research nurses discussed potential participants with the clinical team to
determine if they were appropriate to interview. If suitable, the research nurse then asked if they would be
willing to be interviewed by the trained researcher. Relatives were approached while they were visiting the
patients. The interview topic guides aimed to explore patients’ and relatives’ insights into care, the quality
of communication and information provided and their perception of involvement in critical decisions
regarding care and treatment while in the hospital.
Non-participant observation of the multidisciplinary team meetings
The researcher obtained written informed consent from health-care professionals who had their views and
behaviours observed and recorded in field notes during meetings. For all wards, we recorded who was present
at the meetings, the frequency of the meetings, the length of meetings and the type of conversations relating
to patients identified as fulfilling the inclusion criteria (or identified as AMBER). We also took note of which
professions contributed to conversations, what specific actions were discussed that related to their care and
how decision-making processes developed, including the management of end-of-life issues.
Focus groups with health-care professionals
A focus group was conducted at each of the trial sites. A range of health-care professionals were involved
and provided written consent prior to the focus group. During the focus groups, health-care professionals
shared their experiences of caring for patients with clinically uncertain recovery, and their families, teamwork,
emotional support, communication, trial procedures and outcomes. At the intervention sites, health-care
professionals also shared their views on the AMBER care bundle and made suggestions for its improvement.
Results
Feasibility of trial procedures
We recruited 65 participants, many of whom were elderly, with multiple morbidities. Out of 220 eligible
participants, only 19 (8.6%) declined to participate in the trial, supporting the feasibility of trial recruitment.
We had planned for recruitment to take 3 months at each trial site, but the screening to recruitment rate
and time needed to inform and consent potential participants highlighted that this time frame was not
adequate. We also identified that the majority of participants lacked adequate mental capacity to provide
informed consent, necessitating a proxy to participate.
In addition, the recruitment of potential patients in the control arm proved to be highly challenging.
Health-care professionals had particular difficulty interpreting the ‘patients who are at risk of dying during
their episode of care despite treatment’ eligibility criterion. Simplification of the eligibility criteria and
an objective pre-screening criterion may aid the screening and recruitment of potential participants.
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The trial had a high attrition rate, largely due to discharge from hospital, which made collecting data at
10–15 days after baseline unfeasible. The number of patients discharged made data collection at time
point 2 unfeasible. Based on our findings, capturing potential participants at an earlier stage of their
hospital admission is recommended for a future trial.
Refinements and adaptations of the AMBER care bundle
Our qualitative findings highlighted important refinements needed to the AMBER care bundle before being
tested in a definitive trial. First, the AMBER care bundle inclusion criteria, particularly the criterion ‘risk of
dying during patients’ episode of care despite treatment’ is challenging to interpret, leading to issues when
identifying eligible patients. This criterion relies on prognostic skills that many health-care professionals
believed they did not possess. Health-care professionals noted that more emphasis should therefore be placed
on other criteria when identifying patients. Based on these findings, the eligibility criteria should be simplified,
with the focus on the ‘clinical uncertainty’ of the patient, rather than prognostication. Second, issues around
communication were identified from patients’, relatives’ and health-care professionals’ perspectives. The
health-care professional focus groups highlighted discrepancies in the communication skills and confidence
among different professional groups. Patients and relatives also often mentioned in the interviews that the
main sources of information regarding patients’ conditions and progress were doctors, rather than nurses
who were more accessible. Based on these findings, it is suggested that the communication skills training
that complements that of the AMBER care bundle could be provided to serve different proficiency levels and
improve confidence across all health-care professionals. Moreover, training must be replenished at regular
intervals.
The acceptability and fidelity of the AMBER care bundle
The acceptability of the AMBER care bundle was explored by analysing data from the qualitative components
with health-care professionals and, in some instances, patients and relatives. Broadly, the AMBER care bundle
was accepted by those involved. All stakeholders welcomed the early discussions that emphasised decision-
making around patient and family preferences. At the intervention sites, observations of multidisciplinary
team working and collaborative decision-making regarding the AMBER care bundle suggested further
acceptance of the intervention from health-care professionals. Documenting conversations and decisions
in medical charts, required as part of the AMBER care bundle, was not seen as a burden by health-care
professionals. Health-care professionals also commented on the simplicity of documentation, which provided
a systematic process aligning all those involved in the care of the patient. Although the intervention was
acceptable while they received support from the nurse facilitator, health-care professionals questioned the
acceptability of the AMBER care bundle without dedicated continued support. Critical decisions would need
to be made by health-care professionals to ensure that a dedicated ‘AMBER care bundle champion’ was
available, thus ensuring sustainability of the intervention.
Fidelity of the intervention delivery was assessed via a review of participants’ clinical notes. Compliance
with the AMBER care bundle components was high; however, there were instances when the AMBER care
bundle components were not recorded within the required 12-hour time frame.
Active ingredients
Despite not being able to test the clinical effectiveness of the AMBER care bundle statistically, through
qualitative components, we identified a number of ‘active ingredients’ that should remain in place when
the AMBER care bundle is evaluated in a definitive trial. First, the inclusion criterion ‘recovery is clinically
uncertain’ prompted health-care professionals’ awareness of a patient population, which previously received
less attention, in both trial arms. In addition, the daily review of patients’ ‘AMBER care bundle status’ became
routinised into the clinical practice on intervention wards. Second, the concise documentation associated with
the AMBER care bundle provided a system of conveying important information to ward staff, particularly those
working out of hours. Finally, the role of the nurse facilitator was key to the successful intervention delivery.
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Candidate primary outcome measures
The trial was not powered to detect the clinical effectiveness of the AMBER care bundle. Based on data
available from our candidate outcome measures, we cannot draw conclusions about differences between
the two arms of the trial.
We selected two candidate primary outcomes to be evaluated for a definitive trial. The Integrated Palliative
care Outcome Scale subscale, although not powered to detect differences, showed variance and change
over time, which implied that it would be able to capture a range of scores in a definitive trial. Trends in
this measure indicated that patients experienced moderate levels of anxiety and worry, as expected with
this population. Perceived levels of anxiety and worry for family members were consistently higher during
the hospital stay for both trial arms. The completeness of the data and the acceptability of the howRwe
measure were also good. However, this measure was reported only by patients, which reduces the utility
of the tool. Further exploration is needed to determine whether or not proxy data collection is feasible for
this measure. Notably, for both measures the levels of missing data were relatively small, indicating that
outcomes can be successfully collected from this population.
Health economics and cost-effectiveness
It was feasible to collect the data on health and social care service use, informal care provision and quality
of life at baseline and at 10–15 days. Missing data were not problematic (< 9.0% of data were missing).
Implementation costs are only part of the real intervention costs because changes in time and efforts
from health-care professionals could not be accurately captured. A diary recorded by the nurse facilitator
successfully tracked the resource use in intervention sites. A predetermined format of the diary could be
developed with the prior information on the participating sites in a future trial.
Conclusion
This feasibility trial has demonstrated that an evaluation of the AMBER care bundle, among an acutely
unwell patient population, although technically possible, is not practical. Considerable changes would be
required to evaluate this complex intervention in a pragmatic trial. Specifically, the manner in which the
trial is explained to potential participants, the consent process, the eligibility criteria for the AMBER care
bundle (which, for the purposes of this feasibility trial, informed the inclusion criteria) and the timing of
data collection should be reconsidered. Alternative strategies to undertake a robust evaluation of the
AMBER care bundle are therefore required, including incorporation of a patient-centred outcome measure
(e.g. the Integrated Palliative care Outcome Scale) into routine clinical practice or making use of other
routinely collected hospital data that could identify the potential benefits of the intervention. However,
they too would require feasibility testing to ensure the ‘de-risking’ of a definitive trial. We were unable to
provide a preliminary estimate of the clinical effectiveness or cost-effectiveness of the AMBER care bundle
or to determine the optimum cluster sizes. However, we identified active ingredients crucial to the success
of the AMBER care bundle. We also suggest amendments to the intervention based on these findings.
Trial registration
This trial is registered as ISRCTN36040085. National Institute for Health Research (NIHR) Portfolio
registration number 32682.
Funding
Funding for this study was provided by the Health Technology Assessment programme of NIHR.
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Chapter 1 The management of clinical uncertainty
in hospital settings
Parts of this report have been reproduced/adapted from Koffman et al.1 The Authors 2019. This articleis distributed under the terms of the Creative Commons Attribution 4.0 International License
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction
in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made. The Creative Commons Public
Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made
available in this article, unless otherwise stated.
Summary of the Health Technology Assessment brief
In 2015, the National Institute for Health Research (NIHR) Health Technology Assessment programme
published a commissioning brief with a focus on clinical and applied health research into end-of-life care.
Interventions for patients in the last 30 days of life were of particular interest. Applicants were asked to
consider (1) the use of technologies or interventions that enable and support informed decision-making
and choice during the process of end-of-life care, (2) the use of technologies or interventions that enable and
support a patient’s ability to die at home if they wish and (3) interventions to support patients, carers and
health-care professionals (HCPs) to enable the development of knowledge, skills and confidence in care
delivery. This report contains the research conducted in response to this brief (URL: www.journalslibrary.nihr.
ac.uk/programmes/hta/151017/#/; accessed 8 February 2019).
Summary of current evidence and policy context
Background rationale
The magnitude of dying in hospital settings
Every year, more than 500,000 people die in the UK,2 and this number is rising.3 Of these deaths, more
than half occur in hospital.4 However, 69.2% (range 51–84%) of patients and their families would prefer
to die at home.5 Most deaths are anticipated, with up to 75% of all deaths expected, so there is time
for discharge to home or more familiar and preferred surroundings. Major reasons for hospital death are
poor communication about declining health between patients and HCPs6 and poor identification and
management of patients whose situations are ‘clinically uncertain’.7
Clinical uncertainty in hospital settings
Clinical uncertainty is not a simple concept and a situation of uncertainty usually results from several
inter-related factors. Mishel8 was one of the first to develop an overarching theory of uncertainty in an
illness, and aimed to explain the underlying processes governing patients’ experiences of uncertainty.
Specifically, four concepts contribute to an uncertain state: complexity, unpredictability, ambiguity and
lack of information.8–10 McCormick11 further developed these ideas and described situations of uncertainty
in terms of the probability of events occurring, the temporality of events and individuals’ perceptions of
their situation.
If clinical uncertainty is not explicitly addressed, there are worse psychological outcomes for patients.12,13
Evidence suggests that, in the last 30 days of life, the combination of deteriorating health and clinical
uncertainty are highly distressing for patients in a hospital and their families.14,15 This distress is amplified
when discussions about their situation and preferences for care and location of death are absent; 67–80%
of people want to be informed about poor prognosis.16 However, research shows that discussions about
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prognosis rarely occur,17 increasing the likelihood of hospital deaths, but also leading to poor satisfaction,
mistrust and loss of confidence in HCPs.18–21 Indeed, complaints about care at the end of life in hospital
settings are frequent.22
Clinical uncertainty also affects clinicians’ confidence and their practice. Clinicians frequently struggle
with uncertainty, which can result in overtreatment or overinvestigation,23 increased costs13 and lack of
communication with patients about their future.24,25 Furthermore, clinicians often feel inappropriately
trained to deal with uncertainty; only 4 out of 21 UK postgraduate medical training curricula contain
detailed recommendations and curriculum goals relevant to dealing with uncertainty. However, when
situations of uncertainty are acknowledged and managed alongside high-quality care, particularly at the
end of life, collaborative decision-making is possible.26 This empowers patients and their carers,27–29 and in
turn leads to improved outcomes and increased satisfaction with care.30,31
The potential for better care
Poor hospital care and inadequate communication, which include patient safety and adverse events, have
received increasing attention, particularly regarding the frail elderly and the dying. The Francis Report,32
the independent review of the Liverpool Care Pathway for the Dying Patient33 and the Parliamentary and
Health Services Ombudsman’s report34 into complaints about end-of-life care all highlight the devastating
effect poor communication and lack of honesty can have on patients and their families towards the end
of life. Research has also demonstrated that the costs of patient care in the last year of life are high.35
Yet when specialist palliative care services are available in hospital and community settings, health service
costs can be reduced and patient- and family-centred outcomes improved.36–38
In 2010, a London hospital identified inconsistencies in the quality of care for patients whose situations
were clinically uncertain, for those who were deteriorating and especially for those at the end of life.34
Issues included inadequate decision-making and poor engagement with patients and carers. A potential
solution to caring and supporting patients and their relatives in this situation, developed under the umbrella
of a bundle (Box 1 explains the concept of a ‘care bundle’), is referred to as the ‘AMBER care bundle’,
where AMBER stands for Assessment; Management; Best practice; Engagement; Recovery uncertain.
The AMBER care bundle follows an algorithmic approach to encourage clinical teams to develop and
document a clear medical plan, considering anticipated outcomes and resuscitation and escalation status,
and to revisit the plan daily. The AMBER care bundle encourages staff, patients, and families to continue
with treatment in the hope of a recovery, while talking openly about preferences and priorities should the
worst happen. The bundle is modelled on previous empirical work that includes a literature review and
examination of clinical records to determine need.34 However, this bundle was developed to address an
identified gap in clinical practice, hence it does not have theoretical underpinnings. Once staff have
identified patients who are deteriorating, whose situations are clinically uncertain, with limited reversibility
BOX 1 Explanation of care bundles
The US Institute for Healthcare Improvement describes care bundles as a set of evidence-based interventions
for patients that when implemented in combination are aimed at resulting in outcomes that are superior to
when delivered alone.39 They typically consist of a small number of interventions (normally 4–5), which, when
implemented together, are associated with improvements in clinical outcomes.40 The concept of the care
bundle approach was originally developed in the USA in intensive care units to achieve the highest levels of
reliability in critical care processes that would result in improved outcomes, while at the same time introducing
concepts of enhanced teamwork and communication. Since that time, the development and use of care
bundles within health care have continued to rapidly evolve both inside and outside the critical care setting.
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and who are at risk of dying during their current episode of care despite treatment, the multidisciplinary
team (MDT) is expected to complete the four tasks within the care bundle. This involves asking:
1. Has a medical plan been documented in the patient records that includes current key issues, anticipated
outcomes and their resuscitation status?
2. Has an escalation/de-escalation decision been documented (ward only, high dependency, intensive care)?
3. Has the medical plan been discussed and agreed with nursing staff?
4. Has a patient/carer discussion, or meeting, been held and clearly documented?
With this information, HCPs consider whether or not the patient is still suitable for the intervention, if there
had been any medical changes, and if they need to speak with the patient and their relatives daily.
The patient/carer discussion of the AMBER care bundle includes:
l talking to the patient and family to let them know that the clinical team has concerns about their
condition, and to establish their preferences and wishes
l deciding together how the patient will be cared for should their condition change (i.e. worsen).
The intended benefits of the AMBER care bundle include:
l increased and improved communication
l enabling/supporting informed and shared decision-making and choice during end-of-life care
l improved patient-/family-centred quality of life by reducing anxiety
l enabling home death if preferred
l supporting HCPs to develop knowledge, skills and confidence in end-of-life care delivery
l reducing unnecessary hospital admissions while improving cost-effectiveness (reducing length of
hospital stays) and making more efficient use of health services.
The AMBER care bundle is a complex intervention in that it:
l Comprises multiple components and layers (identification, current and future care planning including
escalation and de-escalation decisions, communication delivery, assessment of patient preferences and
systematic follow-up, acknowledging dynamic wishes and physical conditions).
l Aims to change behaviours of health-/social-care professionals delivering the intervention by enhancing
recognition of clinical uncertainty in clinical outcomes, patients in the last months of life and
management of care expectations.
l Focuses on staff in primary, hospital and voluntary care, thus including different groups and
organisational levels.
l Includes several complex intended outcomes, including changes in patient involvement in decision-
making around situations of clinical uncertainty. The AMBER care bundle is tailored to the individual
patient’s and their family’s need and circumstances.
Why research was needed
The AMBER care bundle was identified by NHS England as one of five key enablers of Transforming End of
Life Care in Acute Hospitals,41,42 and it is currently being used across a network of approximately 40 hospitals
including district general hospitals (DGHs). A further rollout is planned; however, recommendation 7 from
the Liverpool Care Pathway for the Dying Patient has suggested that training programmes focused on clinical
uncertainty and communication with patients and their relatives must be examined.33 It was therefore
imperative that a clinical trial of the AMBER care bundle took place to accurately quantify patient, clinician
and health systems benefits, and that any harms are understood and managed.43
Now more than ever, with ageing populations and increasing numbers of people dying from cancer and
non-malignant conditions,44 health-care systems should provide every patient and their family a dignified
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death.45 Facing deteriorating health and uncertain recovery is distressing for patients who may be dying
and their families. This is particularly due to the frequent, possibly unnecessary, hospital admissions during
the last year of life:46 in England, patients currently spend an average of 29.7 days of their final 12 months
in hospital.35 This is costly for health services and for society. These concerns are endorsed by the NHS
Outcomes Framework,47 which includes two outcomes to improve care for people at the end of life:
(1) the proportion of patients who die in their preferred place of death (PPD) and (2) bereaved relatives’
experiences of care. Interventional research, including an evaluation of the AMBER care bundle, aimed to
understand how these outcomes can be addressed with this intervention.
How the existing literature supports this study
A small but growing body of evidence sheds light on processes and outcomes associated with the AMBER
care bundle. When it was introduced at a major London hospital, inpatient deaths declined (from an
average of 93 to 81 per month).34 A recent single-centre study7 identified that rather than being used as a
tool to identify patients with an uncertain recovery, the AMBER care bundle was principally used when it
became certain that patients would not recover. However, as this was a cross-sectional, observational trial,
we were not able to observe changes over time.
We conducted the first comparative observational mixed-methods study of the AMBER care bundle and
identified a mixed picture.48 First, the AMBER care bundle was associated with increased frequency of
discussions about prognosis between clinicians and patients, and higher awareness of their prognosis by
patients. Second, we observed that those patients who died in locations other than hospitals had shorter
lengths of stay than those who received usual care. The mean length of hospital stay for the patients
supported by the bundle was 20.3 days (range 1–87 days), compared with 29.3 days (range 6–70 days) in
the comparison wards. The mean length of hospital stay for all patients who were discharged and died in
a place other than hospital also differed: the mean length of stay for those supported by the AMBER care
bundle was 17.6 days (range 1–87 days), compared with 21.4 days (range 6–70 days) in the comparison
wards. However, we identified that although the instances of communication were greater, they had lower
clarity in relation to the quality of information transmitted about a patient’s condition. Moreover, relatives
of patients supported by the AMBER care bundle described more unresolved concerns about caring for
them at home. Although this study was informative in evaluating the AMBER care bundle, this was a
quasi-experimental study. Non-random selection of comparison sites may have caused bias.
Qualitative data from the same study identified that the intervention was often used as a tool to label or
categorise patients, and indirectly served a symbolic purpose in affecting behaviours of individuals and
teams. Participants described the importance of training and education alongside the implementation of
the intervention. However, adequate exposure to the intervention was essential in order to witness its
potential added value or to embed it into practice. This was considered to be very variable.49
Although the evidence suggests some potential benefits of the care for those supported by the AMBER
care bundle, it also identifies downsides, specifically regarding information and communication. Therefore,
clinical equipoise in relation to the intervention still exists. These findings pointed to a need for a robust
comparative evaluation of the AMBER care bundle compared with standard care. The first step in this
direction is to conduct feasibility work to optimise the intervention and to understand the most-appropriate
methods to examine its potential benefits.
Feasibility trial aim and objectives
Trial aim
The aim of this exploratory, multicentre, cluster randomised controlled trial (RCT) was to optimise the
design of the AMBER care bundle, and to define the outcomes, for a fully powered definitive trial of the
AMBER care bundle versus standard care.
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Trial objectives
1. To examine recruitment, retention and follow-up rates at both patient and cluster levels.
2. To test trial data collection measures and determine their optimum timing in a larger trial.
3. To assess the degree of contamination at a ward level due to ‘between-ward’ staff and
patient movements.
4. To provide a preliminary estimate of the clinical effectiveness of the AMBER care bundle compared
with standard care to inform sample size calculation for the full trial.
5. To estimate the intracluster correlation coefficient and likely cluster size.
6. To examine differences in the use of financial resources between the AMBER care bundle and
standard care.
7. To examine the extent to which the AMBER care bundle requires further refinement or adaptation
(e.g. referral criteria to identify which patients would benefit most) to suit local conditions.
8. To assess the acceptability of the AMBER care bundle to patients, their families and HCPs.
9. To determine the ‘active ingredients’ of the AMBER care bundle that need to be maintained to ensure
fidelity of the intervention for a full trial.
10. To assess compliance with and barriers to the delivery of the AMBER care bundle.
Objectives 1 and 6–10 pertain at both individual and cluster levels. Objectives 2 and 4 pertain at the
individual level. Objectives 3 and 5 pertain at the cluster level. While assessing acceptability of AMBER,
we explored potential benefits and intended harms.
Patient and public involvement
We have sustained patient and public involvement (PPI) throughout all stages of the ImproveCare trial.
PPI has been an integral part of all of our research processes, from inception and the development of
research ideas, development of the funding application, the application to the NHS Research Ethics Service
and the development of all associated documents, through to the delivery of the research project and
the interpretation of the trial findings. We have engaged with our PPI members in a number of ways.
One of our PPI members (SB) attended the initial Research Ethics Committee (REC) meeting with the chief
investigator of the trial, helping to address the REC’s questions and also providing her experiences and
highlighting the significance of the trial. We ensured that we met with our PPI members regularly and gave
them opportunities to contribute throughout the trial. In close collaboration with our two PPI members
(CE and SB), we benefited from their expert views to help us prioritise the research questions and ensure
that the trial was undertaken in a way that was meaningful and relevant to patients whose situations are
clinically uncertain and their families. We included both our PPI members as part of the Trial Steering and
Data Monitoring and Ethics Committee (TS DMEC), which had oversight and responsibility for the conduct
of the trial. They reviewed information sheets and contributed to substantial amendments to the trial that
aimed to make trial participation easier and more accessible for patients and families. We actively involved
both of our PPI members in the analysis and interpretation of data from different components of this trial.
For instance, our PPI members were involved in the coding of patient and relative interviews. This provided
the trial team with valuable insight in understanding the data and its relevance to addressing the
intervention and conduct of the trial.
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Chapter 2 Design of the feasibility trial assessing
the AMBER care bundle and trial processes
Research design
This trial had a parallel cluster RCT design, with a 1 : 1 allocation ratio. The design of the AMBER care bundle,
and the manner in which it was implemented and then operationalised at a ward level, did not strictly
follow the Medical Research Council (MRC)’s guidance on the development of complex interventions,50
the MORECare statement51 or the recent guidance on process evaluations.52 To address this, and to inform
the design of a definitive clinical trial (Figure 1), we integrated (concurrent) qualitative components of the
trial. Our approach closely followed the guidance (Figure 2).51,53
Quantitative data
collection
• Feasibility cluster
   RCT (baseline
   patient data
   collection and
   IPOS collection
   at time points
   1 and 2)
• Retrospective
   bereavement
   survey, including
   IPOS
Qualitative data
collection
• Non-participant
   observation
• Face-to-face
   interviews with
   patients
• Face-to-face
   interviews with
   relatives
• ‘Standard’ or
   ‘usual’ care
   questionnaire
• Multiprofessional
   ward-based focus
   groups
• Case not review
• Heat maps
Quantitative data
analysis
Qualitative data
analysis
Results: intergration of 
findings from feasibility
cluster RCT, retrospective
survey and qualitative
components
Optimised version of AMBER
care bundle
Model to inform design of
cluster RCT
FIGURE 1 Concurrent mixed-methods design for the feasibility cluster RCT. IPOS, Integrated Palliative care
Outcome Scale.
DOI: 10.3310/hta23550 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 55
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Koffman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
7
Rationale for clustering
The AMBER care bundle is a complex intervention in which ward staff receive training and all patients
within the wards are considered for receiving support from the intervention. It would therefore not
be possible to randomise patients at the individual level within the same ward.54 In order to prevent
contamination of the control participants, which may have led to biased estimates of the intervention’s
potential effect, this trial was designed to be randomised at the cluster level. Clusters, in this case, were
identified as being general medical wards, and were selected from different hospitals, as randomised wards
within the same hospital might have also been contaminated because of between-ward staff movements.
Components of the trial
l The clinical trial of the patients supported by the AMBER care bundle compared with those cared for on
control wards.
l A bereavement survey of relatives/close friends of patients who fulfilled the criteria to be supported by
the AMBER care bundle on intervention and control wards.
l Qualitative interviews with patients and their relatives/close friends.
l Non-participation observation of MDTs at the trial wards.
l Focus groups with HCPs working on the trial wards.
l A usual care questionnaire completed by the HCPs working on the trial wards.
l A review of patients’ case notes and ‘heat maps’ produced at each trial ward.
Consent processes
All participants who provided written informed consent (or assent) to participate in the trial were provided
with a copy of the information sheet and their signed consent (or assent) form to keep (see Appendix 2).
A copy of the signed consent/assent form was filed in the participant’s medical notes, and a copy was sent
to the patient’s general practitioner if they provided their general practitioner’s details. The research team
retained the original signed consent form.
Feasibility/piloting of the AMBER
care bundle
1. Testing procedures
2. Estimating recruitment/retention
3. Determining sample size
Development of the AMBER care bundle
1. Identifying the evidence base
2. Identifying/developing theory
3. Modelling processes and outcomes
Evaluation
1. Assessing effectiveness
2. Understanding change processes
3. Assessing cost-effectiveness
Implementation
1. Dissemination
2. Surveillance and monitoring
3. Long-term follow-up
FIGURE 2 Conceptual framework for the evaluation of the AMBER care bundle showing which elements of the
MRC’s framework have been completed (top box) and those proposed for testing in this feasibility trial (left box).
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Research governance and ethics approval
Favourable ethics opinion was obtained from the National Research Ethics Committee – Camden and
King’s Cross (REC reference 16/LO/2010) on 20 December 2016 and from the Health Research Authority
(HRA) on 25 January 2017. NHS research governance approvals were obtained from each participating trial
hospital. All minor and substantial amendments to trial procedures and material were reviewed and
approved by the REC, HRA and local trial hospitals (referred to as trial sites).
Amendments to the protocol
Six substantial amendments were submitted during the course of the feasibility trial. The changes to the
protocol and the trial procedures are outlined in this section. All amendments were approved by the REC,
HRA and local trial sites (see Appendix 3 for approvals from the REC).
1. The participant information sheets and consent forms for the non-participant observation of MDT
meetings were omitted from the original application and a substantial amendment was issued to ensure
that these documents were reviewed and approved (REC approval date: 23 January 2017).
2. The participant information sheets for focus groups with HCPs were omitted from the original
application and a substantial amendment was issued to ensure that these documents were reviewed
and approved (REC approval date: 22 February 2017).
3. Following the enquiries from the Project Advisory Group (PAG) and REC regarding the ambiguity
around what ‘standard care’ represented in the control arm of the trial, changes were made to the
protocol that aimed to address this issue. A new study measure referred to as the ‘Standard’ or ‘Usual’
Care Questionnaire’ and the accompanying participant information sheet and consent form were
developed. To understand how to characterise ‘standard care’ in the control wards, and to examine
how well the AMBER care bundle was being used and adapted on the intervention wards, we also
added a ‘case note review tool’ and ‘heat maps’ to the trial. Additional questions were included in topic
guides for the HCP focus groups to enhance our understanding of the care provided across trial sites
(REC approval date: 21 April 2017).
4. An amendment was submitted to temporarily change the chief investigator of the trial to Dr Catherine
Evans from Dr Jonathan Koffman. In addition, the trial end date was extended to 31 October 2018.
Owing to delays in recruitment of the nurse facilitator, general planned procedures of implementation
and data collection were amended. To ensure that data from bereavement surveys were collected in time,
changes were made to time points at which bereavement survey packs were sent. Finally, the EuroQol-5
Dimensions, five-level version (EQ-5D-5L) (reference), measure was added at other time points. Owing to
these changes, trial documents and the protocol were updated (REC approval date: 24 July 2017).
5. The bereavement survey was amended to include two health economic evaluation measures and to
improve the overall layout of the questionnaire (REC approval date: 1 November 2017).
6. After experiencing difficulties in recruitment at the control sites, the inclusion criteria for the trial were
amended to remove the ‘Patients who were at risk of dying during their episode of care despite treatment’.
Feedback from the local trial sites and the screening logs identified this criterion as challenging to interpret
and implement. Furthermore, we improved the language used in the participant information sheets and
letters after an incident in which a relative was distressed from a phrase used in the participant information
sheet. This amendment also included an addition to conduct qualitative interviews with patients and
families over the telephone, as several potential participants who were approached previously mentioned
difficulties around arranging a face-to-face interview. Finally, an ‘AMBER readiness criterion’ was included
to examine interventional fidelity to the AMBER care bundle at both intervention sites (REC approval date:
14 December 2017).
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Data collection
The timeline for data collection for different trial components and trial sites is summarised in Figure 3.
Prospective data were collected from the patients at three time points: baseline, 3–5 days and 10–15 days.
After obtaining informed consent (or assent), research nurses conducted face-to-face interviews with patients
(or relatives) to collect data that captured demographic and clinical circumstances. The questionnaire booklets
included candidate patient outcomes using the ‘Patient/family anxiety and communication subscale’ of the
Integrated Palliative care Outcome Scale (IPOS) and the ‘howRwe’ measure (see Appendix 4) and health
performance status using the Australian-modified Karnofsky Performance Status scale (AKPS). Data on health
resource utilisation were collected using the Client Service Receipt Inventory (CSRI). The EQ-5D-5L was used
to measure health-related quality of life.
Testing the candidate primary outcome measures
The first primary outcome measure we tested was the effect of being supported by the AMBER care
bundle on the ‘Patient/family anxiety and communication subscale’ of IPOS.55,56 This proposed outcome
was based on the overall aim of the intervention and findings from our recent comparative observational
study48 in which psychosocial issues were shown to be important patient- and family-centred concerns.
The Patient/family anxiety and communication subscale incorporates items including being in receipt of
information, addressing practical matters, sharing feelings with family, being at peace, and patients’ and
families’ levels of anxiety and depression. A general background to the IPOS measure is presented in Box 2.
We included another candidate primary outcomes measure to be able to determine the measure best
suited to a pragmatic trial.53 HowRwe, a validated patient-reported experience measure,63 was used to
examine changes in patients’ perceptions of their experience of health care, which are highly relevant to
those whose situations are clinically uncertain and their families. A general background to the howRwe
measure is presented in Box 3. This measure is considered succinct (29 words in length) and highly
accessible (Flesch–Kincaid readability score of 2.2). It consists of four items: two relate to the delivery of
clinical care (being treated kindly and being listened and explained to). Two further items relate to the
organisation of their care, including waiting to see a HCP (time wasted) and how well organised patients
perceive the ward to be. The howRwe has been successfully used across inpatient and outpatient general
practice, care homes and in domiciliary care.
These two measures were reassessed at follow-up points 1 (days 3–5) and 2 (days 10–14). The success of
the primary outcomes were examined based on the following criteria:65
l appropriateness – for patients with an advanced illness (e.g. number of missing data)
l reliability – the degree of consistency of the measure (i.e. when it gives the same repeated result under
the same conditions)
l feasibility – is the measure easy to administer to patients in an inpatient hospital setting?
Patient recruitment and consent procedures
We aimed to understand how involvement in the trial might influence participants’ situations. We used a
successful strategy from a recent study examining the effectiveness of dignity therapy for people living with
advanced cancer.66 Participants in both arms were questioned at all time points to evaluate the extent to
which they found participating in the process of obtaining consent and the overall research process ‘helpful’,
‘making life more meaningful’, ‘heightening their sense of purpose’, ‘lessening suffering’ and ‘increasing
their will to live’. We have previously observed that self-reports of the benefits of being involved in the
research process are generally more positive in the intervention group than in the control group.67 However,
qualitative accounts from participants in the control group from the previous study included statements
indicating that being involved in research meant that ‘somebody cared about me’ and represented
‘an opportunity to talk to somebody about problems with a sympathetic and sensitive researcher’.68
DESIGN OF THE FEASIBILITY TRIAL ASSESSING THE AMBER CARE BUNDLE AND TRIAL PROCESSES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
10
Control ward 1
Control ward 2
• Identification of eligible patients
• Recruitment to the trial
• Feasibility assessments
• Testing of patient- and family-centred
   outcome measures
• Conduct of integrated qualitative
   components
• Identification of eligible patients
• Recruitment to the trial
• Feasibility assessments
• Testing of patient- and family-centred
   outcome measures
• Conduct of integrated qualitative
   components
• Clinical implementation of the AMBER
   care bundle
• Identification of eligible patients
• Recruitment to the trial
• Feasibility assessments
• Testing of patient- and family-centred
   outcome measures
• Conduct of integrated qualitative
   components
3 months
Preparation for
implementation
of AMBER care
bundle on
intervention
ward 1
Intensive education
and training
programme on
intervention
ward 1
3 months1 month 3 months1 month
Intervention ward 1
• Clinical implementation of the AMBER
   care bundle
• Identification of eligible patients
• Recruitment to the trial
• Feasibility assessments
• Testing of patient- and family-centred
   outcome measures
• Conduct of integrated qualitative
   components
Preparation for
implementation
of AMBER care
bundle on
intervention
ward 2
Intensive education
and training
programme on
intervention
ward 2
Intervention ward 2
FIGURE 3 Time frame for training on intervention wards and trial recruitment and data collection points.
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BOX 2 The palliative care outcome scale
The POS was developed in the 1990s and includes domains important to patients with advanced progressive
illness.55 It consists of 10 items scored from 0 (best) to 4 (worst). It assesses physical symptoms, psychological
and spiritual needs and provision of information and support. Following patient and clinician feedback, a
symptom module (POS-S, adapted for specific conditions) was added.57,58 Staff versions of POS and POS-S –
important when the target population is so ill and frequently unable to complete patient-reported versions –
are brief, user-friendly clinical outcome measures designed for HCPs to assess an individual’s symptoms and
concerns. They typically take less than 10 minutes to complete. Both patient and staff versions of POS and
POS-S have undergone extensive psychometric study. POS has validity and internal consistency in a variety of
settings, including hospital inpatient care and community and outpatient services, hospice inpatient, day care
and home care.55,59 Moreover, it demonstrates construct validity and re-test reliability, and factor analysis has
identified important underlying constructs relating to psychological well-being and quality of care.56
The IPOS comprises 17 items scored from 0 (best) to 4 (worst) and assesses physical symptoms, psychological
and spiritual needs, and provision of information and support.55 The IPOS has undergone extensive validation
testing including cognitive interviewing to assess acceptability and content/face validity and to identify cognitive
processing issues following the model of Tourangeau.60 Face and context validity of IPOS were refined using
cognitive interviewing.61 A recent study provides evidence that the IPOS is a robust, valid and reliable measure
and would provide discrimination between relevant groups.62 We identified among 373 participants that the
IPOS can discriminate well between patients with different illness and functional characteristics. For example,
in the known-group comparisons (during our testing of construct validity), the total IPOS and subscale scores
discriminated well between patients who were in an unstable/deteriorating phase compared with those in a
more stable phase of illness (total IPOS: F = 15.0, p < 0.001; Patient/family anxiety and communication subscale:
F = 3.6, p < 0.03).
POS, Palliative care Outcome Scale; POS-S, Palliative care Outcome Scale Symptom.
BOX 3 The howRwe
In England, the NHS undertakes many national surveys of patient experience. However, measures are often
unwieldy and lengthy, with many being over 300 words long. The howRwe was developed as the first short
generic patient experience measure for use across all health and social care sectors.63 It comprises just 29 words
and includes two items relating to clinical care (treat you kindly and listen and explain) and two items relating
to the organisation of care (see you promptly and well organised) as perceived by patients. Each item has four
possible responses (excellent, good, fair and poor). The summary howRwe score is calculated for individual
respondents by adding the scores for each item, giving a scale with 13 possible values, from the floor, 0
(4 × poor), to the ceiling, 12 (4 × excellent). When reporting the results for a group comprising more than one
respondent, mean scores are transformed arithmetically to a 0 to 100 scale, where 100 indicates that all
respondents rated all items as excellent and 0 indicates that all rated all items as poor. This allows the mean
item scores to be compared with the summary howRwe score on a common scale. The measure was recently
trialled among 828 older patients and has undergone extensive psychometric testing64 in a variety of settings,
including hospital and care homes in the community. The measure demonstrates good internal consistency,
concurrent validity and discriminant and construct validity.
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Participant inclusion criteria
l Patients located on the intervention or control wards.
l Patients who were aged ≥ 18 years.
l Patients who were deteriorating (in accordance with the AMBER criteria).
l Patients whose situations were clinically uncertain, with limited reversibility (in accordance with the
AMBER criteria).
l Patients who were at risk of dying during their episode of care despite treatment (in accordance with
the AMBER criteria).
l Patients who were able to provide written informed consent or for whom a personal consultee could
be identified and approached to give an opinion on whether or not the patient would have wished to
participate in the trial.
The bereavement survey
The objectives of the bereavement survey within this feasibility trial were to:
1. test feasibility of collecting data retrospectively
2. examine differences in the use of financial resources between the AMBER care bundle and
standard care.
Participant inclusion criteria for the bereavement survey
Potential participants for the bereavement survey included the next of kin (NOK) or named relatives of
deceased participants who were either (1) supported by the AMBER care bundle on intervention wards or
(2) identified as fulfilling the criteria on the control wards. We identified the NOK for participants who died
(1) while they were inpatients or (2) on discharge within 100 days.
Recruitment of participants for the bereavement survey
All identified NOKs were sent a letter from the research nurses at each of the participating DGHs 10–12 weeks
following bereavement, with an introductory letter, the survey questionnaire and a Royal College of
Psychiatrists bereavement support leaflet. Up to two reminders were sent to people who had not responded
at 2 and 4 weeks after the initial posting; the second reminder included a second copy of the questionnaire.
On receipt of a completed questionnaire (see Data collection for the bereavement survey), the research
team recorded the date of receipt into the spreadsheet, checked completion and recorded levels of distress
and grief intensity.
Data collection for the bereavement survey
We used a modified version of the QUALYCARE bereavement survey,69 which has previously been
shown to be highly acceptable to participants in bereavement research.48,70 This survey examines the last
1–2 months of the decedent’s life, including quality and consistency of information and communication
with clinicians.
The survey comprises four brief and robust measurement tools previously used in cancer and end-of-life
care studies. These tools collect information on health and social care services use and informal care
(CSRI71,72), patient palliative outcomes in the week prior to death (IPOS55,56), health-related quality of life
[EuroQol-5 Dimensions (EQ-5D)73] and respondents’ bereavement outcomes (Texas Revised Inventory of
Grief74). Further questions explored preferences for (and actual) place of death, relevant local issues and
sociodemographic and clinical data. The format and navigation of the questionnaire have been refined
according to cognitive theory literature.75 Furthermore, the QUALYCARE questionnaire has been piloted
and improved to enhance acceptability among 20 bereaved relatives recruited via the palliative medicine
department of a London hospital.70
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The qualitative component
The qualitative component of this feasibility trial included interviews with patients, their relatives or close
friends, non-participant observation of the MDT meetings and ward-based focus groups with HCPs.
The specific objectives of these components of work were:
l to examine the extent to which the AMBER care bundle requires further refinement or adaptation
(e.g. referral criteria to identify which patients would benefit most) to suit local conditions
l to assess the acceptability of the AMBER care bundle to patients, their families and HCPs
l to determine the ‘active ingredients’ of the AMBER care bundle that need to be maintained to ensure
fidelity of the intervention for a full trial
l to assess compliance with and barriers to the delivery of the AMBER care bundle.
Participant inclusion criteria for the qualitative interviews
Potential participants included:
l all patients who were recruited to the trial
l relatives or close friends of patients who were recruited to the trial
l patients or relatives who were able to meet face to face or have the interview over the telephone.
Exclusion criteria for the qualitative interviews
Our exclusion criteria for this component of the trial were:
l patients who were not able to provide informed consent because of capacity-related issues
l patients, their relatives or close friends considered by HCPs to be too unwell to be interviewed and/or
too distressed to approach
l relatives/close friends, who were not willing to provide informed consent.
Procedure for recruitment of patients and/or relatives for the qualitative interviews
The research nurses were asked to identify up to 20 patients (five per ward), and/or their relatives, who
matched the inclusion criteria on intervention and control wards. Identified patients were discussed with
the clinical team to see if they were suitable to be approached. Potential participants were also selected
according to pre-agreed criteria (range of age groups, gender, disease type and ethnic group). If they were
deemed to be appropriate, the research nurse then asked if they would like to be interviewed by the
trained researcher.
Relatives were approached while they were visiting the patients and asked if they would be willing to be
interviewed by the trained researcher. All participants were provided with a comprehensive participant
information sheet explaining the nature of the trial and their potential involvement. This document did
not allude to therapeutic promises, nor did it allude to unacceptable inducement or refer to any negative
outcome of not participating. If in agreement, the researcher then contacted the potential participants,
within 24 hours, to address any questions or concerns that they might have and to establish their decision
to take part in the trial or not.
Owing to the challenging nature of the patients’ clinical situations and where the potential participant
was not able to meet face to face, a decision, approved by the REC, was made to conduct such interviews
over the telephone. A mutually convenient time was arranged to conduct each interview. The researcher
explained the trial in full again and the interview commenced after informed consent was obtained (in writing
in a face-to-face interview or verbally recorded in a telephone interview). Verbal consent was documented
by the researcher on the consent form for telephone interviews and signed and dated. A copy of the signed
consent form was sent to the participant after the interview depending on their preference.
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Data collection for the qualitative interviews with patients and relatives or close friends
The interview topic guides aimed to explore patients’ and their relatives’/close friends’ insights into the
delivery of care, and their perception of involvement in critical decisions regarding their care and treatment
while in hospital. Interviews were recorded on an encrypted digital voice recorder. During transcription,
all potentially identifiable information was removed or anonymised. Recordings were destroyed following
completion of the trial in line with King’s College London’s data-management policy.
Non-participant observation of the multidisciplinary team meetings
Informed consent was obtained prior to the meetings. However, in instances in which HCPs arrived late,
informed consent was obtained at the end of the meetings. This was considered the most minimally
intrusive option in the group setting, as it did not disrupt natural behaviours of HCPs already participating
in the meeting.
On the intervention wards, we recorded who was present at the meetings, the frequency of the meetings,
the length of meetings and type of conversations relating to patients identified as fulfilling the criteria
to be supported by the AMBER care bundle. We also took note of which professions contributed to
conversations, what specific actions were discussed that related to their care and how decision-making
processes developed, including the management of end-of-life issues. We conducted similar observations
on the two control wards with prior knowledge from the research nurses of patients who fulfilled revised
criteria. Observations were written down as field notes during the meeting. All field notes that related to
conversations about individual patients and their families were devoid of any identifying characteristics.
Focus groups with health-care professionals
The HCPs were invited to participate in a ward-based multiprofessional focus group to explore their views on
caring for patients whose situations were clinically uncertain, views about the AMBER care bundle (if on the
intervention wards) and views regarding conduct of the feasibility cluster RCT. Specifically, for the intervention
wards, we wanted to understand HCPs’ insights into the ways in which the AMBER care bundle influenced
communication with patients and their family members or close friends, improved HCP confidence,
competence and empowerment in working with patients with advanced disease and facilitated improved
team working, and to explore what changes may be required to enhance its operation. We wanted to
explore their views on the acceptability of the care bundle, particularly their views on whether or not the
AMBER care bundle required modification or refinement. We purposively recruited a range of HCPs with
different levels of experience to share their views on caring for these patients. We worked closely with the
research nurses to promote the focus groups and posted information posters in each of the wards in the
weeks leading up to the focus group taking place. The focus groups were typically organised during lunch
times to optimise participation and were catered with food and refreshments to offset any inconvenience
staff might experience. Participants were asked to give informed consent on arrival at the focus group venue.
The ‘standard’ or ‘usual’ care questionnaire
In clinical trials, reference is often made to evaluating the outcomes of an intervention compared with
standard care.76,77 Few studies, however, explain what this type of care comprises or examine the extent
to which standard care changes during the trial as a result of involvement in the trial. This methodological
issue was highlighted by members of the NHS REC and by our trial statistician. We therefore developed
a tool to characterise best standard care applicable for patients, and their families, whose situations are
clinically uncertain, across all of the trial sites, at the following time points during the trial:
l baseline (prior to implementation of the AMBER care bundle for the intervention wards)
l mid patient recruitment (6 weeks after the recruitment of the first participant)
l at the end of patient recruitment (we were mindful that some of the procedures in the ward might not
change drastically throughout the trial, especially in the control sites, hence why, at the mid patient
recruitment and end of patient recruitment time points, we provided respondents with the option of
answering only the questions that related to when there had been a change in the procedure since the
previous time point).
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We collected data from the perspectives of different HCPs (a consultant, a ward manager/sister, a junior
doctor/senior house officer, a health-care assistant and a staff nurse), rather than just one representative
on each ward, to obtain a broader understanding of this type of care. The format, content and navigation
of the ‘standard’ or ‘usual’ care questionnaire were refined based on expert opinions, including members
of the PAG and senior clinical colleagues at an inner London teaching hospital. Questions addressed
initial care planning and general practices, recognising dying, referral and discharge procedures. The
questionnaire took 10–20 minutes to complete depending on the number of free-text data provided.
Case note reviews
The incorporation of the audit tool, which was developed by the bundle developers as part of the quality
improvement process, aimed to enhance our understanding of ‘standard’ or ‘usual’ care at ward level and
how this might change over time. The nurse facilitator completed the case note reviews. This audit tool
is routinely used in over 30 hospitals internationally, including in England, Wales and Australia. The audit
tool comprises a case note review of hospital patient records in a standardised format and a ‘heat map’
of patient mortality over a 1-year period.
The case note review was completed retrospectively and involved purposively selected 20 patients per ward,
comprising 10 patients who died in the hospital and 10 patients who were discharged and died within
100 days of discharge. It was conducted for all of the trial wards and additionally for the intervention wards
after the implementation of the AMBER care bundle. All identifiable patient information was removed and
anonymised prior to sharing with the research team.
Trial setting
Selection of the wards
Participant recruitment and implementation of the AMBER care bundle were limited to one or two general
medical wards at each hospital site. Wards with the highest number of deaths per year were considered to
be suitable for this trial. Selection of the trial wards at each site was informed by ‘heat maps’ that provided
contextual information at ward level on the number of deaths during admission and up to 100 days after
admission across the hospital wards.
Randomisation and masking
Randomisation was at the level of the NHS trusts via an independent service at King’s Clinical Trials Unit.
Four clusters were randomised at once by randomly sequencing the order of randomisation and then
randomising the sites in this order into fixed blocks of two, those being the control or intervention arms.
All clusters were randomised prior to collection of data at sites but after all sites had agreed to participate.
Quantitative analyses masked for the group allocation were conducted. Research nurses collecting the
outcome measures were not masked for the group allocation.
Trial sites
Participants were recruited from one (or two) purposefully chosen general medical ward of four DGHs in
England. The trial sites were Chesterfield Royal Hospital, East Surrey Hospital, Tunbridge Wells Hospital and
Northwick Park Hospital, which are major secondary care facilities typically providing an array of diagnostic
and therapeutic services to local populations. There are over 250 DGHs in the UK.78 They represent abundant
settings in which to implement and test the effect of the AMBER care bundle; the findings from this feasibility
trial would inform future scalability. However, DGHs are extremely busy environments in which to conduct
research, with patients being rapidly assessed and transferred from medical acute admissions units to other
wards within the hospital. This makes it challenging to track trial participants and obtain accurate reports
of their condition or outcomes. The DGHs selected serve diverse populations including those that comprise
ethnic diversity and material deprivation. The hospitals have different strengths and weaknesses in terms of
their Care Quality Commission ratings (Table 1).
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‘Standard’ or ‘usual’ care across trial sites
The standard care provided to patients who might have clinically uncertain recovery was described using
the self-reported ‘standard’ or ‘usual’ care survey completed by the HCPs and the case note reviews.
The ‘standard’ or ‘usual’ care surveys were completed at the beginning of the data collection at each
trial site by 23 HCPs who represented different seniority levels and professions working on the trial wards
(Table 2). The components of care questioned in this survey did not change during the course of the
trial. All sites had similar processes for clerking, referring patients to palliative care or intensive care unit
(electronic referral and specific triggers) and providing emotional support to the patients and families.
However, professionals had various views on who was responsible for producing a medical plan for the
patients, varying from all of the MDT and the patients and families to the consultant and medical team
only. Delays in recognition of patients’ clinical uncertainty and relaying of information around uncertain
recovery from HCPs to patients and families were shown as the main barriers to referrals to palliative care
and in escalating care at all trial sites by various HCPs. Three ward sisters [sites Int (intervention) 1, Int2
and Con (control) 2] and one health-care assistant (site Con1) stated that the principal reason for delays
in referral to palliative care was the medical team’s decision to continue active treatment: ‘doctors trying
to get the patient well’ (Con2001) and ‘medical team wanting to treat for another 24–48 hours’ (Int1005).
TABLE 1 Trial sites
Cluster Specialties
Number
of beds End-of-life care plan
Care Quality
Commission rating
Control arm
One general
medical ward
l General medicine
l Haematology
l Diabetic medicine
l Geriatric medicine
32 l Last days of life care agreement
l Recognising dying assessment
l Individual care plan
Good
One general
medical ward
l Rheumatology
l Endocrinology
27 Last days of life care agreement Requires improvement
Intervention arm
One general
medical ward
l Respiratory
l Endocrinology
30 Individualised care plan for dying patients Good
Two general
medical wards
Care of the elderly 36 End-of-life care plan Requires improvement
TABLE 2 ’Standard’ or ‘usual’ care survey professions involved
Profession
Number of professions
Trial arm and site
Control Intervention
Con1 (n= 5) Con2 (n= 5) Int1 (n= 8a) Int2 (n= 5)
Consultant 1 1 2 1
Ward sister/manager 1 1 2 1
Junior doctor 1 1 2 1
Staff nurse 1 1 0 1
Health-care assistant 1 1 1 1
Physician associate 0 0 1 0
a Study was based on two adjacent wards.
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The survey also highlighted that advance care plans (ACPs) were devised only once the patient was
considered to be at the end of life: ‘when all the care has been given and the patient has not got any
better’ (Int2001). After the implementation of the AMBER care bundle, HCPs at site Int1 stated ‘recognising
uncertainty’, ‘deteriorating patient’, ‘clinical uncertainty’,7 ‘patient and family wishes’ and ‘frequent hospital
admissions’ as reasons for devising an ACP. Within the same teams, there were disagreements around the
frequency of revisiting the plans made with the patients and families. Although professionals across all sites
stated that they would actively contact families and speak with the rest of the MDT as soon as possible if
a patient’s health status deteriorated, HCPs within the same team were in disagreement about how often
they would update the patients and families.
Survey findings showed inconsistencies in the manner in which standard care was delivered in relation to
shared decision-making among HCPs and the contribution of the MDT to patients’ care and treatment
plans. Although all of the survey participants were able to clearly state the systems in place at all sites,
the recognition of clinical uncertainty and importance of having conversations with patients and families
prior to their last days of life were considered part of the standard care provided.
Case note reviews identified that processes, documentation of plans and discussions at all trial sites were
similar (Table 3). The review showed that the uncertain recovery of patients was documented in patients’
notes for the majority (> 60%) of a purposively selected sample of patients across all the trial sites. The
majority of patients in the control sites had a cancer diagnosis, unlike the patients in intervention sites.
In all trial sites, escalation plans were documented for 60% of participants, and ‘do not resuscitate’ orders
were documented for 75% of the sample. However, the majority (> 60%) of the sample did not have
an ACP documented. Besides site Con1, medical plans were discussed and agreed with the nursing staff at
all other sites. Although the notes identified that discussions with patients and families took place for the
majority of the sample, documentation of patients’ preferred places of care (PPCs) and PPDs and their
wishes around care and treatment require improvement. With the exception of site Con2 participants,
the majority of the sample received daily follow-up. However, it was not possible to examine the quality
and the content of the discussions that took place.
The case note reviews were also conducted for patients who died within 100 days of discharge from
hospital (see Appendix 5) and at the end of the feasibility trial on the intervention wards to identify
changes from before to after implementation (see Appendix 6).
Quantitative analysis
A statistical analysis plan was developed to detail the analysis strategy and statistical considerations
(missing data checks and model assumption checks). This document was approved by project statisticians
and the TS DMEC. We undertook analysis in accordance with the Consolidated Standards of Reporting
Trials (CONSORT) guidelines in collaboration with King’s Clinical Trials Unit; two statisticians (WG and RW),
the chief investigator (JK) and the health economist (DY) were blind to the randomisation.
All percentages, means, medians, ranges, standard deviations (SDs) and 95% confidence intervals (CIs)
were rounded up to one decimal point. No tests of significance were conducted as this was a feasibility
trial with no aim to test the effectiveness of AMBER compared with standard care. However, 95% CIs
were provided to indicate the precision of the estimates from the preliminary trial.
Data entry
All data were entered into predesigned EpiData (EpiData Association, Odense, Denmark) databases. Ten per
cent of the data were double-entered and cross-checks were conducted. No discordance was detected for the
primary outcome measures (100% match for IPOS patient/family anxiety and communication subscale and
howRwe), with very high accuracy for the rest of the questionnaires.
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TABLE 3 Baseline case note review per trial site and trial arm
Descriptive variable
Trial arm and site, n (%)
Control Intervention
Con1 (N= 20) Con2 (N= 20) Int1 (N= 20) Int2 (N= 20)
Age (years)
40–60 2 (10) 2 (10) 0 (0) 3 (15)
61–70 2 (10) 3 (15) 0 (0) 6 (30)
71–80 4 (20) 8 (40) 2 (10) 6 (30)
81–90 8 (40) 6 (30) 11 (55) 5 (25)
≥ 91 4 (20) 1 (5) 7 (35) 0 (0)
Primary diagnosis
Cardiology 0 (0) 0 (0) 4 (20) 0 (0)
Cancer 12 (60) 9 (45) 2 (10) 6 (30)
Acute respiratory 5 (25) 7 (35) 5 (25) 2 (10)
Chronic respiratory 0 (0) 0 (0) 0 (0) 10 (50)
Stroke 0 (0) 0 (0) 0 (0) 1 (5)
Dementia 0 (0) 0 (0) 2 (10) 0 (0)
Sepsis 2 (10) 0 (0) 1 (5) 0 (0)
Frailty 0 (0) 0 (0) 1 (5) 0 (0)
Other 0 (0) 4 (20) 5 (25) 1 (5)
Uncertain recovery documented?
Yes 18 (90) 15 (75) 18 (90) 12 (60)
No 2 (10) 5 (25) 2 (10) 8 (40)
ACP in place?
Yes 4a (20) 8b (40) 7c (35) 2d (10)
No 16 (80) 12 (60) 13 (65) 18 (90)
Escalation plan documented?
Yes 15 (75) 12 (60) 18 (90) 13 (65)
No 5 (25) 8 (40) 2 (10) 7 (35)
DNAR/DNACPR status
Patient for CPR 1 (5) 0 (0) 0 (0) 2 (10)
Patient not for CPR 16 (80) 15 (75) 20 (100) 15 (75)
No documented decision 3 (15) 5 (25) 0 (0) 3 (15)
Medical plan discussed and agreed with nursing staff?
Yes 9 (45) 15 (75) 19 (95) 16 (80)
No 11 (55) 5 (25) 1 (5) 4 (20)
Patient/family discussion?
Yes 19 (95) 14 (70) 19 (95) 13 (65)
No 1 (5) 6 (30) 1 (5) 7 (35)
continued
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Sample size for the feasibility cluster randomised controlled trial
A formal power calculation was not appropriate because effectiveness was not being evaluated. Any
investigations of changes in trial parameters were exploratory only. Based on the information about number
of deaths and prior studies, we aimed to recruit 40 patients per trial arm to meet our feasibility objectives.
TABLE 3 Baseline case note review per trial site and trial arm (continued )
Descriptive variable
Trial arm and site, n (%)
Control Intervention
Con1 (N= 20) Con2 (N= 20) Int1 (N= 20) Int2 (N= 20)
Daily follow-up?
Yes 19 (95) 12 (60) 19 (95) 12 (60)
No – should have received 1 (5) 7 (35) 1 (5) 8 (40)
No – not needed 0 (0) 1 (5) 0 (0) 0 (0)
Assessment of capacity?
Yes 11 (55) 20 (100) 10 (50) 7 (35)
No – it was not needed 7 (35) 0 (0) 9 (45) 12 (60)
No – it was needed 2 (10) 0 (0) 1 (5) 1 (5)
PPC
Person’s own home 3 (15) 7 (35) 2 (10) 10 (50)
Hospital 2 (10) 6 (30) 2 (10) 3 (15)
Care home 0 (0) 3 (15) 6 (30) 3 (15)
Hospice 3 (15) 1 (5) 1 (5) 1 (5)
Preference not documented 11 (55) 1 (5) 6 (30) 3 (15)
Other (including patients who were undecided) 1 (5) 2 (10) 3 (15) 0 (0)
PPD
Person’s own home 4 (20) 3 (15) 1 (5) 3 (15)
Hospital 2 (10) 0 (0) 2 (10) 0 (0)
Care home 0 (0) 4 (20) 1 (5) 3 (15)
Hospice 3 (15) 1 (5) 2 (10) 0 (0)
Preference not documented 11 (55) 9 (45) 3 (15) 12 (60)
Other (including patients who were undecided) 0 (0) 3 (15) 11 (55) 2 (10)
Patient and family wishes documented
Wishes documented 5 (25) 12 (60) 16 (80) 10 (50)
DNAR decision only 4 (20) 0 (0) 0 (0) 5 (25)
No wishes documented 9 (45) 0 (0) 4 (20) 4 (20)
Patient offered discussion but refused 1 (5) 8 (40) 0 (0) 1 (5)
CPR, cardiopulmonary resuscitation; DNACPR, do not attempt cardiopulmonary resuscitation; DNAR, do not attempt
resuscitation; PPC, preferred place of care.
a Three cancer and one acute respiratory.
b Four cancer, three acute respiratory and one acute kidney injury on chronic kidney disease.
c One acute respiratory, one cancer and five other.
d One acute respiratory and one chronic respiratory.
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Economic evaluation
The data analysis in the economic evaluation examined resource implications from both (1) a health/social
care perspective and (2) a societal perspective. We made preliminary cost-effectiveness calculations (e.g.
combining CSRI data on costs and EQ-5D score). Economic evaluation is an emergent area in palliative care
and uncertainty surrounds best practice.72 The feasibility trial tested procedures to inform the economic
evaluation in the full cluster RCT protocol.
Qualitative data analysis
The qualitative data analysis approach was informed by the Framework approach to inductively code and
organise the data and identify emerging themes from the interviews.79 The Framework approach involves a
five-stage matrix-based approach comprising:
1. Familiarisation. We immersed ourselves in the raw data from the interviews by listening in detail to
audio-recordings, reading and rereading transcripts and also studying field notes to list key ideas and
recurrent themes.
2. Identifying a thematic framework. We developed a thematic framework to identify all of the key issues,
concepts and themes so the data could be examined. This was carried out by drawing on a priori issues
and questions derived from the aims and objectives of the trial as well as issues raised by the participants
themselves. The end product of this stage comprised a detailed ‘index’ of the data so we could ‘label’
the data into manageable chunks for subsequent retrieval and exploration.
3. Indexing. We applied our thematic framework to all the data in textual form by annotating the transcripts
with codes from the index, supported by short text descriptors to elaborate the index heading. We made
use of NVivo 11 data analysis software (QSR International, Warrington, UK) to facilitate this process.
4. Charting. We rearranged the data according to the part of the thematic framework to which they related,
and formed charts. The charting process involved a considerable amount of abstraction and synthesis.
5. Mapping and interpretation. Finally, we made use of the charts to define concepts, map the range and
nature of phenomena, create typologies and find associations between themes with a view to providing
explanations for the findings.
We addressed issues of rigour and trustworthiness in the analysis. We (JK, EY and HJ – blinded to
intervention allocation) randomly selected interview transcripts to review the application of the thematic
framework, the coding and the completeness of the framework. When coding differed or areas of the
framework were inconsistent, these issues were reconsidered in detail until a consensus was achieved.80
During this process, we took care to examine what appeared to be more unusual or non-confirmatory
views and considered what the data told us about their causes to avoid making unwarranted claims about
patterns and regularities in the data.80 Excerpts from the interview transcripts are presented to illustrate
themes representing a range of views rather than being reliant on selected individuals. All quotations from
participants (patients, relatives and HCPs, and their specific trial sites) have been anonymised to preserve
confidentiality.
Mixed methods: triangulation of data
The aim of the data integration was to examine different aspects of the AMBER care bundle experience
and participation in the research trial. Data were integrated using a method of data ‘triangulation’, which
combines data sources from more than one source (quantitative and qualitative) to address the same
phenomenon.81,82
The process of triangulating findings from the different methodological approaches took place at the
interpretation stage of a feasibility trial after all data sets have been analysed separately. Specifically, we
listed the findings from each component of a trial and then considered where findings from each approach
agree (convergence), offer complementary information on the same issue (complementarity) or appear to
contradict each other (discrepancy or dissonance). We looked for instances of convergence but also for
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disagreements between findings from different approaches. We believe that disagreement is not a sign that
something necessarily went wrong with our feasibility trial. Indeed, instances of ‘intermethod discrepancy’
may lead to a better understanding of how the intervention operates, its effects and where it can be
improved. We also looked for instances of silence – where a theme or finding arises from one data set but
not from others. Silence might be expected because of the strengths of different methods to examine
different aspects of the bundle.
Implementation of the AMBER care bundle
The process of implementing the AMBER care bundle comprised three stages:
1. Findings from the ‘heat maps’ were shared with the hospital staff to inform them about the suitability
of the wards for the AMBER care bundle and enabled them to use the data for their own quality
assessment. Heat maps did not include any identifiable patient-related information.
2. A baseline review of patients’ clinical case notes was conducted on each of the selected wards prior to
the AMBER care bundle implementation. The case notes were scrutinised to –
i. identify patients who would be suitable to be supported by the intervention
ii. check if a documented plan for their care was in place
iii. identify if there was evidence of an escalation plan and if the medical plan had been agreed with
nursing staff
iv. identify if there was evidence that a conversation had taken place with the patient and their
relatives regarding their uncertain clinical situation and care preferences
v. identify if there was evidence that capacity and or best interests assessments had been
appropriately addressed
vi. identify, for patients discharged from hospital, any non-elective readmissions in the last 100 days,
and the outcome (died or discharged).
3. Once a suitable ward had been identified, the nurse facilitator engaged in four steps to introduce and
implement the AMBER care bundle on each ward. This involved –
i. familiarisation with the ward
ii. introducing the intervention to HCPs and training them on its use
iii. supporting HCPs in the practice of using the AMBER care bundle (role modelling and developing
relevant communication skills)
iv. observing how HCPs used the AMBER care bundle
v. exit plans and completion of a follow-up case note review.
The criteria to determine if the ward was perceived to be ready to support suitable patients and their
families with the AMBER care bundle included fulfilling the criteria described in Table 4.
Prior to start of the data collection at sites Int1 and Int2, the following were achieved in terms of
implementation of the AMBER care bundle:
l More than 90% of the nursing, medical and therapy staff, the discharge planning teams, ward clerks,
the palliative care teams and the respiratory teams were trained; critical care outreach teams were
briefed; education inputs were completed; and clinical processes were adjusted to accommodate use of
the AMBER care bundle.
l HCPs were able to discuss ‘clinical uncertainty’ and care preferences with patients and families supported
by the AMBER care bundle and provide appropriate support (observed by the nurse facilitator).
l HCPs were able to identify patients eligible for the intervention without prompting in MDT meetings,
including senior medical, junior medical and non-medical staff (observed by the nurse facilitator).
l Five randomly selected HCPs at each intervention site were able to correctly describe the AMBER care
bundle, as per the inclusion criteria, to the nurse facilitator.
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l Senior HCPs discussed what they considered to be important to patients, and their escalation plans
when present, at handover meetings (observed by the nurse facilitator).
l Four main components of the AMBER care bundle were completed in more than 80% of patients’
clinical notes; discharge letters regularly contained information as per the AMBER care bundle inclusion
criteria (observed by the nurse facilitator).
TABLE 4 The AMBER care bundle readiness baseline criteria
Aspect of training Baseline criteria
Education inputs completed/clinical processes
adjusted as planned
l > 80% of staff trained
l The AMBER care bundle magnets and localised version of the
bundle (paper or electronic) available
l The AMBER care bundle record (paper or electronic) of all
patients ever supported with the intervention is available
Patients supported by the AMBER care bundle –
open communication (observe in practice/notes) –
patient/family awareness/feel supported (ad hoc
feedback)
l Evidenced by witnessing (in person or within documentation)
open, honest conversations with patient and/or family
(depending on mental capacity) using language/pace tailored to
individual patient/family needs. This should usually include a
discussion of their condition; uncertainty that they will recover
and their choices and preferences including PPC
l Written patient information available on the ward – generally
displayed on notice boards and in individual leaflets for
patient/family
Senior staff (medical, nursing, allied health
professionals, critical care outreach) able to identify
patients (observe white board rounds without
needing to prompt, different HCPs raise the concern)
– effective MDT working and ability to work across
hierarchies around clinical uncertainty of recovery
At MDT meetings and ward rounds, staff are able to identify
patients who meet the AMBER care bundle criteria without prompts
from the nurse facilitator. When asked if there are any patients they
think may have an uncertain recovery and meet the AMBER care
bundle criteria, junior and non-medical members of the team as
well as medical colleagues are able to highlight potential patients
for discussion with the wider team. They may use different
terminology but allude to a clinical uncertainty of recovery – the
patient may or may not recover
Staff able to describe the AMBER care bundle well
(five staff at random) – includes relevant teams
working with the ward
When asked about their understanding of the intervention, staff are
aware that it is used to support very unwell patients who may or
may not be approaching the end of life and patients who have
clinical uncertainty, and that the aim is to have a clear plan
(medical/escalation/resuscitation) and involve patients/families in
discussions regarding care and preferences
NB flexibility is required here – staff may not all use the same
terminology depending on their individual experience, but an
awareness of the principles is the important factor
Awareness of the plan for patients receiving
care supported with the AMBER care bundle
(MDT aware, observation on handover) – what is
important to the patient and escalation plan?
At handover and when asked, senior staff demonstrate an
awareness of the patient’s current medical, escalation and
resuscitation plan. They are aware of the patient’s/family’s wishes/
preferences (e.g. PPC, who they want to care for them)
Good documentation and adherence to standards
processes. Good communication on discharge and
handover to general practitioner and community
teams (notes)
l The AMBER care bundle is filed within the medical notes. Clear
documentation on the AMBER care bundle document or within
notes to include the date, time, HCP and name of staff member
writing the information. This should include medical, escalation
and resuscitation plans and discussions with the patient and/or
family regarding current condition, plan and choices
l Discharge letters should include an explanation of condition/
uncertain recovery, the medical plan and a patient’s/family’s PPC
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Recruitment of the nurse facilitator
The trial successfully recruited a palliative care clinical nurse specialist (CNS) (NHS nursing band 8a) who
possessed extensive experience in implementing the AMBER care bundle across all the wards at another
NHS trust, with an excellent understanding of the AMBER care bundle, end-of-life care, service and quality
improvement, demonstrable knowledge and skills in advanced communication, interpersonal and leadership
qualities, an excellent understanding of the NHS infrastructure and a proven ability to think and plan
strategically.
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Chapter 3 Findings from the feasibility cluster
randomised controlled trial of the AMBER care bundle
F indings in relation to each trial objective are presented in this chapter.
Screening processes and initial approach
The screening process varied across the four trial sites. Screening, providing information about the trial,
consenting and administration of the questionnaire booklets were completed by the research nurses at all
sites. The central research team was updated on a weekly basis.
At site Con1, research nurses screened all of the patients on the trial ward at the beginning of the week
and then checked on a daily basis for recently admitted patients who may meet the trial inclusion criteria.
They then discussed these patients with clinicians and jointly agreed on each patient’s eligibility status. At
site Con2, research nurses screened the patients on a weekly basis. However, the identification of eligible
patients and introducing the trial to potential participants were generally completed by the principal
investigator and his medical colleagues. At sites Int1 and Int2, research nurses made use of the hospital
ward white boards to identify patients who were supported by the AMBER care bundle.
Participant flow
Figure 4 is the CONSORT flow diagram of participant recruitment from screening to baseline to time point
1 (3–5 days), time point 2 (10–15 days) and thenceforth to analysis. In total, 65 patients were recruited
to the trial: 29 participants in the intervention arm and 36 participants in the control arm were consented
and had completed baseline measures. We aimed to recruit a minimum of 80 participants, and were able
to successfully recruit 81.3% of this target. As the AMBER care bundle is an intervention that does not
require active participation of the patients or relatives, the intervention completion is not applicable, hence
it is not included in the CONSORT flow diagram. We had planned for recruitment to take > 3 months at
each of the trial sites, with an average of seven participants consented per month. However, we extended
the recruitment period, as the recruitment rate was slower than expected. Figure 5 presents the monthly
cumulative recruitment figures for each site (bars), the accrual rate (green line) and target accrual rate
(dashed line) over the 9-month data collection period. It should be noted that trial sites opened to
recruitment at different time points. Comparing the gradients of the targeted and achieved accrual, the
recruitment kept up with the planned rate once the initial delays and issues around understanding the trial
were overcome.
Recruitment, retention and follow-up rates
The feasibility of the recruitment strategy was examined by summarising the screening, eligibility, approach
and consent processes, reasons for non-participation and the numbers of participants involved at each stage.
Table 5 presents the number of patients screened and recruited at each of the trial sites. Recruitment took
place between June 2017 and March 2018. The challenging recruitment of participants in the control arm
of the trial is shown: only 1.9% (n = 8) and 8.9% (n = 28) of all those who were screened were recruited
at sites Con1 and Con2, respectively. At the intervention sites, recruitment was more successful: 25.0%
(n = 20) and 18.0% (n = 9) of those who were screened were recruited at sites Int1 and Int2, respectively.
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Four clusters randomly assigned
Two clusters assigned to control arm Two clusters assigned to intervention armEnrolment
Assessed for eligibility
(n = 764)
Baseline completed
(n = 36)
Loss to follow-up
(n = 0)
3–5 days completed
(n = 20)
Assessed for eligibility
(n = 130)
Excluded
(n = 728)
• Did not meet inclusion criteria, n = 647 (88.9%)
• Declined to participate, n = 7 (1.0%)
• Other reasons, n = 74 (10.1%)
Loss to follow-up
(n = 16, 44.4%)
• Discharged, n = 12 (75.0%)
• Died, n = 1 (6.25%)
• Too unwell, n = 3 (18.75%)
10–15 days completed
(n = 5)
Final number analysed
(n = 36)
Excluded from analysis
(n = 0)
Loss to follow-up
(n = 15, 75.0%)
• Discharged, n = 5 (33.3%)
• Died, n = 5 (33.3%)
• Too unwell, n = 5 (33.3%)
Baseline completed
(n = 29)
Loss to follow-up
(n = 0)
3–5 days completed
(n = 16)
Loss to follow-up
(n = 13, 44.8%)
• Discharged, n = 4 (30.8%)
• Died, n = 3 (23.1%)
• Too unwell/no NOK, n = 5 (38.5%)
• Administrative, n = 1 (7.6%)
10–15 days completed
(n = 7)
Final number analysed
(n = 29)
Excluded from analysis
(n = 0)
Loss to follow-up
(n = 9, 56.3%)
• Discharged, n = 3 (33.3%)
• Died, n = 2 (22.2%)
• Too unwell, n = 4 (44.4%)
• Lacks capacity and no NOK, n = 6 (8.1%)
• Too unwell, n = 19 (25.7%)
• Died, n = 0 (0.0%)
• Discharged, n = 13 (17.6%)
• Clinical review/tasks, n = 29 (39.2%)
• No reason given, n = 7 (9.4%)
Excluded
(n = 101)
• Did not meet inclusion criteria, n = 27 (26.7%)
• Declined to participate, n = 12 (11.9%)
• Other reasons, n = 62 (61.4%)
• Lacks capacity and no NOK, n = 14 (22.6%)
• Too unwell, n = 8 (12.9%)
• Died, n = 12 (19.4%)
• Discharged, n = 8 (12.9%)
• Clinical review/tasks, n = 12 (19.4%)
• No reason given, n = 8 (12.8%)
Baseline
3–5 days’ follow-up
10–15 days’ follow-up
Analysis
FIGURE 4 The CONSORT flow diagram. Reproduced from Koffman et al.1 ©The Authors 2019. This article is distributed under the terms of the Creative Commons Attribution
4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public
Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. This figure includes
minor additions and formatting changes to the original text.
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For site Con1, which screened 449 patients and excluded 365 as not eligible, the free-text section of the
screening logs stated ‘not at risk of dying’ for 55 (15.1%) patients, and ‘end of life’ or ‘improving’, hence
not clinically uncertain, for 21 (5.8%) patients. Other sites did not provide this information in their notes.
Participant retention during follow-up, including the number of participants withdrawing or who were lost
to follow-up (hereafter referred to as ‘dropouts’), together with the timing and reason for dropouts, is
presented by trial arm (see Figure 4).
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FIGURE 5 Monthly recruitment rate by site.
TABLE 5 Summary of numbers screened, excluded and recruited, by site
Recruitment
Site (n)
Total (n)Con1 Con2 Int1 Int2
Recruitment period (months) 4 9 6 3
Screened 449 315 80 50 894
Not eligible 365 282 22 5 674
Reasons for non-recruitment
l Lacks capacity and no caregiver 4 2 8 6 20
l Too unwell 19 0 2 6 27
l Died 0 0 7 5 12
l Discharged/discharge planned 13 0 6 2 21
l Declined 5 2 6 6 19
l Clinical review/tasks 28 1 4 8 41
l No reason given 7 0 5 3 15
Recruited 8 28 20 9 65
Reproduced from Koffman et al.1 © The Authors 2019. This article is distributed under the terms of the Creative Commons
Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution,
and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication
waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise
stated. This table includes minor additions and formatting changes to the original text.
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Data collection timing
Based on the date of admission to the trial ward and date of baseline data completion, in the intervention
wards participants completed the baseline measures a median of 10 days (range 0–50 days) after admission
to the ward, whereas in the control wards baseline measures were completed a median of 6 days (range
0–64 days) after admission to the ward. In the intervention arm, the mean number of days between the
date of being identified as an appropriate recipient of the intervention and the date of baseline questionnaire
completion was 6.0 (SD 6.8). In site Int1, the mean number of days between the AMBER care bundle
identification and baseline completion was 7.2 (SD 7.6); in site Int2, the mean number of days was 3.3 (SD 3.0).
Participant demographics
The demographic characteristics of participants by trial site (Table 6) and by trial arm (Table 7) are
presented. Participants in both trial arms were predominantly white British and married. Moreover, most
participants were either ‘living comfortably’ or ‘coping with their present level of income’. Site Con2,
located in an urban setting, had a more ethnically diverse sample profile than the other sites.
TABLE 6 Baseline participant characteristics, by trial site (N = 65)
Characteristics
Site
Con1 (N= 8) Con2 (N= 28) Int1 (N= 20) Int2 (N= 9)
Gender, n (%)
Male 15 (53.6) 15 (53.6) 8 (40.0) 3 (33.3)
Female 13 (46.4) 13 (46.4) 12 (60.0) 6 (66.7)
Age (years), n (%)
50–64 8 (28.6) 8 (28.6) 0 (0.0) 1 (11.1)
65–79 13 (46.4) 13 (46.4) 2 (10.0) 5 (55.6)
≥ 80 7 (25.0) 7 (25.0) 18 (90.0) 3 (33.3)
Age (years), mean (SD) 71.8 (11.0) 71.8 (11.0) 89.0 (5.7) 77.1 (12.0)
Education, n (%)
Did not go to school 2 (7.1) 2 (7.1) 0 (0.0) 0 (0.0)
Secondary school (GCSE/O level) 4 (14.3) 4 (14.3) 9 (45.0) 3 (33.3)
Secondary school (A level) 6 (21.4) 6 (21.4) 5 (25.0) 4 (44.4)
Vocational qualification 1 (3.6) 1 (3.6) 1 (5.0) 1 (11.1)
University 7 (25.0) 7 (25.0) 4 (20.0) 0 (0.0)
Prefer not to say 6 (21.4) 6 (21.4) 0 (0.0) 1 (11.1)
Missing 2 (7.1) 2 (7.1) 1 (5.0) 0 (0.0)
Marital status, n (%)
Single 6 (21.4) 6 (21.4) 4 (20.0) 0 (0.0)
Widowed 8 (28.6) 8 (28.6) 14 (70.0) 3 (33.3)
Married/civil partnership/long-term relationship 13 (46.4) 13 (46.4) 2 (10.0) 6 (66.7)
Divorced 1 (3.6) 1 (3.6) 0 (0.0) 0 (0.0)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
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TABLE 6 Baseline participant characteristics, by trial site (N= 65) (continued )
Characteristics
Site
Con1 (N= 8) Con2 (N= 28) Int1 (N= 20) Int2 (N= 9)
Ethnicity, n (%)
White British 10 (35.7) 10 (35.7) 19 (95.0) 9 (100.0)
Other white 1 (3.6) 1 (3.6) 1 (5.0) 0 (0.0)
White and black African 1 (3.6) 1 (3.6) 0 (0.0) 0 (0.0)
White and Asian 1 (3.6) 1 (3.6) 0 (0.0) 0 (0.0)
Other mixed 1 (3.6) 1 (3.6) 0 (0.0) 0 (0.0)
Indian 7 (25.0) 7 (25.0) 0 (0.0) 0 (0.0)
Pakistani 1 (3.6) 1 (3.6) 0 (0.0) 0 (0.0)
Other Asian 4 (14.3) 4 (14.3) 0 (0.0) 0 (0.0)
Caribbean 1 (3.6) 1 (3.6) 0 (0.0) 0 (0.0)
Other black 1 (3.6) 1 (3.6) 0 (0.0) 0 (0.0)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Income status, n (%)
Living comfortably at present 12 (42.9) 12 (42.9) 8 (40.0) 4 (44.4)
Coping on present income 10 (35.7) 10 (35.7) 5 (25.0) 4 (44.4)
Difficult on present income 0 (0.0) 0 (0.0) 4 (20.0) 1 (11.1)
Very difficult on present income 2 (7.1) 2 (7.1) 0 (0.0) 0 (0.0)
Prefer not to say 0 (0.0) 0 (0.0) 2 (10.0) 0 (0.0)
Do not know 4 (14.3) 4 (14.3) 1 (5.0) 0 (0.0)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
A level, Advanced level; GCSE, General Certificate of Secondary Education; O level, Ordinary level.
TABLE 7 Baseline participant characteristics, by trial arm
Characteristics Whole sample (N= 65)
Trial arm
Control (N= 36) Intervention (N= 29)
Gender, n (%)
Male 33 (50.8) 22 (61.1) 11 (37.9)
Female 32 (49.2) 14 (38.9) 18 (62.1)
Age (years), n (%)
50–64 10 (15.4) 9 (25.0) 1 (3.5)
65–79 25 (38.5) 18 (50.0) 7 (24.1)
≥ 80 30 (46.2) 9 (25.0) 21 (72.4)
Age (years), mean (SD) 77.8 (12.3) 71.8 (10.8) 85.3 (9.7)
Disease group, n (%)
Cancer 30 (46.2) 23 (63.9) 7 (24.1)
Non-cancer 35 (53.8) 13 (36.1) 22 (75.9)
continued
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TABLE 7 Baseline participant characteristics, by trial arm (continued )
Characteristics Whole sample (N= 65)
Trial arm
Control (N= 36) Intervention (N= 29)
Patient had capacity?, n (%)
Yes 23 (35.4) 17 (47.2) 6 (20.7)
No 42 (64.6) 19 (52.8) 23 (79.3)
Education, n (%)
Did not go to school 3 (4.6) 3 (8.3) 0 (0.0)
Secondary school (GCSE/O level) 21 (32.3) 9 (25.0) 12 (41.3)
Secondary school (A level) 15 (23.1) 6 (16.7) 9 (31.0)
Vocational qualification 4 (6.2) 2 (5.6) 2 (6.9)
University 11 (16.9) 7 (19.4) 4 (13.8)
Prefer not to say 7 (10.8) 6 (16.7) 1 (3.5)
Missing 4 (6.2) 3 (8.3) 1 (3.5)
Marital status, n (%)
Single 10 (15.4) 6 (16.7) 4 (13.8)
Widowed 26 (40.0) 9 (25.0) 17 (58.6)
Married/civil partnership/long-term
relationship
27 (41.5) 19 (52.8) 8 (27.6)
Divorced 1 (1.5) 1 (2.8) 0 (0.0)
Missing 1 (1.5) 1 (2.8) 0 (0.0)
Ethnicity, n (%)
White British 45 (69.2) 17 (47.2) 28 (96.6)
Other white 2 (3.1) 1 (2.8) 1 (3.5)
White and black African 1 (2.8) 1 (2.8) 0 (0.0)
White and Asian 1 (2.8) 1 (2.8) 0 (0.0)
Other mixed 1 (2.8) 1 (2.8) 0 (0.0)
Indian 7 (10.8) 7 (19.4) 0 (0.0)
Pakistani 1 (2.8) 1 (2.8) 0 (0.0)
Other Asian 4 (6.2) 4 (11.1) 0 (0.0)
Caribbean 1 (2.8) 1 (2.8) 0 (0.0)
Other black 1 (2.8) 1 (2.8) 0 (0.0)
Missing 1 (2.8) 1 (2.8) 0 (0.0)
Income status, n (%)
Living comfortably at present 26 (40.0) 14 (38.9) 12 (41.4)
Coping on present income 21 (32.3) 12 (33.3) 9 (31.0)
Difficult on present income 5 (7.7) 0 (0.0) 5 (17.2)
Very difficult on present income 2 (3.1) 2 (5.6) 0 (0.0)
Prefer not to say 2 (3.1) 0 (0.0) 2 (6.9)
Do not know 6 (9.2) 5 (13.9) 1 (3.5)
Missing 3 (4.6) 3 (8.3) 0 (0.0)
A level, Advanced level; GCSE, General Certificate of Secondary Education; O level, Ordinary level.
Reproduced from Koffman et al.1 © The Authors 2019. This article is distributed under the terms of the Creative Commons
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There were some notable differences between the trial arms that might influence the interpretation of our
results. First, the control arm had a higher proportion of men than women, compared with the intervention
arm. Second, most patients were aged between 65 and 79 years in the control arm and the majority of
patients were aged ≥ 80 years in the intervention arm. Third, the majority of patients had a cancer diagnosis
in the control arm, whereas most had non-cancer diagnoses in the intervention arm. The older age and
non-cancer diagnoses of the participants in the intervention arm are probably attributable to the inclusion
of two care of the elderly wards, which were located at site Int1.
Reasons for admission and morbidities
Reasons for participants’ admissions to hospital varied; the most common reason was shortness of breath,
followed by falls and confusion (Table 8). Notably, 62 out of 65 participants (95.4%) had an unplanned
admission to hospital through the emergency department. We also collected data on the presence of
participants’ morbidities (Table 9). A range of illnesses were present, the most common being circulatory
disorders, followed by neoplasms and blood disorder/endocrine disorders. Typically, patients presented
with one to four comorbidities, the mean being 2.3 per patient. Participants’ AKPS scores further indicate the
poor health status, ranging between ‘almost completely bedfast’ to ‘totally bedfast and requiring extensive
nursing care by professionals and/or family’, with mean scores at baseline being 34.2 (range 20–70) in the
control arm and 27.3 (range 10–40) in the intervention arm (Table 10).
Participant recruitment to qualitative components
Patient and relative interview demographics
In total, 24 interviews with 25 (including one dyad) patients and relatives were conducted (Table 11).
Twelve interviews were conducted in each of the intervention and control arms of the trial. The reasons for
non-participation are given in Appendix 7. In the control arm, six patients had a cancer diagnosis, compared with
just one patient in the intervention arm. In the control group, seven patients and six relatives were interviewed.
TABLE 8 Reasons for hospital admission, by trial site, trial arm and total
Reasons for hospital
admission
Site (n) Trial arm (n)
Total
(N= 65) (n)
Con1
(N= 8)
Int1
(N= 20)
Int2
(N= 9)
Con2
(N= 28)
Control
(N= 36)
Intervention
(N= 29)
Shortness of breath 0 6 4 5 5 10 15
Fall 1 4 0 3 4 4 8
Confusion 0 5 1 1 1 6 7
Infection 0 1 1 5 5 2 7
Abnormal blood test
result
0 1 1 4 4 2 6
Pain 3 2 0 0 3 2 5
Nausea/vomiting 1 1 0 2 3 1 4
Leg swelling 1 0 0 2 3 0 3
Loss of consciousness 0 0 0 3 3 0 3
Constipation 0 0 0 1 1 0 1
Reduced mobility 0 0 1 0 0 1 1
Other 1 0 0 2 3 0 3
Missing 1 0 1 0 1 1 2
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TABLE 9 Morbidities, by trial site, trial arm and total
Morbidities
Site Trial arm
Total
(N= 65)
Con1
(N= 8)
Int1
(N= 20)
Int2
(N= 9)
Con2
(N= 28)
Control
(N= 36)
Intervention
(N= 29)
Number of morbidities
Mean (SD) morbidities
per participant
2.38 (0.74) 1.84 (0.96) 2.13 (1.13) 2.29 (1.05) 2.31 (0.98) 1.93 (1.00) 2.33 (1.09)
Missing (n) 0 1 1 0 0 2 2
Number (n)
l One 1 9 3 7 8 12 20
l Two 3 5 2 11 14 7 21
l Three 4 4 2 5 9 6 15
l Four 0 1 1 5 5 2 7
Number of morbidities by International Classification of Diseases, Tenth Revision83
l Neoplasms 7 2 1 17 24 3 27
l Respiratory system 0 1 4 7 7 5 12
l Mental disorders 1 11 1 3 4 12 16
l Circulatory system 4 8 3 14 18 11 29
l Musculoskeletal 0 4 2 4 4 6 10
l Blood disorder/
endocrine
4 2 1 11 15 3 18
l Digestive system 3 2 0 3 6 2 8
l Neurological 0 4 3 4 4 7 11
l Other 0 1 2 1 1 3 4
Reproduced from Koffman et al.1 © The Authors 2019. This article is distributed under the terms of the Creative Commons
Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source,
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unless otherwise stated. This table includes minor additions and formatting changes to the original text.
TABLE 10 Descriptive results for AKPS scores at each time point, by trial arm
AKPS score
Trial arm
Control Intervention
Baseline (N = 65)
Score, n (%)
10 0 (0.0) 1 (3.5)
20 14 (38.9) 5 (17.2)
30 7 (19.4) 6 (20.7)
40 3 (8.3) 3 (10.3)
50 3 (8.3) 0 (0.0)
60 5 (13.9) 0 (0.0)
70 1 (2.8) 0 (0.0)
Score, mean (SD) 34.2 (16.2) 27.3 (8.8)
Missing, n (%) 3 (8.3) 14 (48.3)
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TABLE 10 Descriptive results for AKPS scores at each time point, by trial arm (continued )
AKPS score
Trial arm
Control Intervention
3–5 days (N = 36)
Score, n (%)
20 10 (50.0) 4 (25.0)
30 2 (10.0) 4 (25.0)
40 3 (15.0) 3 (18.8)
50 1 (5.0) 1 (6.3)
60 0 (0.0) 0 (0.0)
70 2 (10.0) 0 (0.0)
Score, mean (SD) 31.7 (16.9) 30.8 (10.0)
Missing, n (%) 2 (10.0) 4 (25.0)
10–15 days (N = 12)
Score, n (%)
20 1 (20.0) 1 (20.0)
30 1 (20.0) 0 (0.0)
40 1 (20.0) 0 (0.0)
50 1 (20.0) 1 (20.0)
60 0 (0.0) 0 (0.0)
70 0 (0.0) 0 (0.0)
Score, mean (SD) 35.0 (12.9) 35 (21.2)
Missing, n (%) 1 (20.0) 5 (71.4)
TABLE 11 Interview participants’ demographic characteristics
Characteristics
Trial arm
Control Intervention
Number of interviews 12 12
Interview participants (n)
Patient only 6 2
Patient and relative 1 0
Relative only 5 10
Interview participant ethnicity (n)
White British 9 12
Asian 4 0
Interview participant gender (n)
Female 5 9
Male 8 3
continued
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TABLE 11 Interview participants’ demographic characteristics (continued )
Characteristics
Trial arm
Control Intervention
Relationship with the patient (n)
Wife 1 1
Husband 1 1
Daughter 0 7
Son 2 1
Daughter-in-law 1 0
Brother-in-law 1 0
Patient disease group (n)
Cancer 6 1
Non-cancer 6 11
Patient age (years) (n)
50–64 3 1
65–79 3 3
80–94 6 5
95–109 0 3
Mean patient age (years) 75 84
Median patient age (years) 79 87
Patient age (years) (range) 54–88 61–98
Income (n)
Living comfortably with present income 4 5
Coping on present income 6 3
Difficult on present income 0 1
Do not know 2 2
Pension (n)
State pension 8 10
Attendance allowance 1 4
Private pension 4 2
Registered disabled 1 3
Blue badge holder 0 2
Other benefits 1 0
Missing 1 0
Interview duration (minutes)
Mean 40 43
Median 37 44
Range 20–73 17–69
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In the intervention arm, the majority of interviews were conducted with relatives. The relatively small number
of patient interviews conducted in the intervention arm of the trial is related to a higher number of older
patients, many of whom lacked the mental capacity to consent to be interviewed. The mean interview duration
was 41 minutes (range 17–73 minutes). The interviews took place at various locations including the trial
hospitals, a nursing home and the participants’ homes, and some were carried out over the telephone.
Non-participant observation characteristics
Non-participant observations of MDT meetings were conducted at three time points (at the beginning,
in the middle and towards the end of the recruitment period) at each trial ward (Table 12). At three trial
sites (Int1, Int2 and Con1), daily morning handover meetings were observed; at site Con2, discharge
co-ordination meetings, which took place once a week in the afternoon, were observed. All meetings had
a major focus on discharge. These meetings were attended by a range of HCPs, and their length varied.
The majority of the meetings were led by a senior nursing staff member.
Focus groups
In total, four focus groups were conducted with HCPs; one was conducted per trial site. The characteristics
of the HCPs who participated in the focus groups are presented in Table 13. Focus groups were well
attended by a wide range of HCPs.
TABLE 12 Non-participant observations of MDT meetings
Characteristics
Trial arm and site
Intervention Control
Int1 Int2 Con1 Con2
Number of meetings
observed
6 (3 per ward) 3 3 3
Specialties involved Geriatrics Respiratory l Haematology
l Diabetes
mellitus
l Rheumatology
l Endocrinology
Type of meeting Morning handover Board round/morning
handover
Morning handover Discharge co-ordination
meeting
Professionals involved l Consultants
l Registrars
l SHOs
l F2s
l F1s
l GP trainees
l Ward managers
l Ward sisters
l Ward matrons
l Occupational
therapists
l Physiotherapists
l Physician associates
and trainees
l Consultants
l Registrars
l F1s
l Ward sisters
l Occupational
therapists
l Physiotherapists
l Discharge
co-ordinators
l Palliative care CNS
l Research nurses
l Staff nurses
l Respiratory nurses
l Nurse facilitators
l Consultants
l Registrars
l SHOs
l F1s
l Ward sisters
l Ward matrons
l Occupational
therapists
l Physiotherapists
l Research nurses
l Consultants
l Registrars
l SHOs
l F1s
l Ward sisters
l Occupational
therapists
l Physiotherapists
l Discharge
co-ordinators
l Social workers
Number of participants
per meeting (mean)
7 10 8 7
Duration (minutes) 40 30–40 30 60
Gender ratio
(women : men)
5 : 1 3 : 1 4 : 1 4 : 1
F1, foundation year 1 doctor; F2, foundation year 2 doctor; GP, general practitioner; SHO, senior house officer.
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Feasibility of conducting trial procedures
During the focus groups, HCPs shared their insights into the conduct of the trial. Their views focused on the
following issues: (1) the inclusion criteria for the AMBER care bundle and implications for patient inclusion
in the trial, (2) modification of trial inclusion criteria, (3) trial settings, (4) resources required for recruitment
and consent, (5) patients’ and relatives’ insights into uncertainty, (6) the participant information sheet and
consent forms and (7) the perceived impact of the trial among research nurses and participants.
The inclusion criteria for the AMBER care bundle and implications for patient inclusion
in the trial
Focus group participants shared their experiences of disagreement regarding patients they believed to
be eligible for the trial. The reasons for this disagreement included confusion about the ‘middle ground’
between patients who were being ‘actively treated’ and those at ‘the end of life’. There was also a sentiment
of a power disparity between doctors and nurses, and about how the final decisions were made for patients
who could be approached for the trial. Specifically, at site Con1, the research nurse and ward sister explained
experiencing difficulty in recruitment because the concept of clinical uncertainty was not fully understood by
clinicians as being a legitimate entity in its own right. Often, doctors and nurses had contradictory views
about which patients were suitable for the trial. The following two views exemplify this situation:
I think that’s been particularly difficult in this study. I think that is why we struggled to recruit. Because
what we perceived to be a patient wasn’t certain (i.e. uncertain), was not necessarily the view of the
medical team. I think it’s either ‘We are actively treating’ or ‘End of life’ [approving ‘hmms’ in the
background from the other research nurses]. You know there’s no in-between.
Con1021, female, research nurse
TABLE 13 Focus group participant characteristics
Characteristics
Trial arm and site
Intervention Control
Int1 (n= 11) Int2 (n= 15) Con1 (n= 9) Con2 (n= 11)
Specialties
involved
Geriatrics Respiratory l Haematology
l Diabetes mellitus
l Rheumatology
l Endocrinology
Professionals
involved (gender)
l Consultant geriatrician –
ward X (F)
l Consultant geriatrician –
ward Y (M)
l Ward clerk – ward Y (F)
l Ward sister – ward Y (F)
l Ward manager (F)
l Ward manager
assistant (F)
l Physician associate –
ward X (F)
l Matron – ward X (M)
l Nurse assistant (M)
l Research nurse (F)
l Research nurse (F)
l Junior ward sister (F)
l Staff nurse (F)
l Registrar (F)
l SHO (F)
l F1 (F)
l SHO (F)
l Junior doctor (M)
l Matron (F)
l Palliative care CNS (F)
l Research nurse (F)
l Ward manager (F)
l Junior doctor (M)
l SHO (F)
l Registrar (M)
l F1 (M)
l Locum SHO (M)
l Band 5 occupational
therapist (F)
l Ward sister (F)
l Research nurse (F)
l Research
practitioner (F)
l Matron of research (F)
l Staff nurse (F)
l Palliative care
consultant (M)
l SHO (F)
l Consultant
rheumatologist (M)
l Consultant
endocrinologist (F)
l Physiotherapy
technician (F)
l Research
co-ordinator (F)
l Rheumatology
SHO (F)
l GP SHO (F)
l F1 (M)
l Registrar
rheumatologist (M)
l F1 (F)
Duration (minutes) 50 49 60 65
F, female; F1, foundation year 1 doctor; F2, foundation year 2 doctor; GP, general practitioner; M, male; SHO, senior house officer.
Reproduced from Koffman et al.1 © The Authors 2019. This article is distributed under the terms of the Creative Commons
Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution,
and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication
waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise
stated. This table includes minor additions and formatting changes to the original text.
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Or the medics would say ‘No, they’re not’. But just listening to the handovers, it was like you’d identify
everybody on the ward.
Con1018, female, ward sister
It was also evident from the research nurse perspective that despite attempting to explain their reasoning for
patient inclusion numerous times, the medical staff were not engaging and had a different understanding of
clinical uncertainty. A female research nurse stated the following:
It came to a point where we had explained it, and explained it. I think it got to a point where they
said ‘No, no they’re not eligible’.
Con1021, female, research nurse
Other views, which were shared, drew on the more subtle and subjective characteristics of clinical uncertainty,
which had implications not only for the inclusion of patients who might benefit from intervention but also for
potential recruitment of those individuals to the trial. A consultant from site Int1 believed that the concept
of clinical uncertainty should be open to more subjective assessment and was adamant that it was not an
objective measurable concept:
It’s quite subjective, but that’s probably good. If you put strict criteria, you might miss some. Like we
were saying, it’s almost like a feeling isn’t it, that someone is uncertain. It’s not this metric thing. You
know, otherwise like this is a marker of uncertainty. I quite like the fact that the criteria is . . . uncertain.
Int1013, male, consultant
Issues around the inclusion criteria extended further to the risk of dying during their episode of care
despite treatment. This criterion relied heavily on the ability to prognosticate, rather than clinical need,
which was often challenging.
There was confusion about what represented an ‘episode of care’. In site Con2, a consultant shared his
frustration in relation to his understanding of what an ‘episode of care’ implied, wanting to believe that
the patients’ and families’ understanding of an episode of care extended far beyond the experience on a
particular hospital ward:
My reflection is really, I think it’s just a bad expression; it’s the question of defining what the ‘episode of
care’ is. It’s really what’s it came down to, wasn’t it? Initially, I was told that the episode of care finishes
as the patient leaves the back door, which really isn’t true, is it? That’s the whole point of whoever is
following their care to the community, as far as a patient is concerned. I’m hoping their perception
of episode of care isn’t the ‘back door is closed, you’re in the ambulance going home and that’s it’.
Con2020, male, consultant
Concern about the ‘risk of dying’ criterion also opened up a discussion about variability in its perception
across trial sites. The same consultant believed that different HCPs might have different interpretations
about a patient’s clinical findings, which would have implications for estimating their risk of dying, rather
than focusing on their clinically uncertain recovery. He implied that the trial should either focus on all
patients where situations of clinical uncertainty exist or be more concrete about what risk of death
entailed, and how this could be interpreted with high fidelity across different trial sites:
Yeah, he was very clear; he said probably 50/50 and that’s from his experience of because they’re using
the AMBER care bundle in real life. So actually putting something like . . . well actually people will then
think, actually there is a 50/50 chance of them surviving this episode of care, actually I would’ve found
that much more helpful, because I look at their charts and I look through their organs, and the other
things like scores and you can get mortality with the score and 20% chance of dying, is that fitting you or
not really. How does that fit against the AMBER care bundle that is to be half and half, so it is difficult?
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My worry when we set out originally is what happens when that one of your study groups has an 80%
death rate and the other has 20% death rate on the other site because they just slightly differently
interpreted ‘the risk of death’. So I think being a bit more concrete about risk of death would be good.
Con2020, male, consultant
Modification of trial inclusion criteria
Patient recruitment in the control arm of the trial proved to be highly challenging. At site Con1, 55
patients were logged as ‘not eligible’ in the screening, principally because they were ‘not at risk of dying’
during their episode of care. Without appropriate education and training, research nurses and clinicians
experienced enormous difficulty interpreting this criterion. Providing the level of education and support
that was available to the intervention sites would have resulted in usual care being altered in the control
sites. Consequently, there was considerable variability in the interpretation of this criterion, with the
tendency for prognostication rather than consideration of risk. We therefore reviewed this inclusion
criterion and how it was working at the control sites across a 4-month recruitment period with our PAG,
TS DMEC and the principal investigators of both control sites. Because one of our feasibility objectives was
to examine how the trial operated under field conditions and to make changes where necessary, we made
a pragmatic decision to remove this criterion.
This change was adopted at the control sites after REC, HRA and local approvals for Substantial Amendment 6
were received (14 December 2017). We planned to monitor the effect of this change on recruitment. However,
one of the control sites (site Con1) stopped recruitment owing to challenges around this inclusion criterion
and did not have the capacity to reinitiate recruitment by the time REC, HRA and local research governance
approvals were obtained. The other control site, site Con2 recruited eight more participants after the change
in the inclusion criteria.
Trial settings
The control sites experienced a number of different challenges. It became evident from the principal
investigator of site Con1 that consultant oversight of the trial ward was a key factor to take into account
when setting up a trial. By the time the consultant on the ward had become familiar with the trial and its
requirements, he or she was replaced by a new consultant who similarly needed to be introduced to, or
reminded about, the trial:
Because there is a system where the consultant haematologist changes every week and there’s that
five or six of them, aren’t there? So, they’re there every fifth week and you know, you happen to tell
them every week about the study, remind them that the study is going on. Even the diabetologists
change every, is it 2 weeks or month?
Con1023, male, consultant
Because identification of potential participants required clinical input, engagement of HCPs on the ward
was crucial to recruitment success. A research nurse highlighted the lack of enthusiasm in relation to the
trial from the HCPs:
For the patients, I don’t think there was negative impact . . . I don’t think the staff on the ward
were keen.
Con1021, female, research nurse
Contradictorily, a research nurse located at one of the intervention sites witnessed enthusiasm for the
intervention, and for her presence in relation to recruitment and data collection. This exceeded her
expectations having come from a research background where the focus was not on older people:
So from my perspective, I’m mainly working in paediatric and reproductive health. So coming to
care of the elderly, it was completely different and it gives me a unique insight into what’s going on
the ward because I’m seeing it completely objectively. So, a few things to say . . . I was really, really
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impressed about how on board everybody was and everybody knew what AMBER was. On the
whole, generally 90% of the time people were very supportive of our presence and what we needed
to do.
Int1033, female, research nurse
Resource required for recruitment and consent
Focus group participants discussed the practicalities of identification and recruitment of potential trial
participants and the emotive and complex nature of this trial. According to one research nurse at site Con1,
they had hoped to access a larger team of research nurses to work on the trial. However, only a few nurses
were willing to attend handover meetings and be involved in patient identification and recruitment. Other
members of the research team were not comfortable working with a group of very unwell patients. For the
research nurses who did collect data, it had been a tiring process:
To start off with as a research team we did it totally different. But then it was just two members of
staff who came up every day, looking. A lot of the other staff felt uncomfortable working in this area
is if we are honest. The two who did found all the end-of-life care tiring, even though it wasn’t a
strictly end-of-life care study. The fact is that we got a paediatric nurse and a stroke nurse and they
felt a bit out of their depth.
Con1020, female, research practitioner
Other research nurses drew attention to the challenges of recruiting patients who lacked mental capacity to
consent. This was primarily because relatives who might have been able to talk about patients’ intentions
regarding their participation were often not immediately available. The ramifications of this were that
research nurses had to go back to the ward frequently:
The actual recruitment process was sometimes quite difficult because of what you said, the families
not being here. Most of the patients we approached, we had to contact the relatives because the
patients were too unwell. So being able to liaise with the families was difficult. We can’t be waiting
for the families here, so we were called back about relatives that were here and popping back and
asking the ward staff to tell us when they’re here. So the practicalities were difficult.
Int1033, female, research nurse
The non-participant observational work corroborated this concern, whereby a conversation initiated by
an occupational therapist informed the rest of the ward staff that she had made numerous attempts to
contact a patient’s wife but had yet to successfully speak to her.
Patients’ and relatives’ insight into uncertainty
On several occasions, research nurses spoke of the mismatch between some patients’ inability to comprehend
their clinical situation even though they had previously talked in detail to clinicians about the context of the
trial and their potential place within it. HCPs who had discussions with patients and relatives would assume
that the individual understood that their recovery was uncertain. However, responses that research nurses
got in relation to discussions with these patients did not always convince them that this was the case.
The following female research nurse based at site Int2 stated the following:
I’m asking someone to do something because they’re on this AMBER care bundle, because they might
get worse, or they might get better, and they say ‘Well no, I’m not going to get worse’. It’s not
convincing for them to take part in the research project really. If they haven’t got full understanding.
Int2003, female, research nurse
A registrar located at site Con2 shared a similar sentiment, although this time it was focused more on the
family members of patients who were very unwell. Although site Con2 had been reasonably successful in
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the identification and recruitment of patients, there were a few instances where it proved challenging to
discuss a patient’s situation with family members as their willingness to accept the situation was critical:
Sometimes it’s like depends on their perception, sometimes you have a patient who’s far more
advanced into the illness, whereby unable to give you a ‘Yes’ or ‘No’. So in those cases, you rely on
family and it depends on their perception of what they think. So that’s where it . . . It sometimes
becomes very tricky. But so far I think the ones who we’ve been trying to recruit, I think most of
them have been quite successful. It’s probably one or two perhaps.
Con2019, male, registrar
Participant information sheet and consent forms
Comments here focused on the excessive length and detail of the participant information sheets and the
consent forms. Although the development of the participant information sheets and other documentation
was reviewed in detail by our PPI members, a research nurse stated that, from her experience, most
individuals involved in PPI groups were notably different from the patient population we were aiming to
recruit in this trial:
All the PPI groups I’ve ever dealt with are ex-professionals or current professionals, so they are very
differently motivated group than actually in a bed, 80 years old, struggling to breathe, still got
capacity, you know, you give that to an 80 year old.
You give a four-sided A4 to somebody like. It’s very different.
Int1003, female, research nurse
The nature of the trial documents and the manner in which the trial was sometimes explained to relatives
were critical for its success. For instance, while the trial was being introduced to one relative, it became
apparent that she interpreted this to mean that the patient was at the end of life. This caused her great
distress. Although this was managed sensitively, and the individual was reassured that this was not the
case, the principal investigator at the site exemplified the unexpected consequences as follows:
The daughter of the patient told me I was ‘Dr Death’ and ‘the Grim Reaper’! They were very upset
about it and I think it was largely because they didn’t understand . . .
Con2020, male, consultant
The research nurse from site Int2 provided comments on the reality of conducting research with an
inherently unwell and unstable patient group. Radical modifications to the level of detail of the trial
documentation accompanied by a more streamlined process of explaining the trial and less burdensome
consent processes should be considered. With these changes, the research nurse believed the trial had
a much better chance of success, stating that many potential patients had been put off of the trial:
The consent process also needs to be changed. If you can get away some sort of ‘implied consent’
[would work better]. Because I’ll tell you what, this is a non-CTIMP [Clinical Trial of an Investigational
Medicinal Product], so GCP [good clinical practice] is not legal, or the medicines so MHRA [Medicines
and Healthcare products Regulatory Agency] doesn’t apply here. The law only applies to CTIMPs. So
with this, there is nothing to say, you have to get a written consent form and I think you need to be
pushing these boundaries with the ethics committees. This is why research in this specialty is not being
done. You would’ve had dozens more questionnaires completed, dozens. Why can’t when I go in to a
see a patient ask ‘Mr Smith would you mind answering some questions about your condition and how
we’ve been treating you?’. ‘Yes, no problem.’ ‘OK.’ ‘Mr Smith you do understand that you don’t have
to do this?’ ‘Yes.’ ‘You do understand that you can stop at any time.’ ‘Yes.’ So I can tick those and
start asking questions. You would’ve had an 80% completion rate.
Int2003, female, research nurse
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The design of the consent forms needs to be adjusted. There’s lots of improvement to make it easier
to get people to consent. Not in a ‘We’re trying to fool people to get them into the study’. But you
know reading the patient information leaflet for somebody who is very, very sick. It knackers them out
and that’s just day 1. Day 1, talk to them. Day 2, reading the information leaflet. Day 3, I go back to
do the consent form and they passed away or gone on to end of life, or they’re just too sick to even
contemplate doing it. And it’s quite it’s a long process to trying to read somebody a 3–4 page long
document, because they can’t read it themselves. They say read it to me, I get halfway through and
they’re falling asleep because they are so, so sick.
Int2003, female, research nurse
The perceived impact of the trial among research nurses and patients
Ward staff who were responsible for potential participants’ care believed that they may have had some
influence over patients agreeing to participate in the trial. Although some patients expressed interest
in participating in the trial to HCPs who were caring for them, when research nurses followed up, patients
declined to participate:
They didn’t want to upset me, because actually, potentially, I’ve done something to improve the quality
of their life by giving them symptom control. So they’re thinking, ‘She’s done something for me, I’ll do
something for her’. But when the researchers came along, whom they’d never met before, they said ‘no’.
Int2012, female, consultant
Although the research trial had been challenging for many of the research nurses, from consenting
potential participants to data collection among an unwell patient population, one research nurse spoke
emotively about the relationships she and her colleagues built with patients and/or their relatives during
the trial. Unlike some of the studies that they had previously worked on, they felt that the focus of the trial
provided them with a privileged position and opportunity to develop relationships with the participants.
For example, the following research nurse stated that the perceived impartiality of the trial and her
ongoing relationship with certain patients and family participants permitted them to talk frankly about
their situation, which they did not feel able to share with the HCPs. When these nurses felt that it was
appropriate, they actively encouraged these patients and families to communicate their concerns with the
HCPs caring for them so that they could be served to better effect. A research nurse stated:
I think, the same as the other researchers, worked on the study, can’t be here today, he gave us a
unique relationship with the relatives. So in a strange way, you’re in a unique position that they
talk to you about things that sometimes they feel that they can’t take forward with certain ward
staff. So we are able to encourage them into having those conversations making sure that those
communications were taking place with the ward staff if they, the family has signed society,
or certain query. So, whether because we were seen as external or whether we would able to
form a relationship over questionnaires being done at different points, I just don’t know.
Int1033, female, research nurse
Patients’ views of being involved in the trial also highlight the impact of positive relationships being
formed between research nurses and the participants as a reason for their continued involvement in the trial.
Further refinements and adaptations required for the AMBER care bundle to suit
local conditions
Qualitative trial components were used to understand if, and in what ways, the AMBER care bundle required
refinement or modification for it to work successfully in the field, prior to its formal testing in a definitive
trial. This included the focus groups held with HCPs at the intervention sites and the non-participant
observations of the MDT meetings. Refinements and adaptations required to the intervention focused on
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the following areas: (1) pragmatic interpretation of the AMBER care bundle criteria, (2) reconsidering the
daily reviews, (3) concerns about the ‘labelling’ of the intervention and (4) competences and confidence in
advanced communication skills.
Pragmatic interpretation of the AMBER care bundle criteria
A critical issue associated with the delivery of the AMBER care bundle was the inclusion criteria. HCPs shared
views on the inherent challenges associated with identifying patients using the criteria. At site Int1, two
consultants discussed that their focus was on identifying ‘situations of clinical uncertainty’ in comparison with
the criteria of being at ‘risk of dying during their episode of care despite treatment’. This suggested the need
for simplified criteria:
There are some people that we’ve been trying to go down . . . sort of get them better but they’re not
improving. I think those are the patients I kind of sort of see as uncertain or sort of unpredictable in
this recovery. They’re the ones that we identify.
Int1013, male, consultant
I think most of our patients in the elderly ward are already coming in with uncertainty, because
generally they’re aged, they’re frail, their history. So for me a lot of my patients would already be on
AMBER before they’re even come in to hospital.
Int1018, female, consultant
At site Int2, the issue of who might benefit from being supported by the AMBER care bundle was
constricted to the risk of dying. At this site, a female junior doctor explained that although many patients
were unwell, with a possibility of dying within the next several months, unless a decision was made that
this was likely to happen much sooner, they might not qualify to be supported by the AMBER care bundle.
This reiterates the issue that the criteria do not focus exclusively on a patient’s clinical need but on
prognostication:
Well sometimes it’s hard predicting whether they’ll die during this admission or when they’re going
home. So for example, they might not die in this admission, but they are at the end of life in the next
few months.
Int2019, female, senior house officer
Views shared by HCPs during the focus groups were corroborated by the non-participant observations of
the MDT meetings that took place at sites Int1 and Int2. We observed a CNS asking her colleagues if they
considered a patient as ‘being likely to die during their admission’ as part of their decision-making about
whether or not the patient should be supported by the AMBER care bundle. During the same MDT meeting,
two patients supported by the intervention were discussed in detail, yet the clinicians mentioned that they
possibly had ‘a few more months left to live’. This was inconsistent with the AMBER care bundle inclusion
criterion that states that patients should be at ‘risk of dying during their episode of care despite treatment’.
We frequently observed that the clinical team made decisions about if a patient was going to be (or continued
to be) supported by the AMBER care bundle not based on risk of dying but on their clinical morbidities,
their disease progression (e.g. late stage of dementia/Parkinson’s disease), their likelihood of responding to
medication or their ceiling of care escalation [e.g. if a patient was documented to be DNAR (do not attempt
resuscitation), HCPs mentioned this as a reason].
Incidentally, the non-participant observations on the control wards identified that clinicians were practising
‘AMBER care bundle-like’ rules of care with some of their patients. For example, one doctor was heard to
say, ‘If he [the patient] doesn’t respond to antibiotics, we should talk with his wife’. Others were observed
as listing a patient’s morbidities and deciding at a MDT meeting that the patient was considered to be frail,
with multimorbidities, and they should arrange to speak with the family. However, we did not observe
instances in which patients discussed in this manner were also discussed as being at a risk of dying during
their episode of care.
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This concern about the AMBER care bundle inclusion criterion was also demonstrated in the account of a
relative of a patient participant supported by the intervention. We identified a divergence between how
this relative viewed their loved one’s situation in comparison to the HCPs who were caring from them,
at least in relation to their decline. Despite the intervention’s intention to create awareness among HCPs
around the risk of a patient dying during the episode of care, some relatives were surprised that HCPs did
not see, or did not want to see, what relatives considered to be obvious. The daughter of a white British,
85-year-old patient participant with acute renal failure illustrated this tension:
I remember having a conversation with the doctor and saying, ‘Do you really actually think he’s going
to be discharged out of here? Because he looks like he’s a dying man to me.’. The doctor just said to
me ‘You have to be optimistic’, and I just said ‘Optimistic or realistic?’. You know.
Int1017, carer
Reconsidering the daily reviews
The recommendation for the daily monitoring and review of patients supported by the AMBER care bundle
was met with a critique. A consultant geriatrician at site Int1 clearly stated that he had accommodated the
notion of uncertainty and wanted to instil it into his team. The uncertainty was very likely to be the normal
state for many patients from one day to the next. Revisiting daily at the end of each shift to identify whether
or not they were still suitable for the intervention, whether or not there had been any medical changes and
whether or not a conversation had taken place with the patient and their family was therefore seen as
unnecessary:
I think I prefer to have the team feel that there is always an element of uncertainty. It’s unlikely that
tomorrow they won’t have any uncertainty. Because even if they recover, our patients they just go
back quickly [agreeing chatter in the background]. So I prefer the review to be less often unless there
is a drastic change in the person or you know sometimes people make a really good recovery.
Int1013, male, consultant
Building on the concern about the daily review, a junior doctor stated perceiving the overengineering
of frequent reviews and sometimes frequent conversations to be distressing for patients and families.
This may have been because some patients were frail, elderly and occasionally confused. It may also have
been due to the nature of the discussions. Regardless, some individuals were interpreting the discussions
differently, which might cause undue distress:
If you discussed it once and explained everything very well, the frequency of further discussions was
possible I felt was too high trying to say that to them every day. Again the discussion can go from
what we’re doing to make you better and then discussing the uncertainty again every day and it could
be quite distressing because a lot of our patients are elderly and going through this with them, they
just felt like ‘Oh that means I made progress. I’m well again.’.
Int2022, male, registrar
The concern surrounding the daily reviews also extended to the requirement of placing a sticker on the
patient’s clinical notes in addition to recording their ongoing situation in the notes in detail. A male
registrar said:
One thing I would dispose of are those stickers everyday about if it has been discussed with them, and
there’s a prompt for discussing there.
Int2022, male, registrar
The HCPs’ concerns around the daily review sometimes contrasted with relatives’ expectations of how
often they wanted to be kept updated about their loved one’s situation. Relatives suggested that when
they came to visit their loved ones, they did not visit just to be with them but also because they wanted
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to get an up-to-date understanding of their loved one’s clinical situation. The daughter of a white British,
89-year-old patient participant with aspiration pneumonia illustrated this point:
Yeah, well I was there every day, so I spoke to someone every day. Yes, they kept me informed. When
they were sending her home, they sat and did the form online with the nurse in charge of the ward.
Every single day I was there.
Int1011, carer
For some relatives, visiting daily and seeking out someone to learn about any developments in the patient’s
situation was far more challenging and led to frustration. The husband of a white British, 61-year-old
patient participant with multiple sclerosis said:
No, it is a little bit in the dark. You got to go and find out yourself . . . The information is not
volunteered readily. I think you got to go and find someone to try to explain it to you.
Int2008, carer
Concerns about the ‘labelling’ of the intervention
Some focus group participants raised concerns about the introduction of jargon, such as ‘AMBER’ to
patients and families. At instances, family members were confused about the terminology and did not
understand the use of the intervention in supporting their loved one. Being informed that their dependant
was being supported by the AMBER care bundle became reminiscent of the now-withdrawn Liverpool
Care Pathway for the Dying Patient,33 in which families became distressed. A junior doctor said:
We’d keep the family informed, but I think now it’s a bit confusing for the families like ‘Oh what is
this AMBER bundle? Is my relative dying?’. And they just get overwhelmed.
Int2017, female, senior house officer
Competence and confidence in advanced communication skills
Focus group participants were aware that the support of patients whose situations were clinically uncertain
often involved engaging in difficult conversations that demanded advanced communication skills. Although
the nurse facilitator provided training on the rudiments of conducting difficult conversations, there were
some HCPs, principally nurses, who were still hesitant about engaging in conversations. It was apparent that
advanced training in communication was still required to deliver the AMBER care bundle. Consequently,
some suggested that, in future, additional training should be made available to HCPs to enhance their skills
and confidence in this area of care. A ward manager said:
So I would have that conversation anyway. I wouldn’t be frightened but I know but I know some
of my nurses won’t at all. They wouldn’t talk with them . . .
Int2014, female, ward manager
Some of the HCPs’ hesitancies in having difficult conversations with patients and their families, and their
need for more training in advanced communication skills, was also evidenced in the accounts of relatives
of patients who had been supported by the AMBER care bundle. For example, during a period of a female
patient’s acute deterioration, a doctor spoke with her husband about escalation decisions and tersely
brokered information to him about her deteriorating situation. A nurse stepped in, realising how distressed
he looked on receiving the news:
But I thought that could’ve been handled a lot better. Especially when he glanced over her and said
‘Well it doesn’t look good, does it?’. And I thought ‘What are you actually saying then? You’re saying
that’s it?’ and he said ‘Anyway, I’ll give you a bit of time.’. And then a nurse stepped in and said
‘We’re not saying we’re giving up on her. We’re not at that stage yet. We are still gonna keep treating
her.’. But the way it was described to me was that was it. They’ve done as much as they could do and
if anything, else happens, that’s it. I didn’t think that’s handled well . . . Like I say, there was a lot of
activity around her and I spoke, sort of thrown and get involved to see what was happening and
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then a doctor sort of said to me ‘We need to know your wishes on resuscitation. If she has a sudden
collapse, you know stops breathing or health failure or something, do we resuscitate?’ and I thought
well that’s a question. Right, straightaway, literally as soon as I walked in the door really and they said
‘You’re the next of kin. We can’t ask [Int2008]; she’s completely unconscious. What are your views on
it?’. Well I said ‘I know what [Int2008’s] views would be’. But I thought that could’ve been handled a
lot better. Especially when he glanced over her and said ‘Well it doesn’t look good, does it?’.
Int2008, carer (husband of a white British,
61-year-old patient participant with multiple sclerosis)
Perceived acceptability of the AMBER care bundle to patients, their families and
health-care professionals
The acceptability of the AMBER care bundle was explored by analysing data from the qualitative components.
In some instances, we were also able to explore the acceptability of being supported by the AMBER care bundle
from patients’ and their relatives’ perspectives. We assessed the acceptability of the AMBER care bundle in
terms of the resources required, perceived effectiveness and benefits, understanding of the intervention,
self-efficacy of HCPs to deliver the intervention and the intervention’s fit within the team’s culture.84
Prioritisations of patients’ preferences
The HCPs welcomed the departure from solely focusing on patients’ physical symptoms and placing more
emphasis on engaging in early and important discussions with patients and their families about their
preferences, and the inherent value of documenting these discussions.
Participants stated that they believed that conversations with patients whose situations were clinically
uncertain were taking place earlier than they had previously taken place as a result of the intervention.
Conversations now included a focus on patients’ and families’ PPC and PPD, whereas previously
conversations primarily focused on physical symptoms. Moreover, they believed that the AMBER care
bundle discussions not only respected patients’ autonomy but also placed them in a better position to
realise their wishes. The following two HCPs, a physician associate and a consultant, shared these views:
It’s actually massively important to the patients, isn’t it? We didn’t appreciate it. Going more than
patients want out be out of pain, they want dignity and I think at the end of life, they want control
and some of that control is about the environment that they’re in. I think it’s about respecting that
patient’s wishes and uhmm empowering them and give them their last wishes.
Int1013, male, consultant
I think it prompted conversations earlier. Because we recognise and we’re looking for these patients,
we then initiate the conversations earlier than we may have done previously.
Int1002, female, physician associate
The relatives of patients supported by the AMBER care bundle provided accounts of how they perceived
the care. There were instances where holistic care and open and compassionate communication were
evident, which chimed with one of the intended benefits of the AMBER care bundle: a reduction in anxiety
levels. This was typified by the following accounts from the relatives of three participants:
I think it was, erm, we were very impressed, the doctors worked well, they, yes, they spent a lot of
time, in fact, in a way, erm, you could say too much time, because I think they were concerned that
my father would be upset, so they had sort of prepared themselves for a very difficult meeting,
interview, discussion . . . They were very caring in a sense, they were very concerned that he, you
know, that, about how he might react, er, and, it went fine. It was good because the conversation
was always involving him too, even though he was in bed or sometimes his hearing isn’t brilliant.
Int1001, carer (son of a white British,
98-year-old patient participant with prostate cancer)
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They couldn’t have been more helpful. They really listened to us . . . When we had meeting with the
doctors or whatever, they would say to us ‘do you have any questions?’ and they, everyone knows how
short of time everyone in the NHS is but they appeared to have all the time in the world for us, which
was very comforting. They were happy to, erm, answer as many questions as we had and to give us a
full medical explanation . . . They were very open and helpful.
Int1005, carer (daughter of a white British,
84-year-old patient participant who had a heart attack)
Yes, I have to say that the doctors, one doctor in particular, she was very good, she would take us to
another room and explain it to us and asked us if we had any questions. And she would stop to
explain to dad and to us at the bedside. She was the best doctor there because she could
communicate with you and she could come down to like dad’s level of comprehension.
Int1003, carer (daughter of a white British,
96-year-old patient participant who had a heart attack)
However, a number of relatives of participants were disappointed with the lack of appropriate and
thoughtful discussions, which they felt were in their dependants’ best interests. The step-daughter of a
white British, 92-year-old patient participant who had multiple fractures stated that her family’s views
about the patient were never adequately canvassed. Moreover, when they were involved in discussions,
the discussions appeared to be conducted in a manner that merely informed them about what was
happening, often without consideration of their understandably heightened emotions. This was despite the
family appreciating that what was planned was probably appropriate:
No, absolutely nothing . . . We weren’t asked anything about our preferences for her care in the future
. . . We were told rather than asked by a consultant a week or ago that they wouldn’t uhm . . . they
wouldn’t do anymore to her. Now, I felt I mean I agree with that, but I felt that he said it in such a
way that ‘Well, we won’t do it’ [what we wanted]. Never mind what you’re thinking . . .
Int1016, carer
The daughter of a white British, 96-year-old patient participant who had a heart attack stated that although
care was provided to her father, she felt that her concerns and questions regarding his care were often
dismissed. Moreover, she believed that the HCPs avoided her and were not particularly interested in
engaging with the family despite their daily presence on the ward:
You know they sort of ‘poo pooed’ what I was saying . . . The doctors took care of him and but there
could’ve been more communication I think, really. We wanted more communication. We were there
every day, so there was no reason why they did not stop and speak to us. They did at the end and
realised that we were obviously interested in his care and what happened to him uhmm but yeah too
many times, they could’ve stopped and spoken to us.
Int1003, carer
Involvement of health-care professionals in the decision-making process and teamwork
At the intervention sites, care and treatment decisions about patients with clinical uncertainty were made
with the involvement of the MDT. A consultant stated that although it was the doctors who were perceived
as being pivotal in the patient’s care, the views of other professional groups also contributed towards
patient-centred decisions. This illustrates the acceptability of the ‘distribution of decision-making process’
among all HCPs, which is a component of the AMBER care bundle:
So it’s an MDT decision, because sometimes you know we as doctors, you know we go in, we see the
patient on a ward but we’ve not been caring for the patient. HCAs [health-care assistants], everyone,
everyone is involved in the decision.
Int1018, female, consultant
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Instances of enthusiastic teamwork were observed during the handover meetings. At site Int2, we
witnessed a range of HCPs contributing to discussions about patients’ suitability for the AMBER care
bundle. This suggested acceptability of the identification part of the intervention and showed that the
team understood its potential in helping patients and their families. This observation was slightly tempered
by a number of HCPs, who required the nurse facilitator or the consultant to occasionally prompt them to
consider potential patients who might benefit from the AMBER care bundle.
Joint acceptance and teamwork were also observed at site Int1. During a morning handover meeting,
when the usual consultant was not available, a colleague from an adjoining ward stepped in to help.
During this instance, we observed a number of HCPs informing him about the intervention and carefully
explaining the various steps they took when making decisions about which patients were suitable for the
intervention. Moreover, talking through the intervention components appeared to be natural and well
rehearsed. During this discussion, a number of professionals volunteered information to the other team
members about the progress of particular patients they were caring for. Moreover, they also told them
they were trying to get hold of close relatives to explain to them the patient’s situation and condition.
Another example of enhanced teamwork was observed when the MDT made clinical decisions together
and prioritised understanding the preferences of patients who were supported by the AMBER care bundle.
A MDT (a physiotherapist, the ward sister and a consultant) discussed in detail the decision of whether or
not to continue to actively treat an elderly patient. They also wanted to discuss the implications of this
decision with the patient and learn more about his/her preferences. However, the consultant importantly
mentioned that this could not happen before they comprehensively assessed the patient’s mental capacity
(which is also highlighted in the AMBER care bundle tool).
Participants’ and their relatives’ perspectives on decision-making processes varied. We identified a number
of instances where the views of focus group participants closely corroborated those provided by relatives
of patients supported by the AMBER care bundle. For example, they spoke about the various ward staff
being closely aligned in getting to know the patients, their thinking about a patient’s situation and their
actions regarding care. They spoke of this as being akin to being ‘on the same page’. This is illustrated by
the following two comments:
They all seemed to get on very well, yes. All on the same wavelength and saying the same things.
Yeah when they sent her home there was an OT [occupational therapist], and he came to the house.
The doctor phoned. The nurses made sure she had her cuddly toy with her. They all seemed to
group together.
Int1011, carer (daughter of a white British,
89-year-old patient participant with aspiration pneumonia)
They did work well together, I felt, yeah it was a very nice atmosphere on the ward. I mean everybody,
for example, the swallowing team and then physio[therapy], and then there was [name of the
geriatrician] and [name of the physician associate], and mostly the same nurses who got to know
mum, so, I think, there was definitely, erm, a good atmosphere.
Int1002, carer (daughter of a white British,
91-year-old patient participant with Alzheimer’s disease)
For a relative of a patient who had experienced less-satisfactory care in other parts of the hospital prior to
their admission to the intervention ward, good teamwork was particularly welcome. The following account
illustrates her sentiments:
Ward Y was particularly good from the point of view that they did seem to have some very good
support of staff from the point of view of the physiotherapist, the occupational therapist there. It was
quite a relief to go on to ward Y and suddenly everybody was planning what they were and how it
DOI: 10.3310/hta23550 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 55
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Koffman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
47
was going, and um, you know a care plan was actually made for her. And so yeah from that point of
view it was they kind of stepped up a notch.
Int1018, carer (daughter of a white British,
95-year-old patient participant with mixed dementia)
Nevertheless, there were times when teamwork was not evident and had negative repercussions for patient
care. The daughter of a white British, 84-year-old patient who had a heart attack (Int1005C) mentioned that
many of the HCPs had been very considerate and caring, exemplified by the comment ‘They couldn’t have
been more helpful . . . very kind’, but she then explained that her father had been in receipt of unnecessary
tests by the same HCPs who may not have been aware of the de-escalation for his clinical situation:
Sometimes we’d have people coming to do his blood pressure, erm, and his temperature and when
I mentioned to this, to, erm, the consultant geriatrician at ward X, she was notably irritated because
people had been instructed not to monitor him and they’d gone back to monitoring, I think, well
for whatever reason, lack of communication.
Int1005, carer (daughter of a white British,
84-year-old patient participant who had a heart attack)
Relatives appreciated the challenge of clinical uncertainty but felt that more could be done to keep them
in the loop of ‘not knowing’. In the following case, a relative had to take it upon themselves to seek out
answers, often from different doctors. The husband of a white British, 61-year-old patient participant with
multiple sclerosis stated:
No, it is a little bit in the dark. You got to go and find out yourself. I don’t . . . the information is not
volunteered readily; I think you got to go and find someone to try to explain it to you. I suppose it’s a
. . . just explanations could’ve been a bit better I suppose but . . . I think once they made up their mind
that it was a chest infection, then everyone was heading towards the chest infection for treatment
but before that it was a bit inconsistent because there was a lot of doctors with a lot of opinions.
Yes, I can. I think that’s the bit that could have been handled better.
Int2008, carer (husband of a white British,
61-year-old patient participant with multiple sclerosis)
Inconsistencies in sharing information were at times frustrating for some relatives. Relatives appreciated
that treatment plans may change as necessary; however, these changes in treatment plans were not
always shared with them in a timely manner. In the following case, the wife of a white British, 70-year-old
patient participant with corticobasal degeneration became confused by the mixed messages from various
HCPs about her husband and began to question her own recollection of what had happened. This might
have amplified her distress:
One would said one thing, and one would say another, and so it was a little bit like, what’s really
happening? What’s going on? Erm, because if they had changed their minds and then I most probably
hadn’t been told or heard, do you know what I mean?
Int2012, carer (wife of a white British,
70-year-old patient participant with corticobasal degeneration)
Although our findings from the focus groups and non-participant observations shed light on the acceptability
of the AMBER care bundle, we did not observe the MDT meetings prior to implementation of the intervention.
Therefore, it is difficult to identify the impact of the AMBER care bundle on teamwork and shared decision-
making. Final decisions regarding patients’ care and their treatment are the consultants’ responsibility. Seeking
information about patients and taking the MDT members’ views into consideration could depend on the
individual consultant. The AMBER care bundle provides a platform for HCPs from various disciplines to share
their input about patients whose situations are clinically uncertain. Our findings support the intended benefit of
the intervention: enabling the sharing of information for decision-making among HCPs. However, we cannot
confidently conclude whether or not the decisions were shared.
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The value and simplicity in documenting discussions with patients
Participants expressed views on the value of talking openly with patients about their situation and having a
clear plan. The devised plan is beneficial for other HCPs to understand and act on participants’ preferences
for care, while acting as an aide-memoire for the person who devised the plan. In a busy ward environment,
it could be easy to overlook or to forget important issues without a clear plan. The following core medical
trainee voiced this view:
It makes you think about communication and especially when you’re busy and you focus on the
medical aspect of it, you [then] remember that we promised the communication with the family.
Int2007, male, specialty registrar–core training 1
The documentation that accompanied the conversations was not perceived as a burden, which is important
for HCPs who would be using it:
I think the documented discussion is very important. For the purposes of out of hours, we know the
patient during the day and we have the conversations with the family and it’s there documented.
At night, they know what the plan is . . . the escalation plan. I think that’s paramount really.
Int1018, female, consultant
This was amplified when HCPs could see that, overall, the document was simple to complete, a departure
from many that had been used in the past. A junior doctor illustrates this view:
I think the simplicity of the paperwork itself is good. Because it actually doesn’t . . . we hate paper
work. I think keep the simplicity of the paperwork.
Int2017, female, senior house officer
Delivery of care preferences
Where it was possible, the intervention required HCPs to engage in open conversations with patients
about their situation and discuss their PPC and in some instances PPD. If HCPs were not honest during
conversations about the feasibility of care and treatment options, patients may verbalise preferences that
could not be delivered. This highlights the need for allocating adequate time for preparing for these
conversations to ensure that the intervention is not causing distress. The following consultant suggested
that conversations had the potential to disappoint patients when the system was not able to deliver:
We are . . . giving the patients the impression that we can give them what they want but then not
being able to give them what they want. This may disappoint them.
Int1013, male, consultant
Acceptability of inclusion criteria
The HCPs questioned the acceptability of the current inclusion criteria. They felt that modification of the
inclusion criteria from ‘patients being at risk of dying in the next 1 to 2 months’ to ‘risk of dying during
their episode of care despite treatment’ meant that a reduced number of patients would benefit from the
support of the intervention. Although the inclusion criteria are acceptable, alteration of the ‘risk of dying’
criterion might limit their utility. A female consultant stated:
Previously, when I used it before, this was what we talked about before, wasn’t it? [To EY] It was the
2 months or so and obviously they changed it, which meant that now we put less people on AMBER.
Int1018, female, consultant
Long-term acceptability of the AMBER care bundle
In order to operate and sustain the intervention over time, HCPs would need to make critical decisions
about (1) who would be the ‘the AMBER care bundle champion’ and (2) what could be de-prioritised to
create time for the bundle’s sustainability. HCPs considered the intervention acceptable while they received
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support from the nurse facilitator; however, they questioned the sustainability of the intervention without
dedicated support. A female ward sister said:
The trouble is everyone has so many other responsibilities. Whereas the nurse facilitator’s role was to
come in and to facilitate that. So she could focus on that. Whereas everyone else, if you’re asking
someone else to take that role on, that’s not going to be their only focus. I feel like it needs someone
to drive it.
Int1014, female, ward sister
Active ingredients of the AMBER care bundle to be maintained for intervention fidelity
for a definitive trial
To determine the active ingredients of the AMBER care bundle, we explored the perspectives of HCPs from
the focus groups, the perspectives of participants and their relatives from interviews and our observations
of MDT meetings. The following themes emerged from our analysis: (1) the value in the identification of
patients whose situations were clinically uncertain, (2) the routinisation of active engagement and discussion
with patients and relatives, (3) the documentation of patient-centred plans, (4) the daily review and
re-engagement with patients and (5) the role of the nurse facilitator.
The value in the identification of patients whose situations were clinically uncertain
The AMBER care bundle inclusion criteria were cited as being critical in prompting HCPs to actively
consider patients on the ward who might benefit from the intervention. The following physician associate
explained that, whereas previously this particular patient group had been absent from the clinical radar,
now they had assumed a greater priority in the line-up of daily tasks:
I think for me it [the criteria] bumped it up the priority list, if that makes sense with jobs. Whereas
before, it wasn’t highlighted as much . . . I think having conversations with families and updating
them. I think what the AMBER care bundle really helped for me was the advance care planning side of
doing things.
Int1002, female, physician associate
This finding was corroborated by the observations, where we witnessed discussion among MDTs about
patients who fell into three main groupings: those who were acutely unwell, those who were deteriorating
and, importantly, those whose recovery was uncertain. Regarding this last group, we often witnessed
descriptions of patients as being ‘inbetween-y’ or those who were ‘up and down’.
The routinisation of active engagement and discussion with patients and relatives
Engagements with patients and families became routinised into the daily clinical practice of staff on the
intervention wards. One female ward manager stated that although similar conversations with patients like
this had previously taken place, the intervention prompted the HCPs to actively seek and prioritise these
patients as part of standard practice:
We always recognised them but it became more embedded in our daily board round discussion about
highlighting those patients and making a priority that we’re having those conversations but we would
think to have those conversations with the relatives when they come in next whereas it’s be more of a
we ask them to come in to have the discussions. So we were being more proactive about having those
conversations rather than waiting.
Int1022, female, ward manager
We also witnessed instances when HCPs talked about patients who were supported by the AMBER care
bundle, their PPCs and their families’ understandings of their situations. For example, we observed a
conversation at site Int1 in which a HCP had discussed in detail the situation of a recently admitted patient
with the patient’s daughter, who had unrealistic expectations about her mother’s recovery. Discussion
moved on to how this conversation had progressed, taking on board the daughter’s views and what she
FINDINGS FROM THE FEASIBILITY CLUSTER RANDOMISED CONTROLLED TRIAL OF THE AMBER CARE BUNDLE
NIHR Journals Library www.journalslibrary.nihr.ac.uk
50
considered to be her PPC for future care. Furthermore, at site Int2, when the nurse facilitator prompted
the team to consider a patient to be supported by the AMBER care bundle, she discovered that the team
had already identified the patient in question and had spoken in detail with her family.
Documentation of patient-centred plans
The documentation of conversations with patients and families and the development of a clinical plan
were perceived to be an active ingredient of the intervention. This ensured transparency among team
members. It was particularly useful for staff who worked out of hours, who would have otherwise been
less knowledgeable about a patient’s situation. A female consultant and a male trainee doctor shared their
perspectives:
I think the documented discussion is very important . . . Oh for the purposes of out of hours, we know
the patient during the day and we have the conversations with the family and it’s there documented
and this is what we’ll do if they become unwell or whatever. If they get called at night, then they
know what the plan is, the escalation plan. I think that’s paramount really.
Int1018, female, consultant
The AMBER care bundle . . . sort of encourages you to have the discussions you wouldn’t have, and
then it formalises it in a plan that can be followed by other colleagues. It’s there in writing and we’re
requested to engage with that process.
Int2007, male, specialty registrar–core training 1
Documentation of plans and discussions is also intended to provide continuity of the information shared
with patients and families by different HCPs. The following example highlights the importance of clear
and detailed notes to ensure the correct flow of information to patients and relatives. The instance below
highlights the importance of clear and detailed notes to ensure the correct flow of information to patients
and relatives. It is here that some study participants suggested that the training that accompanied the
AMBER care bundle placed enormous emphasis on understanding their concerns rather than being be
delivered in a ‘tick-box’ manner. A white British, 65-year-old patient with motor neurone disease who was
supported by the AMBER care bundle at the time of the interview stated the following when asked about
the consistency of the information he receives:
Interviewer: OK, so it became clearer over time. So when you first got admitted, they weren’t that
clear and then it got clearer?
Int2009: Ask questions as we go.
Interviewer: So you ask questions as you go?
[He had a notepad that he used to communicate with the staff. He was not able to communicate
verbally. He showed the interviewer all the questions he had asked before in his notepad.]
Interviewer: OK, so do you think that you’re getting consistent information from all the doctors and
nurses or does it change or differ sometimes?
Int2009: Occasionally different. Like a drug this morning. The nurse said no I am not for that drug.
I questioned that. I was right.
Daily review and re-engagement with patients
Although initial discussion with patients and/or their relatives was considered to be an important ingredient
in supporting their care and treatment, the subsequent re-engagement component of the intervention was
also considered crucial. This took place daily and required the team to review whether or not a patient’s
clinical uncertainty was still ongoing (whether they had deteriorated or improved). Re-engagement with
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the patients served two main purposes: checking the clinical uncertainty/AMBER care bundle status of the
patient, which was fed back to the team for daily review, and following up about their requests, concerns
and preferences highlighted during the initial discussion. Whereas follow-up conversations previously
occurred on an ad hoc basis, the intervention required the HCPs to review and re-engage in conversations
with the patient and their family throughout their admission. This helped the HCPs to understand how the
patient’s situation and their preferences changed in the intervening time. The following core medical trainee
stated that this drip-feed effect of continuing to address issues and engage with them had the benefit of
improving overall communication:
So previously we might have discussed it with the family when they come in initially. Obviously, the
admitting doctor is different to the ongoing team and then there may be ‘Oh someone else has talked
about it, we won’t need to re-engage with it’, but I think with AMBER care bundle, because they have
you have to keep discussing with patient, etc., it does encourage with this process of re-engagement
with the family and therefore it probably does improve the communication with the family.
Int2007, male, specialty registrar–core training 1
The HCPs were also observed discussing the clinically uncertain recovery of the patients who were supported
by the AMBER care bundle during their daily handover meetings. In the following instance, a patient who
was currently supported by the AMBER care bundle had started to recover and the team were reconsidering
mobilising him. The ward manager was noted to say ‘He’s no longer AMBER’ and then made sure that
that the letter ‘A’ (indicative of being supported by the AMBER care bundle) was removed from the white
board next to his name.
The role of the nurse facilitator
Although not considered to be a component of the intervention, a number of focus group participants
spoke in positive terms about the critical role the nurse facilitator played in implementing the intervention
both on wards and in supporting staff in its delivery to relevant patients and their families. The facilitator
should be seen as an ‘active ingredient’ in the delivery of the intervention because achieving the intended
benefits would be highly challenging, if not impossible, without her presence. According to the HCPs, she
prompted them to think about issues that previously would not have been identified until the last days of
life. She also supported the staff at critical moments, for instance when reflecting on the emotive challenges
of having difficult conversations with patients and their families. The following male medical consultant and
female ward manager explained:
I think the nurse facilitator showed that it works having someone like that. Two phrases that always
stick to my mind were ‘preferred place of care’ and ‘preferred place of dying’ which is not something
I would think about for a patient probably until we got to the discharge stage. Now, it’s sort of when
I’ve seen the patient and identified that they’re AMBER, it’s almost uhm you know I kind of address
that sooner so I guess that’s been a good thing.
Int1013, male, consultant
I was just going to say, having a dedicated facilitator helped the staff in having those conversations
and supported them with the practical aspects of AMBER.
Int1022, female, ward manager
Our findings from the non-participant observations corroborate the views regarding the importance of
the nurse facilitator in the delivery of the intervention. We observed at numerous points that the nurse
facilitator encouraged and prompted HCPs to discuss patients’ day-to-day needs and to critically consider
their clinical uncertainty. Typically, at handover meetings, the list of patients on the ward was briefly
discussed by different HCPs. The following dialogue illustrates the role of the nurse facilitator in directing
discussion towards thinking in what ways the AMBER care bundle might be appropriate for a patient.
Patient 6 was briefly discussed and a junior doctor stated ‘We made him palliative’. This was followed by
a discussion between the palliative care CNS and the junior doctor about whether or not they felt that he
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might die during that admission. After fielding the discussion between the two HCPs, the nurse facilitator
summarised the situation by stating that the patient ‘sounded AMBER’ to her and an escalation plan was
required. We also observed the nurse facilitator stating ‘She looks quite fail. She’s 90 years old. She looks
AMBER, looking at her notes. COPD [chronic obstructive pulmonary disease] and vascular dementia.’.
Other HCPs discussed in what ways the patient could be supported.
At other points during the same meeting, the fast pace of discussion was interrupted to focus in more
detail on a patient’s situation. The nurse facilitator’s role in ensuring the intervention’s fidelity was evident:
she was heard to say ‘Also still AMBER?’, to which the consultant replied ‘She’s not. She has definitely
stabilised.’. A junior doctor stated ‘She came off [AMBER]’. The facilitator then reminded the team that
they must now document the patient’s new clinical status regarding the AMBER care bundle in her notes.
She was similarly noted to have told the team that when writing a discharge letter about a patient supported
by the AMBER care bundle, they should remember to clearly state the patient’s clinical situation and the
escalation decisions that had been made previously.
Overall, our findings suggest that a dedicated facilitator for the AMBER care bundle is needed to
ensure that HCPs are trained, supported and prompted to consider all components of the intervention
regularly.
Compliance with and barriers to the delivery of the AMBER care bundle
First, we examined the extent to which the five key components [(1) documentation of a medical plan
(current key issues, anticipated outcomes), (2) documentation of an escalation plan, (3) a medical plan
discussion and agreement with nursing staff, (4) discussion with patient/family and documentation of the
discussion and (5) daily review of the patient’s clinically uncertain recovery] associated with the delivery of
the intervention were fulfilled by looking at the clinical notes of the participants recruited in the intervention
arm of the trial. Documentation of these components enabled HCPs to learn about a patient’s situation and
act on them. Second, the focus groups with HCPs, held on the intervention wards, explored views on the
components of the intervention that they believed were central to its success in supporting patients. Last,
we drew on the findings from the non-participant observations of the MDT meetings.
The review of the clinical notes identified acceptable compliance in relation to the delivery of the five
components (Table 14). It is possible that there were also instances when tasks may have been carried out
but were not recorded, which has implications for the staff caring for and supporting these patients and
their families. Moreover, we also identified that in many instances tasks were not recorded within the
required 12-hour window stipulated by the AMBER care bundle guidance.
TABLE 14 Compliance with the components of the intervention as evidenced in the participants’ clinical notes
Site
Compliance with component, n (%)
Discussion with
patient/family
held and
documented
Medical
plan (current
key issues,
anticipated
outcomes)
Escalation plan
documented
Medical plan
discussed and
agreed with
nursing staff
Daily
review
All completed
within 12 hours
Int1 (N = 20) 18 (90) 18 (90) 16 (80) 18 (90) 8 (40) 5 (25)
Int2 (N = 9) 6 (67) 7 (78) 7 (78) 6 (67) 6 (67) 5 (56)
Total (N = 29) 24 (83) 25 (86) 23 (79) 24 (83) 14 (48) 10 (35)
Time of the components was not recorded in the patients’ notes, hence it was not possible to check whether the
components were completed within 12 hours or not. Components were accepted as completed if they were completed on
the same day.
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Availability of relatives and health-care professionals
Participants in the focus groups stated that a large number of patients who had clinical uncertainty were
elderly, confused and lacking mental capacity. Engaging in conversations about their situation with them
was often challenging and not always possible. It was in the patients’ best interests that timely discussions
took place with their relatives to better understand the patients’ preferences. However, relatives were
not always available when required, and when they did come in, for example at the weekend, key staff
familiar with their circumstances were often not present on the ward. The following ward manager made
this clear:
Sometimes the families are not available. So a lot of the time we have some patients who come and
their relatives don’t always come or they come in the weekend, or they come in the evening and
then there aren’t the people [HCPs] there to have those conversations with them. So, I suppose the
challenges on our ward, our patients have confusion or have dementia, and quite often those relatives
are not on that same page necessarily . . .
Int1022, female, ward manager
The non-participant observations on the intervention wards corroborate this concern in relation to the
unavailability of family members. For example, we witnessed a discussion about a patient’s wife who was
receiving chemotherapy, and therefore would not be available to come in that day to have a discussion.
In another case, a relative was not fully aware that her mother had dementia, and a significant time would
need to be allocated to talk through the dementia diagnosis before it was reasonable to discuss her loved
one’s situation of clinical uncertainty.
Communication skills and emotional labour
Focus group participants spoke in detail about communication being central in delivering important
information to patients and their families. Communication skills are also critical for understanding patients’
concerns and worries and how they could be resolved. Participants believed that good communication
was dependent on the possession of well-honed skills and confidence in having difficult conversations.
Some consultants reported that they were experienced in this area, illustrated by the following comment:
It’s our bread and butter and we understand, we are better would you say, not better, better is not
the right word but we’re a bit more . . . we can have those conversations.
Int1018, female, consultant
This was reiterated by other medical staff who felt that the intervention was acceptable as they already
possessed the skills and knowledge required for the delivery of the AMBER care bundle components,
such as the identification of clinical uncertainty and communication:
I think a lot of our . . . at least the medical side of it, a lot of our training has been around medical
ethics, communication, breaking bad news, so it’s kind of drilled into us from the get go, I’ll probably
say it’s a large part of our training.
Int1013, male, consultant
However, other HCPs, particularly nurses, stated that skills and confidence related to having difficult
conversations were not necessarily equally shared. The following ward manager stated:
I think from a nursing point of view, for the junior staff to have some more kind of advanced
communication training about you know breaking bad news and having those difficult conversations.
Because for a lot of us it comes with experience and I don’t think you were saying in the doctors’
training there’s a lot of focus on it, the nursing training there isn’t.
Int1022, female, ward manager
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The emotive context in which discussions regarding clinical uncertainty are required to take place was
highlighted as a potential barrier to the delivery of the AMBER care bundle by some junior doctors. A ward
manager reiterated this concern, suggesting that there is a need to engage in clinical supervision to support
the staff involved in emotive discussions. This concern was challenged by the lack of protected time required
to debrief and discuss what had potential to have a negative impact on the staff. The following two
quotations illustrate these issues:
Broaching it with the family. It’s quite negative with the patients with uncertainty . . . we have to
discuss the end-of-life care, DNACPR [do not attempt cardiopulmonary resuscitation]. So it’s hard to
make it a positive thing that we are gonna keep with treatment and then nothing changes with taking
care, if that make sense.
Int2023, male, foundation year 1
I mean it is a very emotive subject and you’re at the front of it. You know the relatives can take their
frustration out on you uhmm so I think it is important that we all support each other with that and
you know, having some kind of clinical supervision would be excellent. Because then as a team,
we don’t ever have protected time to have a debrief, or discuss the difficult situations.
Int2022, female, ward manager
Some of the HCPs’ hesitancies around having difficult conversations with patients and their families,
and their need for training in advanced communication skills, were also evidenced in the interviews with
relatives of patients who had been supported by the AMBER care bundle. For example, during a period of
acute deterioration, the husband of a patient recounted how tersely a doctor had spoken to him about his
wife’s clinical situation and the consequent escalation decision.
Candidate primary outcome measures
Completion rates for all the patient/proxy responses to the questionnaires, as well as missing item-level data,
are summarised at each of the data collection time points. In this section, missing data are classed as a
category in their own right, and all percentages are calculated using the total number of participants expected
in the relevant population as the denominator (i.e. including participants with missing data for that variable).
Missing outcome measures data
Table 15 presents the level of missing data for the IPOS patient/family anxiety and communication subscale
for those participants who continued in the trial from baseline to subsequent time points. The level of
missing data for each of the IPOS symptoms, at all three time points, are also presented (see Appendix 9).
Notably, the numbers of missing data were relatively small, with very few people choosing ‘I don’t know’,
indicating that the participants could report outcomes using the IPOS.
Table 16 reports the level of missing data for the howRwe. The howRwe is a patient-only-reported
measure of their experience of care and was not supplemented by proxies, such as a relative or close
friend. For those who completed this measure, completeness of data could be considered to be very good,
with virtually no missing data at all three time points.
Missing participant demographic data
Completion rates for all participants’ responses to the outcome measures, as well as missing item-level
data, are summarised at each time point. Within this section of the analysis, missing data are classified as a
category in their own right and all percentages are calculated using the total number of participants in the
relevant population.
Characteristics of participants with missing outcome data
We described the factors with regard to the levels of missing data for the IPOS. In Table 17, we identified
that the only meaningful factor associated with missing data was the hospital site. Sites Int1 and Con2 had
more missing data at baseline and 3–5 days than the other two sites.
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Descriptive analyses of primary outcome measures
Exploratory analysis of patient primary outcomes for the patient/family anxiety and communication subscale of
the IPOS and the howRwe are reported in Table 18 as descriptive statistics (means and 95% CIs) for each of the
measures at each of the three time points. We also provide the descriptive statistics for the patient/family
anxiety and communication subscale of the IPOS and the howRwe by trial arm (see Appendix 10). Table 18
presents the descriptive analysis of the two measures for those participants with data at each of the time points.
This feasibility trial was not intended to be powered to detect differences in outcome measure scores, only
to understand to what extent the measures were able to identify to what extent the support provided by
the AMBER care bundle to patients whose situations were clinically unstable differed to best standard care.
In this section, we present tables comparing the IPOS patient/family anxiety and communication subscale
and the howRwe scores across the two trial arms. Subsequent tables examine each of the measures in
more detail to explore their ability to capture data across their respective domains of interest.
TABLE 15 Missing data level from participant self-reported outcome measure (IPOS patient/family anxiety and
communication subscale)
Trial time point Item
Completeness, n (%)
Complete
‘Cannot
assess’
‘I don’t
know’ Missing
Baseline (N = 65) Feeling anxious and worried 57 (87.7) 6 (9.2) 0 (0.0) 2 (3.1)
Friends and family feeling anxious and worried 65 (100.0) 0 (0.0) 0 (0.0) 0 (0.0)
Feeling depressed 60 (92.3) 5 (7.7) 0 (0.0) 0 (0.0)
Feeling at peace 62 (95.4) 2 (3.1) 0 (0.0) 1 (1.5)
Sharing feelings with family and friends 61 (93.9) 3 (4.6) 0 (0.0) 1 (1.5)
Being informed 55 (84.6) 9 (13.9) 0 (0.0) 1 (1.5)
Resolving practical issues 61 (93.9) 4 (6.2) 0 (0.0) 0 (0.0)
Total 49 (75.4) 12 (18.5) 0 (0.0) 4 (6.2)
3–5 days (N = 36) Feeling anxious and worried 31 (86.1) 4 (11.1) 0 (0.0) 1 (2.8)
Friends and family feeling anxious and worried 34 (94.4) 0 (0.0) 1 (2.8) 1 (2.8)
Feeling depressed 32 (88.9) 2 (5.6) 0 (0.0) 2 (5.6)
Feeling at peace 32 (88.9) 2 (5.6) 0 (0.0) 2 (5.6)
Sharing feelings with family and friends 32 (88.9) 2 (5.6) 1 (2.8) 1 (2.8)
Being informed 32 (88.9) 3 (8.3) 0 (0.0) 1 (2.8)
Resolving practical issues 32 (88.9) 3 (8.3) 0 (0.0) 1 (2.8)
Total 26 (72.2) 7 (19.4) 1 (2.8) 2 (5.6)
10–15 days (N = 12) Feeling anxious and worried 12 (100.0) 0 (0.0) 0 (0.0) 0 (0.0)
Friends and family feeling anxious and worried 11 (91.7) 0 (0.0) 1 (8.3) 0 (0.0)
Feeling depressed 12 (100.0) 0 (0.0) 0 (0.0) 0 (0.0)
Feeling at peace 12 (100.0) 0 (0.0) 0 (0.0) 0 (0.0)
Sharing feelings with family and friends 11 (91.7) 0 (0.0) 1 (8.3) 0 (0.0)
Being informed 12 (100.0) 0 (0.0) 0 (0.0) 0 (0.0)
Resolving practical issues 12 (100.0) 0 (0.0) 0 (0.0) 0 (0.0)
Total 11 (91.7) 0 (0.0) 1 (8.3) 0 (0.0)
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TABLE 16 Missing data level from participant self-reported outcome measure (howRwe)
Trial time point Item
Completeness, n (%)
Complete Missing ‘Not applicable’
Baseline (N = 24) Treating you kindly 24 (100.0) 0 (0.0) 0 (0.0)
Listening and explaining 24 (100.0) 0 (0.0) 0 (0.0)
Seeing you promptly 24 (100.0) 0 (0.0) 0 (0.0)
Well organised 24 (100.0) 0 (0.0) 0 (0.0)
Total 24 (100.0) 0 (0.0) 0 (0.0)
3–5 days (N = 12) Treating you kindly 11 (91.7) 1 (8.3) 0 (0.0)
Listening and explaining 11 (91.7) 1 (8.3) 0 (0.0)
Seeing you promptly 11 (91.7) 1 (8.3) 0 (0.0)
Well organised 11 (91.7) 1 (8.3) 0 (0.0)
Total 11 (92.7) 1 (8.3) 0 (0.0)
10–15 days (N = 4) Treating you kindly 4 (100.0) 0 (0.0) 0 (0.0)
Listening and explaining 4 (100.0) 0 (0.0) 0 (0.0)
Seeing you promptly 4 (100.0) 0 (0.0) 0 (0.0)
Well organised 4 (100.0) 0 (0.0) 0 (0.0)
Total 4 (100.0) 0 (0.0) 0 (0.0)
TABLE 17 Descriptive characteristics of patients with missing IPOS patient/family anxiety and communication
subscale data at each time point
Characteristics
Time point, missing data
Baseline (N= 16) 3–5 days (N= 10) 10–15 days (N= 1)
Site, n (%)
Con1 3 (18.8) 2 (20.0) 0 (0.0)
Int1 6 (37.5) 3 (30.0) 0 (0.0)
Int2 1 (6.3) 0 (0.0) 0 (0.0)
Con2 6 (37.5) 5 (50.0) 1 (100.0)
Gender (male), n (%) 8 (50.0) 6 (60.0) 1 (100.0)
Age (years), mean (SD) 78.3 (14.5) 77.7 (13.4) 78.0a
Disease (non-cancer), n (%) 10 (62.5) 8 (80.0) 1 (100.0)
Education, n (%)
Did not go to school 2 (12.5) 1 (10.0) 0 (0.0)
Secondary school (GCSE/O level) 6 (37.5) 3 (30.0) 0 (0.0)
Secondary school (A level) 2 (12.5) 3 (30.0) 1 (100.0)
Vocational qualification 1 (6.3) 0 (0.0) 0 (0.0)
University 3 (18.8) 2 (20.0) 0 (0.0)
Prefer not to say 2 (12.5) 1 (10.0) 0 (0.0)
continued
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The mean IPOS patient/family anxiety and communication subscale score at baseline was 13.1 (i.e. within
the moderate range). This remained fairly consistent across time points (mean score of 13.8 at 3–5 days and
13.2 at 10–15 days). Although the howRwe scores changed across time points, it is not possible to speculate
whether or not this change is clinically significant. Furthermore, owing to a high rate of attrition between
time points, it is not possible to know if the patients who were lost to follow-up would show a change in
their scores based on the communication and care received from the HCPs and their levels of anxiety.
TABLE 17 Descriptive characteristics of patients with missing IPOS patient/family anxiety and communication
subscale data at each time point (continued )
Characteristics
Time point, missing data
Baseline (N= 16) 3–5 days (N= 10) 10–15 days (N= 1)
Marital status, n (%)
Single 2 (12.5) 2 (20.0) 0 (0.0)
Widowed 7 (43.8) 3 (30.0) 0 (0.0)
Married/civil partner/long-term relationship 7 (43.8) 4 (40.0) 0 (0.0)
Divorced 0 (0.0) 1 (10.0) 1 (100.0)
Ethnicity, n (%)
White British 11 (68.8) 7 (70.0) 1 (100.0)
Other mixed 1 (6.3) 1 (10.0) 0 (0.0)
Indian 2 (12.5) 2 (20.0) 0 (0.0)
Other Asian 1 (6.3) 0 (0.0) 0 (0.0)
Other black 1 (6.3) 0 (0.0) 0 (0.0)
Income, n (%)
Living comfortably at present 9 (56.3) 4 (40.0) 0 (0.0)
Coping on present income 1 (6.3) 3 (30.0) 1 (100.0)
Difficult on present income 1 (6.3) 0 (0.0) 0 (0.0)
Prefer not to say 1 (6.3) 0 (0.0) 0 (0.0)
Do not know 2 (12.5) 2 (20.0) 0 (0.0)
Missing 2 (12.5) 1 (10.0) 0 (0.0)
A level, Advanced level; GCSE, General Certificate of Secondary Education; O level, Ordinary level.
a n = 1; no SD.
Note
Characteristics not assessed for participants with missing howRwe data as only one patient had missing howRwe data
(at time point 3–5 days).
TABLE 18 Descriptive analysis of participant self-reported outcomes
Participant-reported outcome
Time point, mean score (95% CI)
Baseline 3–5 days 10–15 days
IPOS patient/family anxiety and communication
subscalea
13.1 (11.9 to 14.2)
(n = 50)
13.8 (12.3 to 15.4)
(n = 26)
13.2 (10.1 to 16.3)
(n = 11)
howRweb 12.9 (11.8 to 14.0)
(n = 23)
13.5 (11.9 to 15.0)
(n = 11)
13.3 (9.7 to 16.8)
(n = 4)
a In the IPOS patient/family anxiety and communication subscale (and symptoms), a higher score is worse for patients.
For the subscale, there are seven items scored 0–4; possible score ranges from 0 to 28.
b In the howRwe, a higher score is better. Four items are scored from 1 to 4; possible score ranges from 4 to 16.
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Focusing on participants with data available at baseline and 3–5 days (n = 24), scores on the IPOS patient/family
anxiety and communication subscale slightly increased, indicating poorer outcomes for patients (Table 19).
Scores on the howRwe (n = 10) suggested a slight improvement in patients’ care. The discrepancy in the
direction of change for these outcome measures may be explained by a large number of relatives completing
the IPOS patient/family anxiety and communication subscale, in contrast to the patient self-reported
howRwe measure.
Interviews with patients and relatives who were supported by the AMBER care bundle provided contextual
information about the overall experience of participants. Although some participants reported receiving
excellent communication from the clinical team, others highlighted the overall complexity of the situation, and
their anxieties around discharge from hospital, which could explain the slight increase in the IPOS patient/family
anxiety and communication subscale during participants’ hospital stays. Below, the quotation from a relative
of a patient who received care at site Int1 provides support for how proxy-completed outcomes might have
had an influence in the increase in IPOS patient/family anxiety and communication subscale scores:
We were very impressed, the doctors worked well, they, yes, they spent a lot of time, in fact, in a way,
erm, you could say too much time, because I think they were concerned that my father would be
upset, so they had sort of prepared themselves for a very difficult meeting, interview, discussion, and
my father said ‘oh well that’s fine’ he sort of said ‘well I’m not surprised, I’ve had my time, it doesn’t
bother me whether it’s 3 months, 6 months’ and the doctor sort of said ‘look we need, we are going
to try and make your last few months as comfortable as possible so, you know’ and he was, he was
fine, I, for me it is a bit of a shock, when you consider he’s been there for all of my life.
Int1001, carer
In the following quotation, another relative of a patient who received care at site Int1 praised the care
provided while expressing her concerns around discharge:
My anxiety levels absolutely rocketed because I just wanted him to stay comfortable in hospital where
the care was fantastic, but as they said, and I’d been reassured, well it had been reaffirmed to me
from people I know that no the hospital won’t keep you in if you’re stable.
Int1005, carer
The comparison of primary outcome scores at baseline across trial arms showed that we were able to
recruit similar patient populations (Table 20). Both groups scored at a relatively moderate range on the
IPOS patient/family anxiety and communication subscale. It is not possible to make valid interpretations
about the changes in the scores of the howRwe measure because only two participants completed this
measure in the intervention arm.
TABLE 19 Descriptive analysis of participant self-reported outcomes for participants with data at baseline and
3–5 days
Participant-reported outcomes
Time point, mean score (95% CI)
Baseline 3–5 days 10–15 days
IPOS patient/family anxiety and communication
subscale (n = 24)
13.3 (11.3 to 15.4) 14.0 (12.3 to 15.6) 12.8 (9.4 to 16.2)a
howRwe (n = 10) 12.8 (11.1 to 14.5) 13.5 (11.8 to 15.2) 13.3 (9.7 to 16.8)b
a n = 10.
b n = 4.
Adapted from Koffman et al.1 © The Authors 2019. This article is distributed under the terms of the Creative Commons
Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated. This table includes minor additions and formatting changes to the original text.
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In Table 21, the scores of each howRwe item are presented by trial arm. In both trial arms, participants
rated being treated kindly by the HCPs as ‘good’ to ‘excellent’, whereas being organised was perceived as
less satisfactory. The small number of patients who had capacity to complete this self-reported outcome
measure limits our ability to interpret scores over time.
TABLE 20 Descriptive analysis of participant self-reported outcomes for participants with data at baseline and
3–5 days, by trial arm
Primary outcome measures
Time point, mean (95% CI)
Baseline 3–5 days 10–15 days
IPOS patient/family anxiety and communication subscale (n = 24)
Control (n = 12) 13.3 (10.3 to 16.4) 13.3 (10.9 to 15.8) 10.3 (7.5 to 13.2)a
Intervention (n = 12) 13.3 (10.1 to 16.6) 14.6 (12.0 to 17.2) 13.9 (8.9 to 18.8)b
howRwe (n = 10)
Control (n = 8) 13.1 (11.1 to 15.2) 13.9 (11.8 to 16.0) 14 (9.0 to 19.0)c
Intervention (n = 2) 11.5 (N/A) 12.0 (N/A) 11 (N/A)d
N/A, not applicable.
a n = 3.
b n = 7.
c n = 3.
d n = 1.
TABLE 21 The howRwe item scores, by trial arm
Item
Trial arm, mean score (95% CI)
Control Intervention
Baseline (control, n = 17; intervention, n = 7)
Treating you kindly 3.7 (3.5 to 3.9) 3.7 (3.3 to 4.2)
Listening and explaining 3.4 (3.0 to 3.8) 3.4 (2.9 to 3.9)
Seeing you promptly 2.9 (2.4 to 3.4) 3.1 (2.3 to 4.0)
Well organised 2.8 (2.3 to 3.4) 3.1 (2.3 to 4.0)
3–5 days (control, n = 8; intervention, n = 3)
Treating you kindly 3.8 (3.4 to 4.1) 3.3 (1.9 to 4.8)
Listening and explaining 3.5 (2.9 to 4.1) 3.0 (N/A)
Seeing you promptly 3.3 (2.5 to 4.0) 3.0 (N/A)
Well organised 3.4 (2.8 to 4.0) 3.0 (N/A)
10–15 days (control, n = 3; intervention, n = 1)
Treating you kindly 3.7 (2.2 to 5.1) 3.0 (N/A)
Listening and explaining 3.7 (2.2 to 5.1) 4.0 (N/A)
Seeing you promptly 3.3 (1.9 to 4.8) 2.0 (N/A)
Well organised 3.3 (1.9 to 4.8) 2.0 (N/A)
N/A, not applicable.
FINDINGS FROM THE FEASIBILITY CLUSTER RANDOMISED CONTROLLED TRIAL OF THE AMBER CARE BUNDLE
NIHR Journals Library www.journalslibrary.nihr.ac.uk
60
Although findings from howRwe indicate ‘good’ to ‘excellent’ experience outcomes, and qualitative data
corroborating these findings were recorded, contradictory instances were also obtained from the interviews
with patients and relatives. On some occasions, patients and relatives from both intervention sites and
control sites felt dismissed and not listened to. The following quotations from a patient participant who
was cared for at site Con2 and from a relative of a patient who received care at site Int2 illustrate instances
of poor hospital experience:
They just didn’t acknowledge me at all and by that time I had had it, I had it from 6 in the morning
from these two, I’m thinking I gotta, and I let rip, I was like ‘Would you two effin’ listen to me, I’ve
had enough of this since I got here at 6 o’clock you’ve been nothing but rude, you’re ignoring not
only me but all the other patients that really need help, that can’t stick up for themselves, that can’t
ask for things themselves’ and they still wouldn’t answer.
Con2002
You know, if you’re saying something, I find this very much with the NHS, that they don’t listen.
To them you’re a layman, you don’t know what you’re talking about. You know, uhmm they know
how to treat, they have the training, they know it but they don’t listen to the relatives. The relatives
do know that patient and what they might want or they might not want. What they need.
Int1003, carer
In Table 22, the scores of each IPOS patient/family anxiety and communication subscale item are presented
by trial arm. When asked about how the patient participant was feeling over the previous 3 days, scores
indicated that the concerns they selected for each item were experienced either ‘occasionally’ or
‘sometimes’, with the exception of friends and family experiencing ‘anxiety and worries’ ‘most of the time’.
Baseline scores indicate that participants in both trial arms experienced some issues that had potential to
be addressed by the intervention. With the exception of slight differences across time points, scores
remained relatively stable for each arm. The trial data do not enable us to draw conclusions regarding the
measures’ responsiveness to capture the impact of the intervention. Friends’ and families’ ‘anxiety and
worry’ remained relatively high; this was consistent across both arms.
Although participants reported scores about patients’ concerns as experiences ‘occasionally’ or ‘sometimes’,
several interviews with participants indicate acceptance of their clinical situation. For instance, when asked
about how they were feeling, patients from site Con2 who were interviewed during their hospital stay
replied with short answers:
I’m alright, I’m in good care. Fine . . . none . . . no complaints.
Con2021
Yeah I’m OK. What can you do? What will happen, will happen.
Con2024
Detailed descriptive analysis of each of the IPOS symptoms identifies that ‘weakness or lack of energy’,
‘pain’ and ‘poor appetite’ were perceived to be concerns for participants in both arms of the trial
(see Appendix 8).
Preliminary effectiveness of the AMBER care bundle
Based on data available from our outcome measures, we cannot draw conclusions about differences
between arms. Despite this, our outcome measures indicate that patients experienced moderate levels of
anxiety and worry, as expected with this population. In comparison, the perceived experiences of anxiety
and worry for family members were consistently higher during the hospital stay for both trial arms.
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Choosing the primary outcome measure for a definitive trial
The primary aim of a definitive trial would be to observe a clinically important difference in the outcome and
the experience of care between (1) those supported by the AMBER care bundle and (2) those supported by
standard care. We selected two ‘candidate’ primary outcomes to be evaluated for a future definitive trial:
the patient/family anxiety and communication subscale of the IPOS55 and the patient-reported experience
measure, the howRwe.63 The IPOS patient/family anxiety and communication subscale, although not
powered to detect differences in this feasibility trial, showed variance and change over time, which indicates
that it will probably detect the differences required as the primary outcome measure in a definitive trial.
The completeness of the data and the acceptability of the howRwe measure were good; however, this is
a patient-only-reported measure, which reduces the utility of the tool. Further exploration is needed to
determine whether or not proxy data collection is feasible for this measure. The primary end point of the
trial was at time point 1 (3–5 days), at which 44.6% of participants were lost to follow-up.
TABLE 22 The IPOS patient/family anxiety and communication subscale item scores, by trial arm
Item
Trial arm, mean score (95% CI)
Control Intervention
Baseline
Feeling anxious and worried 2.2 (1.5 to 2.8) (n = 32) 1.8 (1.3 to 2.3) (n = 25)
Friends and family feeling anxious and worried 3.3 (3.0 to 3.7) (n = 36) 3.1 (2.7 to 3.5) (n = 29)
Feeling depressed 1.6 (1.0 to 2.1) (n = 35) 1.7 (1.2 to 2.2) (n = 25)
Feeling at peace 1.7 (1.3 to 2.2) (n = 33) 2.3 (1.8 to 2.8) (n = 29)
Sharing feelings with family and friends 1.6 (1.0 to 2.1) (n = 33) 1.7 (1.2 to 2.2) (n = 28)
Being informed 1.6 (1.0 to 2.1) (n = 32) 1.9 (1.4 to 2.4) (n = 23)
Resolving practical issues 1.8 (1.2 to 2.3) (n = 33) 1.9 (1.2 to 2.5) (n = 28)
3–5 days
Feeling anxious and worried 2.1 (1.3 to 2.9) (n = 18) 1.8 (1.07 to 2.6) (n = 13)
Friends and family feeling anxious and worried 3.4 (3.0 to 3.9) (n = 18) 2.8 (2.1 to 3.4) (n = 16)
Feeling depressed 1.5 (0.8 to 2.2) (n = 17) 1.7 (0.8 to 2.5) (n = 15)
Feeling at peace 2.4 (1.6 to 3.2) (n = 16) 2.4 (1.8 to 3.0) (n = 16)
Sharing feelings with family and friends 1.4 (0.6 to 2.2) (n = 17) 2.3 (1.5 to 3.1) (n = 15)
Being informed 1.4 (0.7 to 2.1) (n = 19) 2.0 (1.1 to 2.9) (n = 13)
Resolving practical issues 1.8 (0.9 to 2.7) (n = 16) 1.9 (1.1 to 2.7) (n = 16)
10–15 days
Feeling anxious and worried 1.6 (0.2 to 3.0) (n = 5) 1.9 (0.7 to 3.0) (n = 7)
Friends and family feeling anxious and worried 3.5 (2.6 to 4.4) (n = 4) 3.1 (2.3 to 4.0) (n = 7)
Feeling depressed 1.0 (–0.2 to 2.2) (n = 5) 1.7 (0.6 to 2.9) (n = 7)
Feeling at peace 2.2 (–0.1 to 4.4) (n = 5) 2.1 (0.9 to 3.4) (n = 7)
Sharing feelings with family and friends 1.8 (–1.5 to 5.0) (n = 4) 2.0 (1.2 to 2.8) (n = 7)
Being informed 1.0 (–0.5 to 2.5) (n = 5) 1.6 (0.7 to 2.5) (n = 7)
Resolving practical issues 2.4 (–0.3 to 5.1) (n = 5) 1.4 (0.4 to 2.5) (n = 7)
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During the focus groups, HCPs also shared their views on the candidate primary outcome measures.
When asked whether or not the proposed measures could capture the intended benefits of the AMBER
care bundle on patient outcomes, a research nurse raised an important point about the potential bias due
to involvement of hospital staff in data collection. The following discussion illustrates views on the IPOS
patient/family anxiety and communication subscale and howRwe:
Int2003, female, research nurse: I think the howRwewill give you better feedback about communication.
It’s difficult though. ‘Are we treating you well?’Well I’m a health-care professional sat in front of them.
That’s kind of . . . that’s question is a little bit loaded, do you knowwhat I mean? You know, when
somebody stood there, kind of servicing your car ‘Are you happy with our service?’. Well you got my car
or do you knowwhat I mean, my dog in your hands. ‘Yeah, yeah I’m happy.’ That question, I don’t
know . . . A bit biased because I’m sat there asking this question.
Jonathan Koffman: And the IPOS bits? Do you think those might be things that move in a different
direction as a result of AMBER?
Int2003, female, research nurse: No. Because of I think the underlying anxiety from their condition.
This is just another admission in a series of admissions. This isn’t, you know our communication
in one admission isn’t going to change their anxiety and the fact that this is their third admission
in a year, they’re struggling to breathe more and more, how’s gonna take care . . . you know several
of our patients are carers for their husbands or wives with dementia. Who’s gonna look after them?
Who is gonna look after the dog? I’m supposed to be doing . . . I’m gonna miss my daughter’s
wedding. These are . . . AMBER care isn’t gonna make to that scoring. It’s overall gonna give a better
satisfaction of the care they’re receiving on this ward, but to their overall well-being I would give it a
3% importance. The other 95–97% of their concerns is about everything else that is going on. This is
what I got from the patients.
Another research nurse commented on the potential utility of collecting data regarding patients’ symptoms
and concerns (referring to IPOS):
Con2022, female, research co-ordinator: They, OK if they completed the patient outcome measures,
they are more conscious, like if they’re in pain, they can actually justify that, how much is the pain.
It’s more about their consciousness.
Catherine Evans: OK, so being able to articulate ‘How much pain I’m in?’ because we’re asking them
to tick.
Con2022, female, research co-ordinator: Yeah and their concerns when here.
Sample size
The screening and recruitment data, the attrition rate, the completeness of outcome measures and the
size and context of each cluster obtained in this trial will provide useful information to guide future sample
size calculations. We were not able to calculate the intracluster correlation coefficient because of the
insufficient number of clusters.
Acceptability of trial length and time points
The screening to recruitment rate and time needed to inform and consent potential participants showed
that a 3-month recruitment period was not adequate. We found out that the majority of the potential
participants lacked capacity and required availability of a proxy to participate in the trial. In a future trial,
more time should be allocated to familiarising the local research and ward staff about the trial as the
number of recruited participants per month increased once the trial was embedded and queries about the
trial procedures were addressed. Data collection at 10–15 days (time point 2) was not feasible owing to
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high attrition (81.5% of participants). A suggestion to overcome loss to follow-up due to discharge may
be to recruit participants earlier (i.e. closer to their hospital admission). By recruiting the participants earlier
during their hospital stay, data collection at 10–15 days may be feasible and the outcome measures may
be able to detect changes over time.
Descriptive analysis of views on being involved in the trial
Participants with sufficient mental capacity were asked to provide their views on being involved in
the trial. The findings in Table 23 identify that no patient participant regarded their involvement in the trial
as being negative. Only one participant in the control arm stated that they were not happy to complete
this questionnaire (no further reason provided). Free-text comments highlighted that participants were
happy to take part in the trial. Specifically, some stated that this was due to the positive interaction with
the research nurses. This is typified by the following free-text comment: ‘the research coordinator is very
polite and explained everything about the study’ (Con2014). Some stated that it was due to their sense
of altruism, believing that their involvement would help others and improve services, illustrated by the
following free-text comment: ‘If you can help others, then it’s worth doing’ (Int2007). A number of
participants also recommended that other patients take part in the trial, reiterating that their involvement
would ‘help others’. The views of proxies’ (i.e. personal consultees of patients who lacked capacity)
participation in the trial were not within the scope of the trial, as a patient-reported measure was used
to capture this data.
TABLE 23 Views on being involved in the trial, by trial arm and for all participants
View
Experience of being involved
in the trial, n (%)
Would recommended the trial
to other patients, n (%)
Control Intervention Total Control Intervention Total
Baseline N = 17 N = 6 N = 23 N = 17 N = 6 N = 23
Positive 7 (41.2) 3 (50.0) 10 (43.5) 9 (52.9) 4 (66.7) 13 (56.5)
Neutral 5 (29.4) 3 (50.0) 8 (37.8) 0 (0.0) 0 (0.0) 0 (0.0)
Negative 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Don’t know 2 (11.8) 0 (0.0) 2 (8.7) 5 (29.4) 1 (16.6) 6 (26.1)
Missing 3 (17.6) 0 (0.0) 3 (13.0) 3 (17.6) 1 (16.6) 4 (17.4)
3–5 days N = 8 N = 3 N = 11 N = 8 N = 3 N = 11
Positive 1 (12.5) 2 (66.6) 3 (27.3) 4 (50.0) 3 (100.0) 7 (63.6)
Neutral 3 (37.5) 1 (33.3) 4 (36.4) 0 (0.0) 0 (0.0) 0 (0.0)
Negative 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Don’t know 2 (25.0) 0 (0.0) 2 (18.2) 2 (25.0) 0 (0.0) 2 (18.2)
Missing 2 (25.0) 0 (0.0) 2 (18.2) 2 (25.0) 0 (0.0) 2 (18.2)
10–15 days N = 4 N = 0 N = 4 N = 4 N = 0 N = 4
Positive 2 (50.0) N/A 2 (50.0) 3 (75.0) N/A 3 (75.0)
Neutral 1 (25.0) N/A 1 (25.0) 0 (0.0) N/A 0 (0.0)
Negative 0 (0.0) N/A 0 (0.0) 0 (0.0) N/A 0 (0.0)
Don’t know 1 (25.0) N/A 1 (25.0) 1 (25.0) N/A 1 (25.0)
Missing 0 (0.0) N/A 0 (0.0) 0 (0.0) N/A 0 (0.0)
N/A, not applicable.
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Health economics and cost-effectiveness of the intervention
The objective of the health economics component of the trial was to examine differences in the use of
financial resources between the intervention and standard care arms. An auxiliary objective was to explore
the feasibility of conducting a cost-effectiveness analysis of the AMBER care bundle.
Data on resource use were collected using the CSRI,71,72 which measured the use of health care, social
care and informal care 3 months prior to the hospital admission, at the baseline interview and during the
inpatient stay in hospital at 10–15 days. The EQ-5D-5L73 was used to measure health-related quality of life
both at baseline and at the follow-up interviews.
The descriptive statistics of service use showed that use was within plausible ranges; for example, length of
stay in hospital did not exceed 3 months (Table 24). Patients interviewed at 10–15 days reported the use
of investigations/tests and the informal care provided, but health services were not used.
TABLE 24 Health and social care use and informal care provision for the previous 3 months recorded at the
baseline interview
Service use
Trial arm
Control Intervention
N
Users Use
N
Users Use
n % Mean SD n % Mean SD
Overnight stay
Intensive care unit 36 6 17.0 4.2 5.4 29 0 0.0 N/A N/A
Inpatient ward 36 22 61.0 10.8 10.2 29 15 52.0 22.3 25.9
Hospice 36 3 8.0 60.0 N/A 29 0 0.0 N/A N/A
Nursing home 36 2 6.0 3.0 N/A 29 1 3.0 76.0 N/A
Residential home 36 2 6.0 69.5 13.4 29 4 14.0 55.0 29.8
A&E 36 15 42.0 1.9 1.1 29 12 41.0 1.8 1.7
Emergency ambulance 36 15 42.0 1.9 1.3 29 13 45.0 1.5 0.7
Outpatient
Palliative care 36 4 11.0 2.0 0.8 29 1 3.0 1.0 N/A
Radiotherapy 36 7 19.0 2.0 1.2 29 0 0.0 N/A N/A
Oncology clinic 36 13 36.0 2.5 1.5 29 1 3.0 2.0 N/A
Other appointment 36 12 33.0 2.5 1.4 29 6 21.0 2.0 1.3
Hospital transport ambulance 36 2 6.0 12.5 16.3 29 4 14.0 7.3 5.6
GP face to face 36 28 78.0 2.7 1.6 29 25 86.0 3.4 2.6
GP on the telephone 36 24 67.0 2.9 1.2 29 17 59.0 2.6 2.5
Nurse
Marie Curie (London, UK) 36 4 11.0 1.3 0.5 29 1 3.0 2.0 N/A
Macmillan Cancer Support (London, UK)
or palliative care
36 9 25.0 3.4 2.3 29 1 3.0 1.0 N/A
Other 36 4 11.0 1.5 0.7 29 3 10.0 1.0 0.0
continued
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TABLE 24 Health and social care use and informal care provision for the previous 3 months recorded at the
baseline interview (continued )
Service use
Trial arm
Control Intervention
N
Users Use
N
Users Use
n % Mean SD n % Mean SD
Palliative care or ‘hospice at home’ team 36 7 19.0 3.0 2.6 29 0 0.0 N/A N/A
Physiotherapist 36 8 22.0 2.4 0.9 29 7 24.0 2.5 1.9
Occupational therapist 36 6 17.0 2.0 1.1 29 6 21.0 2.4 1.5
Psychiatrist 36 0 0.0 N/A N/A 29 0 0.0 N/A N/A
Psychologist or counsellor 36 3 8.0 1.7 1.2 29 0 0.0 N/A N/A
Spiritual care person 36 0 0.0 N/A N/A 29 3 10.0 6.3 3.8
Social worker 36 5 14.0 3.5 4.4 29 0 0.0 N/A N/A
Paid formal carer 36 4 11.0 90.0 0.0 29 13 45.0 20.7 24.0
Dietitian 36 9 25.0 1.8 0.7 29 4 14.0 3.0 2.6
Voluntary service 36 1 3.0 0.0 N/A 29 0 0.0 N/A N/A
Other professionals 36 4 11.0 1.0 0.0 29 2 7.0 35.5 48.8
Investigation/diagnostic tests
Blood test 36 35 97.0 13.8 8.7 29 18 62.0 5.6 6.5
X-ray 36 28 78.0 3.3 3.8 29 13 45.0 2.7 1.1
Echocardiogram 36 9 25.0 1.5 0.5 29 5 17.0 1.0 0.0
Electrocardiogram 36 20 56.0 1.9 1.0 29 10 34.0 1.2 0.4
Ultrasound 36 17 47.0 1.5 0.8 29 3 10.0 1.5 0.7
CT/CAT scan 36 27 75.0 1.8 1.0 29 7 24.0 1.2 0.4
Magnetic resonance image 36 13 36.0 1.6 0.9 29 1 3.0 2.0 N/A
Other 36 17 47.0 4.3 6.0 29 7 24.0 1.2 0.4
Informal care (hours)
Personal care 36 20 56.0 30.9 44.8 29 15 52.0 16.3 29.6
Help with medical procedures 36 18 50.0 8.4 5.6 29 12 41.0 5.5 9.2
Help inside the home 36 24 67.0 6.6 4.3 29 17 59.0 6.5 4.2
Help outside the home 36 25 69.0 8.3 6.9 29 17 59.0 2.3 1.4
Time spent ‘on call’ 36 13 36.0 26.5 51.7 29 11 38.0 48.2 68.6
Other 36 4 11.0 4.7 2.5 29 4 14.0 7.3 9.5
EQ-5D index score 33 N/A N/A 0.00 0.33 28 N/A N/A –0.08 0.14
A&E, accident and emergency; CAT, calibrated automated thrombography; CT, computerised tomography; GP, general
practitioner; N/A, not applicable.
Reproduced from Koffman et al.1 © The Authors 2019. This article is distributed under the terms of the Creative Commons
Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated. This table includes minor additions and formatting changes to the original text.
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Responses to the five items in the EQ-5D-5L were used to generate the index score for each patient and
each time point. Theoretically, the index score ranges from 0 (death) to 1 (full health), but some EQ-5D-5L
profiles are evaluated as below zero, implying that the individual considers her or his current quality of life
as worse than death.
Missing data
For health and social care service use variables, < 5.0% of data were missing at baseline and 100% of data
were missing at follow-up, except for the investigations/tests, which means that nobody reported health and
social service use between baseline and 10–15 days. Less than 9.0% of data for informal care items were
missing at baseline and 0% were missing at follow-up. Three out of 33 participants in the control arm and
1 out of 29 participants in the intervention arm did not complete all five items of the EQ-5D-5L at baseline.
Three out of five remaining participants in the control arm and all (n = 7) remaining participants in the
intervention arm completed all five items at follow-up.
Intervention costs
Implementation costs, which form part of the intervention costs, could be obtained from the diary kept
by the nurse facilitator (NHS band 7), who worked for 6 months preparing and implementing the
intervention. The nurse facilitator recorded details of her work (e.g. preparation of materials for staff at the
intervention site, travel, meetings with staff, communication with the research team and writing case
notes). Senior management was provided by an associate with expertise in quality improvement and was
focused in the earlier months of the nurse facilitator’s work. This diary also recorded each of the meetings
held at the intervention sites, for example the duration of meetings, the types and grades of participants at
the meetings and a short description of the discussion at the meeting.
Resource use in participating sites was extracted from the nurse facilitator’s diary (see Appendix 11). The
nurse facilitator had meetings with individual HCPs or joined the regular MDT meetings. Individualised
meetings were arranged depending on the availability of HCPs and their needs for implementing the AMBER
care bundle. At the introduction stage, the AMBER care bundle meetings were devoted to teaching, case
review, discussion and evaluation, but as the bundle was embedded, it was discussed at the MDT meetings
as part of the routine activities.
Sites Int1 and Int2 had differences in the types of HCPs and time spent on the AMBER care bundle‘s
implementation, which may reflect differences in characteristics of each hospital, such as staffing, care
provision, types of patients and catchment population. Many activities in site Int1 happened during the
MDT meetings, and HCPs other than doctors and nurses (health-care assistants, clinical social workers,
physiotherapists and occupational therapists) were involved in care provision. Implementing the intervention
in site Int2 necessitated more individualised contacts with HCPs in addition to the MDT meetings.
Summary
It was feasible to collect the data on health and social care service use, informal care provision and quality
of life at baseline and at 10–15 days (see Appendix 12). Missing values in the data were not problematic
(< 9.0%). However, health service use at follow-up could be replaced by exploring patients’ medical
records assuming that all patients stay in wards. Costs associated with care service use would then be
obtained using unit costs for each service item and opportunity costs (e.g. minimum salaries).
Implementation costs are only part of the real intervention costs because changes in time and effort from
HCPs cannot be accurately captured. Thus, implementation costs can be considered as the minimum of the
actual intervention costs that we could measure. A diary recorded by the nurse facilitator in the central
research team successfully tracked the resource use in intervention sites. A predetermined format of the diary
could be developed with the prior information on the participating sites in future studies. Implementation
costs would be calculated by combining HCPs’ time and salaries in addition to the nurse facilitator’s salary
and supervision during the trial period.
DOI: 10.3310/hta23550 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 55
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Koffman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
67
Adverse or unforeseen events
Throughout the trial, we were mindful to identify and record any adverse and unforeseen events associated
with the trial or associated with the delivery of the AMBER care bundle. All research nurses were provided
with a distress protocol.
Research-related events
In two instances, individuals were identified as being distressed as a direct result of the trial. In the first
case, a relative was distressed about the wording of the participant information sheet because she was
not adequately aware of her relative’s current clinical condition. Consequently, the research nurse and
the principal investigator of the trial were required to have a conversation to sensitively inform her of the
situation, and the issue was subsequently resolved. We also simplified the language on the information
sheets following this incident. In the second case, a relative of a bereaved participant informed us that
she was distressed about an administrative error in judging the postage of the bereavement survey. The
respondent was required to go to the Post Office sorting office to retrieve the letter and pay the cost of
the inadequate postage. As a result, conversations took place between the chief investigator and principal
investigators at each of the trial sites to remind them, and their research staff, to check the cost of posting
bereavement surveys at each trial site. Subsequently, no errors were reported.
Notably, because the inclusion criteria focused on identifying potential participants who had a clinically
uncertain recovery with a risk of dying during their episode of care despite treatment, we made a joint decision
with our TS DMEC that ‘death of participants’ should not be recorded as an ‘adverse event’ during the course
of the trial. Instead, death in this population is a possible outcome. We did not prespecify events such as
emergency readmissions as potential adverse events of the trial or intervention. Emergency attendances are
increasing at the end of life,85 hence emergency attendances were also expected in our sample. Nevertheless,
we extracted information regarding non-elective readmissions within 30 days discharge for patients who were
recruited and discharged from the trial ward. Six participants (16.7%) in the control arm (site Con1, n = 3;
site Con2, n = 3) and five participants (17.2%) in the intervention arm (site Int1, n = 3; site Int2, n = 2) were
readmitted within 30 days of their discharge.
Intervention-related events
We also observed instances in which the AMBER care bundle might have been causing additional distress
to patients, relatives and HCPs. Although no one in our sample explicitly stated that they had been
distressed as a direct result of being involved in the intervention, our data raised a number of issues.
For patients and relatives, the main concerns involved the use of confusing terminology and communication.
Instances when patients and relatives were confused about the term ‘AMBER’ and what it means in the
context of their care were identified. During the implementation of the AMBER care bundle, HCPs were
advised not to mention the term ‘AMBER’ to patients and families. However, this instruction regarding
not mentioning the AMBER care bundle, and keeping this term within the team as jargon, was not
implemented at the intervention sites. However, even when HCPs did not mention the term ‘AMBER’ during
their interactions with the patients and families, the AMBER care bundle stickers were placed on patient
notes, and the letter ‘A’ positioned next to the patients’ names on the white boards could have been seen
by the patients and/or their relatives, which would evoke further questions. Use of unfamiliar terminology
might not always necessarily lead to distress if it is explained to the patients and families. However,
unanswered questions have the potential to lead to confusion and false assumptions about what the
intervention might entail.
Patients and relatives also mentioned instances of poor communication, for example not being informed
about their relative’s discharge and not being listened to when they volunteered information regarding
their relative’s other health conditions. As instances of poor communication were reported in both arms of
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the trial, it is difficult to ascertain whether or not the AMBER care bundle was directly responsible for these
experiences. The quotations from a junior doctor and a relative of a patient who was supported by the
AMBER care bundle from the same trial site provide examples of poor communication:
We’d keep the family informed, but I think now it’s a bit confusing for the families like ‘Oh what is
this AMBER bundle? Is my relative dying?’. And they just get overwhelmed.
Int2017, female, senior house officer
But I thought that could’ve been handled a lot better. Especially when he [referring to a doctor]
glanced over her and said ‘Well it doesn’t look good, does it?’. And I thought ‘What are you actually
saying then? You’re saying that’s it?’ and he said ‘Anyway, I’ll give you a bit of time.’.
Int2008, carer
For HCPs, our main concern was regarding inadequate communication skills, which could subsequently
affect patients and relatives, and the personal impact of having difficult conversations and managing
patient and relative expectations. The AMBER care bundle encourages HCPs to open up conversations
about clinical uncertainty and the end of life, and includes training at the implementation phase, with
continuous support from the nurse facilitator. However, some team members might have been engaging
in the complex conversations that they were not ready for. Having difficult conversations requires advanced
communication skills, which might not be guaranteed to be acquired by every HCP through the training
provided during the AMBER care bundle implementation. In addition, HCPs, including a consultant, alluded
to distress caused to themselves as a result of not being able to match patients’ and relatives’ expectations,
especially when talking about future care preferences:
It was a patient that I had that discussion with but then I felt that I wouldn’t, I wanted him to make
this important . . . that he aired what his PPD was but uhmm in a way I felt bad because I couldn’t
give him what he wanted. I think with some of patients the PPD is home, but in reality, there’s no way
we’ll be able to support them at home or the palliative care would be able to support them at home
or social services or fast track. So . . . about sort of giving the patients the impression that we can give
them what they want but not them not being able to give them what they want. Disappoint them.
Int1013, male, consultant
Although these were not unexpected instances, they highlight the need for a greater emphasis to be
placed on acquiring communication skills.
Assessing contamination at the control sites
When designing the trial, we were concerned that there might be a transfer of information about the
AMBER care bundle to the ward staff at the control sites as a result of staff moving. A cluster RCT design
was specifically chosen to mitigate this. Despite this, we were not able to systematically measure
contamination of AMBER-related knowledge.
Although site Con1 experienced frequent turnover of medical staff, to the best of our knowledge no HCPs
were familiar with the AMBER care bundle. Moreover, no HCPs were practising similar interventions. At
site Con2, we learned that one of the registrars was well informed about the intervention and had been
applying some of the principles of the intervention in his practice. Furthermore, during the focus group
conducted at site Con2, participants stated that merely thinking about clinical uncertainty had an effect
on their clinical practice. HCPs mentioned that the trial provided them with a platform to broach difficult
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topics such as clinical uncertainty and ACP with the patients and families. The findings from the focus
groups provide important information to understand this situation. For example, a registrar explained:
I mean, I’ve learned a lot from my seniors and especially being involved in the ImproveCare study,
I think it made it much more comfortable for me to go for these discussions. I think when I was
earlier, pretty early in my training days, it was very difficult, when we got asked all these different
questions, probably I didn’t have answers for and they kept asking why can’t we do this, why can’t
we do that and I didn’t understand but then when you get better understanding of it, if you’re
comfortable in touching these subjects, it just makes it easier. It takes some time, some people take
it easier within few minutes or few presentation and we have some time to say, some people it just
takes a bit longer but the point is if you are confident and you put it in a way that we just understand
it and I think the more you do it, the more comfortable you get. I find it more comfortable to discuss
these though compared to 2 years ago.
Con2019, male, registrar
A consultant from site Con2 stated in the baseline standard care survey that her team found palliative care
not to be appropriate for non-cancer patients. However, at the focus group conducted at the end of the
trial, she stated the following, which alludes to an effect of identifying potential patients for the trial:
Con2021, female, consultant: It helps us I think reflect a bit more on non-cancer patients.
Researcher: What reflections are they? How did that help you?
Con2021, female, consultant: It made the team more aware that this may be a group that we
previously missed in terms of getting them identified and also support for end of life.
It was important to record the number of patients who died during their admission and those who died
within 100 days after discharge to understand if the correct patient population was recruited to the trial
(Table 25). Patients with clinically uncertain recovery are expected to have a condition with limited
reversibility. By this definition, it was expected that most of the patients recruited to the trial would die in
the given time frame. Overall, 60.0% of participants died, either during their hospital admission or within
100 days after discharge. Similar findings were present for the control arm (58.3%) and the intervention
arm (62.1%). Although we were not able to record the survival status of the remaining 26 participants,
the number of patients who died and the number of days between discharge and death for each trial arm
provide some evidence that, from the perspective of ‘being near to end of life’, we were able to identify
the correct patient population.
TABLE 25 Patient participant deaths, by trial arm and total
Characteristics of deceased patients
Trial arm
TotalaControla Intervention
Number of participants recruited 36 29 65
Number of participants who died, n (%) 21 (58.3) 18 (62.1) 39 (60.0)
Died within 100 days after discharge, n (%) 13 (61.9) 10 (55.6) 23 (59.0)
Died during admission, n (%) 8 (38.1) 8 (44.4) 16 (41.0)
Duration between discharge and death (days)
Mean (95% CI) 19.2 (2.3 to 36.0) 26.7 (12.0 to 41.5) 22.6 (12.1 to 33.1)
Median (range) 8.5 (2–85) 25 (2–61) 13.5 (2–85)
a Not normally distributed.
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The bereavement survey
The main purpose of the bereavement survey was to retrospectively examine and compare the experiences
of care for deceased patients who were recruited to the trial from the perspectives of their close relatives.
This approach was included as part of the trial design to assess the feasibility of collecting data
retrospectively from NOKs.
In order to identify potential respondents to the survey, research nurses at each trial site checked the death
status of the participants on a regular basis. If the patient participant died during their hospital admission or
within 100 days after discharge from the trial hospital, research nurses sent out a bereavement pack to the
NOK between 10 and 12 weeks after the participant’s death. If there was no response, two subsequent
reminder letters were sent in the following month at fortnightly intervals.
As shown in Table 26, out of 65 participants, 39 participants were eligible for the bereavement survey.
We were able to successfully identify NOKs and send out surveys for 36 (92.3%) participants. In total,
25 (69.4%) NOKs sent a response to the research team, with 15 of the NOKs completing the survey.
Out of 10 relatives who declined to participate, six did not provide a reason, one mentioned ‘not having
capacity/time to complete the survey due to other responsibilities related to their relative’s death’ as
their reason for declining to complete the bereavement survey and two mentioned ‘completing multiple
components of the study already’ as their reason for declining. We did not know what proportion of
our participants would be eligible for the bereavement survey. Although the high response rate and the
completeness of the data are indicative of a feasible data collection method, consideration must be given
to the potential number of patients who would be eligible.
It became evident that the bereavement survey was not a practical or effective way of collecting
meaningful information about care. Identifying participants who died outside the hospital was challenging
due to problems in the accuracy of electronic records. Furthermore, this required a great deal of additional
research nurse time to prepare.
A total of 36 NOKs were identified and 30 received an initial pack and two reminder packs. Of these 30,
only six NOKs provided a response prior to receiving a reminder pack.
Based on the previous comparative study of AMBER conducted by Bristowe et al.48 that also made use
of this bereavement survey, we chose to focus on questions that were related to communication around
clinical uncertainty and those questions about care that might be affected by the AMBER care bundle
(see Appendix 13). Owing to the inadequate number of responses to the survey questionnaire, a fair
comparison between the two arms is not viable.
TABLE 26 Bereavement survey eligibility and response rate
Eligibility/response
Trial arm, n (%)
Total, n (%)Control Intervention
Eligible for bereavement survey (n) 21 18 39
No NOK 2 (9.5) 1 (5.6) 3 (7.7)
Mailed to 19 (90.5) 17 (94.4) 36 (92.3)
Returned – completed 7 (36.8) 8 (47.1) 15 (41.7)
Returned – declined 4 (21.1) 6 (35.3) 10 (27.8)
No response 8 (42.1) 3 (17.6) 11 (30.1)
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Chapter 4 Discussion and conclusions
In this chapter, we discuss our findings in relation to the overall aim and objectives of the feasibility trial,the trial limitations and the implications for future research in this area of health care.
Further refinements or adaptations of the AMBER care bundle
Following the MRC’s guidance50,52 and the MORECare statement,51 we identified the refinements and
adaptations required for future implementation and sustainability of the intervention in different settings.
Eligibility criteria
Our qualitative findings from the focus groups and non-participant observations of MDT meetings suggest
that the AMBER care bundle eligibility criteria require further refinement. This is particularly related to the
criterion ‘risk of dying during their current episode of care’. Although the eligibility criteria prompted the
HCPs to prioritise a group of patients who previously received less attention, this criterion restricted their
ability to identify a wider group of patients who might have potentially benefited from the intervention.
In addition, our observations of HCPs’ decision-making process around which patients should be supported
by the AMBER care bundle showed that, in many instances, their focus was on patients’ clinical uncertainty,
responsiveness to medication, age, multimorbidities and frailty. The ‘risk of dying’ criterion was frequently
not considered when making these decisions.
Furthermore, HCPs often felt uncomfortable with the concept of prognostication and attributing ‘risk’ at the
identification stage, despite appreciating that in many instances the identified patients were likely to die. This
is also evidenced by the deaths of 60% of participants who were recruited in the trial using the AMBER care
bundle eligibility criteria. Previous studies have shown that when HCPs are asked to predict life expectancy,
their predictions are frequently inaccurate.86,87 HCPs’ hesitation around prognostication of death observed in
our trial is in line with current evidence. The manner in which ‘risk’ is interpreted can often vary among
HCPs. The Neuberger review into the use of The Liverpool Care Pathway for the Dying Patient33 therefore
recommended that ‘evidence-based education and competency-based training should be promoted to
improve prognostic skills’ (contains information licensed uncle the Open Government License v3.0). However,
there is currently no clear guidance on how prognostication of death can be better identified by HCPs.87
Based on the evidence from this trial, to ensure fidelity in the implementation of the AMBER care bundle
in different contexts, the eligibility criteria should be simplified to focus solely on the ‘clinical uncertainty’
of the patient and their clinical needs. Criteria that do not require the need for prognostication would
enable HCPs to quickly and more efficiently identify patients who would benefit from the intervention.
Daily reviews and follow-up
Based on qualitative findings and clinical notes review of participants who were supported by the AMBER
care bundle, we identified inconsistencies in compliance with reviewing ‘the AMBER care bundle status’ of
patients and the daily follow-up. HCPs focused their attention on two aspects: (1) reviewing the clinically
uncertain recovery status daily for some patients is unnecessary and (2) discussing issues related to clinical
uncertainty with the patients and families had the potential to cause additional distress. In our trial, daily
review was evidenced in the notes for only 48% of the participants, whereas the other four components
of the intervention showed compliance at around 80%.
Our findings from interviews with patients and relatives identified that, although appreciating the workload
and time pressures of HCPs, they greatly valued brief daily updates about the current clinical situation from all
ward staff, not only doctors. The patient- and proxy-reported outcomes highlighted the high levels of anxiety
experienced by family and friends in both trial arms [IPOS patient/family anxiety and communication subscale
at baseline: control arm mean 3.3 (95% CI 3.0 to 3.7), intervention arm mean 3.1 (95% CI 2.7 to 3.5)] during
DOI: 10.3310/hta23550 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 55
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Koffman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
73
the patients’ hospital stay. This finding further supports the need for more attention and time to be devoted
to communicating and sharing information with relatives.
We suggest that the frequency of reviewing changes in patients’ clinical uncertainty within the clinical
team should be adapted locally. Regardless of patients’ ‘AMBER care bundle status’, daily brief updates are
often valued by the patients and families, and should be prioritised by the whole MDT.
Enhancing competences and confidence in advanced communication skills
Issues around communication were identified from all stakeholders’ perspectives. Findings from the HCP
focus groups highlighted discrepancies in the communication skills and confidence of different professional
groups. Although a number of doctors stated that they already possessed advanced communication skills,
there was a strong sentiment that proficiency in this area was unequally distributed among the ward
staff, with implications for patient care. This was especially true for nurses, who, despite having received
training around having difficult conversations, when conveying important information to patients and their
relatives from the nurse facilitator, still felt unprepared.
Findings from patient and relative interviews also reiterated the range in HCPs’ communication skills.
Patients and relatives often mentioned that the main source of information regarding patients’ conditions
and progress was provided by doctors. When clinical updates were sought from nurses, they were often
unable to provide answers, and patients and relatives were signposted to a doctor. Communication with
patients and relatives by nursing staff across both control sites and intervention sites was similar, regardless
of the communication training received as part of the AMBER care bundle training. Considering that nursing
staff are often more present on wards where there are potentially more opportunities to communicate with
patients and their families, the lack of confidence in brokering uncertainties around recovery or treatments
should be addressed with adequate support and training.
In future, communication skills training that complements supporting patients with the AMBER care bundle
must be broadened to serve different levels of proficiency and confidence across all groups of HCPs. Moreover,
evidence from other studies88,89 highlights the need to continue to provide this training at future intervals to
build on and consolidate the knowledge and skills HCPs already possess.
Active ingredients of the AMBER care bundle to be maintained in a full trial
Although we were not able to measure the direct effect of the specific components of the AMBER care
bundle statistically, through our qualitative data collection methods we nevertheless attempted to identify
the ‘active ingredients’ of the bundle that should remain in place. The following were identified:
l Criteria to identify patients. Asking if the patient’s ‘recovery is clinically uncertain’ compelled HCPs to
think carefully about the patient’s status, which previously would have received less attention in both
trial arms. This initiated a process of discussion and engagement with the patient and their family.
l Daily review and follow-up with patients and their families. Continuous engagement with the patients
and families was critical. Checking the clinical uncertainty/AMBER care bundle status of the patient should
be open to local interpretation. Discussing patients’ needs and plans became routinised into the daily
clinical practice on the intervention wards, and was considered to be a central feature of the intervention.
l Simple documentation. The simple documentation associated with the AMBER care bundle was quick to
complete and valued by all HCPs. This provided an assured system of conveying important information to
all ward staff, particularly those who worked out of hours and at the weekend.
l The role of the nurse facilitator. The nurse facilitator was pivotal to successful delivery of the intervention,
not only in introducing ward staff to the concept of clinical uncertainty and how to respond to it, but
also in providing valuable clinical supervision for staff who were now engaging in a style of care that
came with emotive consequences. Continuous training and support provided by a dedicated AMBER
care bundle facilitator is required for sustainability of the intervention.
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Acceptability of the AMBER care bundle
We identified that the AMBER care bundle was broadly acceptable to patients, their families and the HCPs
who delivered it. However, there are still some concerns that might have an impact on the intervention’s
acceptability. These include potentially negative consequences for patients and relatives from poor
communication and delivery of information, and HCPs’ reluctance to take responsibility for sustaining the
AMBER care bundle on their ward.
Focusing on the holistic needs of patients and their families
The HCPs welcomed the intervention as a means of not only focusing on patients’ physical symptoms but
also placing greater emphasis on engaging in early and important discussions with them and their families
about more-holistic concerns and preferences.
Transmission of information
Some HCPs stated that although conversations with patients and their families had previously taken place
in a manner commensurate with the AMBER care bundle, the detail of these conversations had not always
been adequately recorded. HCPs therefore widely endorsed the documentation associated with the AMBER
care bundle, which provided them with a system of conveying important information to all ward staff.
Wider involvement in contributing to patient-centred decisions
The AMBER care bundle promoted wider involvement of HCPs in important decisions about the care of
patients and their families. Although this suggests a greater democratisation of involvement, the final
decisions about which patients were deemed to fulfil the AMBER care bundle eligibility criteria rested with
clinicians. Nonetheless, our findings indicate that teamworking in decision-making aligned with the
intended benefits of the AMBER care bundle.
Sustainability of the AMBER care bundle in the absence of a nurse facilitator
Based on feedback received from HCPs, wards were often short-staffed. The departure of the nurse
facilitator and absence of a ward champion to support HCPs in delivering the intervention raised concerns
that some of the intervention components and the identification of potential patients might not be
sustained. HCPs at intervention sites were reluctant to take on this responsibility, which raised questions
around the acceptability and value of the intervention, particularly in the longer term.
Inclusion criteria
The HCPs found the inclusion criteria broadly acceptable, but had differing interpretations of ‘risk’. There
were concerns around the wider utility of the intervention for their patient population on the ward, which
was limited by the ‘risk of dying’ criterion.
Communication and information
Patients and relatives found discussions around clinically uncertain recovery acceptable, and when these
conversations did not take place, they mentioned that they would have welcomed HCPs to communicate
with them. HCPs, specifically doctors, found it acceptable to have difficult conversations, which is a core
component of the intervention. However, HCPs should be mindful about the information recorded on the
patients’ notes and should be aware of the feasible options when discussing preferences for care.
Compliance with and barriers to the delivery of the AMBER care bundle
Regarding the completion of core components of the AMBER care bundle, the review of the clinical
records of participants identified that, with the exception of the daily review, components associated
with the intervention were completed. However, there were some doubts about the completion of
these components within the required time frame (12 hours).
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Completing initial conversations and follow-ups with the patients, or their family if they lacked capacity,
was generally delayed owing to the unavailability of relatives when the clinical team taking care of the
patient was on the ward.
Inadequate communication skills and confidence in communication led to issues in compliance across
components. Owing to inconsistency in the skills of ward staff, delivery of difficult conversations and
subsequently care and treatment planning were reliant on specific HCPs, and therefore were sometimes
delayed.
Implementation of the intervention was standardised and delivered by the same nurse facilitator in both
intervention sites, and the embeddedness of the intervention was assessed against predetermined criteria
to ensure high fidelity. HCPs complied with the components of the intervention for the duration of the
trial. However, it is important to state that the fidelity in which the AMBER care bundle is delivered
and recorded can only be viewed as a ‘process measure’ in contributing towards positive patient- and
family-centred outcomes.
Feasibility of conducting trial procedures
Overall, although we identified that the trial procedures were technically possible, we provide evidence
that scaling up to a future trial of the AMBER care bundle compared with standard care would not be
practical. Alternative study designs would need to be feasibility tested to ensure that they provide robust
evidence to inform a future evaluation of the AMBER care bundle. Without considerable changes and
retesting, ‘de-risking’ of a definitive trial of the AMBER care bundle could be not be ensured.
Feasibility of recruitment
We were successful in recruiting 65 participants, many of whom were elderly with multiple morbidities.
Prior to the trial, we hypothesised that patients with clinical uncertainty would die either during their
current hospital admission or within a limited time frame (100 days); this was informed by previous quality
improvement work carried out by the AMBER care bundle developers. Of 65 recruited participants, 60%
did indeed die (n = 39). Of those who died, 41% died during their hospital stay and the remainder died
within 100 days of hospital discharge. We are aware that some participants died more than 100 days after
hospital discharge, but considering this was not within the scope of this current trial.
Of 220 eligible participants, only 19 (8.6%) declined to participate in the trial; this finding supports the
ability of the trial to recruit and the willingness of patients to be involved. Furthermore, these findings
provide additional evidence that it is possible to recruit acutely unwell patients (our intended target
population) via the screening and recruitment processes developed in this trial. Although we were able to
recruit, the yield of recruitment from screened numbers was low.
This feasibility trial provides valuable insights regarding adjustments that would be required to improve
recruitment of similar patient populations in similar future trials. First, having a recruitment period of
3 months, with an intended target of seven recruits per month, was not possible. To improve this, the
eligibility criteria for the identification of potential patient participants should be reconsidered. If the
AMBER care bundle criteria are going to serve as inclusion criteria for a future study, they warrant a
discussion with the AMBER care bundle developers. Simplification would be needed, and including age
and multimorbidities among other factors in the inclusion criteria would potentially be helpful. The current
eligibility criteria are variably understood, and in some instances there is resistance to enact them due to
lack of confidence and skills. Second, we would suggest increasing the recruitment period, particularly the
time taken to familiarise research staff with the eligibility criteria.
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Feasibility of data collection
All participants (n = 65) consented into the trial completed baseline measures. The attrition rate for the trial
was high, a finding also evident in other trials of this nature. At time point 1, 29 participants were lost to
follow-up; of these, 16 (55.2%) were discharged. At time point 2, 24 participants were lost to follow-up;
of these, 8 (33.3%) were lost because of discharge from the hospital. Owing to the number of participants
discharged throughout the duration of the trial, data collection at time point 2 was not feasible. Interestingly,
the median time from ward admission to baseline data collection for participants in the control and
intervention arms was 6 (interquartile range 11) and 10 (interquartile range 11) days, respectively. Based on
our findings, capturing potential participants at an earlier point of their hospital admission is advisable for
studies of this nature. This may minimise the number lost to follow-up because of discharge at time point 2,
and would ensure that data collection could take place over a longer time frame.
Overall, levels of missing data for patient participant self-reported outcomes and those provided by proxies
were very low for both of the primary outcome measures we used. For the IPOS patient/family anxiety and
communication subscale, 6.2% of data were missing at baseline, 5.6% were missing at time point 1 and
0% were missing at time point 2. For howRwe, 0% of data were missing at baseline, 8.3% were missing
at time point 1 and 0% were missing at time point 2. We are mindful that data completeness for the
howRwe should be understood within the limitation that it is a patient-completed measure and therefore
could not be used for those who lacked adequate mental capacity. Nevertheless, the findings indicate that
data collection among an older population with multimorbidities was possible through face-to-face
research nurse interviews. We therefore suggest that those undertaking future studies that attempt to
conduct research among this patient population, and importantly of the interventions designed to benefit
them, may wish to consider embedding the measurement of patient-centred concern, as recorded by the
IPOS. This could be incorporated into their daily patient care, as demonstrated by the recent Outcome
Assessment and Complexity Collaboration project that was designed to support the implementation of
patient-centred outcome measures in specialist palliative care settings in the UK.90 The use of ‘patient-
centred’ rather than ‘patient-reported’ outcome measures is particularly useful in this type of research in
which often patients have impaired cognition or are too unwell to complete the measures themselves.91
Proxy-completed measures have previously been found to be a fair substitute for patient response for
assessing symptoms and quality of life.92 Alternative approaches to data collection might also be
considered. For example, it may be prudent to make use of population-based, retrospective hospital-based
data to examine and compare patients supported by the AMBER care bundle with controls, adjusted for
propensity matching. Similar approaches have been successfully employed to examine the quality of care
of cancer patients.93 Specifically, domains of care would have to be specified for patients who died during
their hospital stay or within 100 days of discharge and, importantly, for those who survived. Domains of
interest might include informing family members when death was imminent, the use of validated tools to
assess common symptoms (e.g. pain), prescribing drugs for anxiety, the use of bereavement support
(where available), length of hospital stay, preferred and actual place of death, number of hospital
readmissions and admissions to emergency departments.
Within the scope of our feasibility trial, we have refuted the legitimate concerns about engaging with
vulnerable patient populations at the end of life.94–96 This feasibility trial demonstrates that when ethical
and pragmatic decisions are made in relation to trial design and combined with highly sensitised research
nurses and researchers, the voice of patients can be heard.
We have shown that it was possible to collect the data on health and social care service use, informal care
provision and quality of life at baseline and at 10–15 days (time point 2). The level of missing data was
very low. However, in future, health service use at follow-up should be replaced by exploring patients’
clinical records, assuming that all patients stay in wards. The nurse facilitator’s time working on the wards
was recorded in a diary, but the costs associated with this represents only a part of the AMBER care
bundle intervention. This is because it was not possible to accurately quantify the time and work of other
HCPs. In future studies, a predetermined ‘diary’ format should be developed to record all relevant HCPs’
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activities and the time spent delivering the intervention. This could then be combined with HCPs’ salaries,
the nurse facilitator’s salary and the cost of supervision to provide a more accurate estimate of cost during
the trial period.
Data collection using qualitative methods was also possible. We were able to conduct 24 interviews,
representing 36.9% of our participants. Our focus groups were well attended by a wide range of HCPs.
In this trial, it was possible to collect data prospectively using both qualitative research methods and
quantitative research methods. Nonetheless, there were challenges associated with the collection of data,
and possible refinements to methods are required to overcome these. Based on the feedback we received
from participants and the research nurses, the number of sections in the questionnaire booklets and
additional trial components, for example the bereavement survey, was perceived as burdensome. Based
on this finding, it is recommended that the number of data collected directly from patients and relatives
is reduced to the essential components only. Other data sources, such as CSRI and AKPS, should be
extracted from the patients’ medical notes.
We are conscious that the acceptability of data collection extends to understanding how participants perceived
the experience of being involved in the trial. Their positive motivations, including notions of altruism, build on
a small but growing evidence base that studies of this type are possible and indeed permissible.97,98
Limitations and key learning points from our trial
This feasibility trial has identified important study limitations to the generalisability and validity of findings.
The limitations, their implications and how they may be resolved in similar future studies are discussed
in this section.
Sample size
We aimed to recruit 80–90 participants throughout the trial. However, we were only able to recruit
65 participants. This limited our ability to identify differences in the candidate primary outcome measures,
hence limiting the assessment of the preliminary effectiveness of the intervention. In addition, the small
number of clusters included in the trial meant that we were not able to calculate the intracluster correlation
coefficient required for a future trial. In future, we would extend the number of clusters included in the trial
and implement learning from the screening and recruitment phase.
Inclusion criteria
Using inclusion criteria based on the eligibility criteria for the AMBER care bundle required subjective clinical
judgement. This greatly limited the HCPs’ ability to reliably identify and then recruit patients. Consequently,
we simplified the inclusion criteria at the control sites. Although we were not able to capture the effect of
this change within the time frame of the feasibility trial, any future study examining this clinical issue would
be required to adopt simplified inclusion criteria in order to improve the reliability of the identification of
potential participants. Alternative recruitment strategies might also include recruiting and consenting all the
patients within the clusters. Patients who fulfilled the simplified inclusion criteria in relation to their situation
of clinical uncertainty could then be retrospectively identified from their clinical notes, an approach
previously used in our comparative study of the AMBER care bundle.48 However, the quality and level of
detail of information contained within patients’ clinical notes can be highly variable.
Participant information sheets
The participant information sheets, although developed in close collaboration with our PPI members,
require further improvement, particularly when attempting to engage frail older people. There were strong
views from the research nurses that the documentation developed was overly lengthy, too detailed and
too complex for our intended target patient population. Consequently, a number of potential participants
were discouraged from engaging in the trial, preventing them from sharing their experiences. Little
guidance exists in this research area in developing trial information documentation that is acceptable
in both level of detail and length to both potential participants and research ethics committees.99
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Future studies working in this area of health care should be permitted to evaluate to what extent briefer
participant information sheets convey adequate information about the trial and the potential benefits and
risks to potential participants and the influence of this in relation to trial uptake. This could be compared
with the current standard typically required by the HRA and research ethics committees.
Consent processes
Closely related to the above issue is the perceived burdensome manner in which advanced consent was
obtained from patients, many of whom were frail, elderly and fatigued. According to the Department of
Health and Social Care, informed consent can be written, oral or given ‘by implication’.100 Therefore, it has
been suggested that written consent is neither sufficient nor necessary for valid consent to be present.101
Based on the previous section, we propose that a future trial incorporates a more pragmatic process of
obtaining consent in which the patient participant explicitly agrees to what is proposed by the researcher,
and the researcher then notes this. Again, this approach should be compared with approaches currently
used to examine the relative acceptability of interventions.
Loss to follow-up
In our trial, the main reason for loss to follow-up was discharge from the trial ward. This limited our ability
to utilise the data collection at the follow-up points. This finding was evident in both arms of the trial.
As our data collection was limited to the time frame of patients located in the trial ward, we were not able
to carry on collecting data from the participants. In response to this limitation, any future study examining
this area of health care with a similar patient population should consider designing a study that either
aims to recruit patients at an earlier point in their hospital admission or allows follow-up after discharge.
A potentially more appropriate commencement point for recruitment within the hospitals could be acute
medical units. Instances of clinical uncertainty and decisions regarding patients’ further treatment and
care within the hospitals often take place in the acute medical units. This would extend the potential of
collecting data at time point 2 for a larger number of participants who would otherwise have been
discharged at this point.
Selection of trial wards
Guided by the AMBER care bundle development team, we made use of the ‘heat map’ approach to
identify wards with the largest numbers of patient deaths. Consequently, we did not identify wards with
similar specialties across the trial arms. This resulted in a case mix of patients who were quite different.
The effect of this was most pronounced with the inclusion of care of the elderly wards that skewed
the age balance between the trial arms. The mean age of the participants in the intervention arm was
inevitably higher than that in the control arm. Future studies should not base the selection of trial wards
solely on the number of deaths per ward, but also on other factors, importantly including ward specialty,
the potential active engagement of ward staff and the presence of the principal investigator on the ward.
Selection bias
Although the opportunity to participate in the qualitative components was offered to all participants
(patients or their relatives and HCPs), it is possible that those who chose to participate differed from
those who did not. This may limit the transferability of qualitative findings to different contexts and has
implications for conclusions made about the acceptability of the intervention. We aimed to purposively
sample a range of patients and their relatives and HCPs. However, more time and resources should be
allocated to approaching potential participants who might have opposing views about the trial and
intervention to overcome these biases.
Conclusions
This feasibility trial was difficult to undertake for many logistical and methodological reasons, yet provided
vital evidence to inform the decision about progressing to a full trial. In this trial, the stringent inclusion
criteria for trial participation, which were adapted from the intervention, based on prognostication rather
than clinical need, were not compatible with trial procedures. HCPs, especially at the control sites, reported
that they lacked the confidence and skills to identify, approach and introduce the trial to patients whose
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situations were clinically uncertain. Introduction of the trial, including the language on the participant
information sheets, required an explanation of the potential patient participant’s clinical situation. This
‘gatekeeping’ function prevented many potentially eligible patients from being invited to consider whether
or not they wish to participate in this trial. Although we have shown that the feasibility cluster RCT was
technically possible, in the light of the aforementioned concerns, a full trial of the AMBER care bundle is
not practical. This represents an important trial outcome for a feasibility trial that is specifically designed to
address research questions of this nature.102–104 Alternative study designs that wish to examine interventions
focused on this complex patient group are required. Moreover, they too will need to be tested; examples
include embedding patient-centred outcome measures, for example the IPOS,55,56 into routine clinical
practice, or the analysis of routinely recorded hospital-based data.93 Both have appeal but would need to be
tested to ensure that they address the anticipated benefits of the AMBER care bundle that are relevant to
patients, their families and health-care services.
This feasibility cluster RCT of the AMBER care bundle identified a number of active ingredients that are
required to deliver potential positive HCP and patient- and family-centred outcomes. The trial also identified
a number of areas that require further consideration to benefit a highly complex group of patients with
multimorbidities and whose situations are clinically uncertain. The trial highlighted a number of important
contextual moderators that need to be taken into account when implementing the intervention across
different settings. This demonstrates that early work in identifying and then appraising existing evidence
alongside identifying a theoretical framework for an intervention prior to its use is paramount. In future,
complex interventions of this nature should strictly follow guidance developed by the MRC50,52 and the
MORECare statement.51
This trial has shown that research in this area is, at times, challenging. Any future study that focuses on
this patient group and interventions designed to serve such patients should simplify study procedures.
First, consideration is needed with regard to the type of wards that are being compared across each arm
of the study to improve the homogeneity of patients. Second, the manner in which patients in receipt of
the intervention and comparable patients on control wards are recruited should be reconsidered. Although
labour intensive, recruiting all patients admitted to each arm of the study and then retrospectively
identifying those who fulfilled the specific study criteria may be more acceptable to principal investigators
and research staff, particularly in the control arm of the study. Finally, consent procedures should be
simplified and only data that are vital in addressing the study objectives should be collected directly from
the patients and relatives.
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Appendix 1 The AMBER care bundle tool
Reproduced with permission from Guy’s and St Thomas’ NHS Foundation Trust.
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Appendix 2 Recruitment of patients
The recruitment of patients at risk of reduced capacity
To comply with the Mental Capacity Act 2005 (MCA),105 research ethics approval was obtained to seek
a ‘personal consultee’ or ‘nominated consultee’ agreement for patients with impaired capacity and for
participants who lost capacity following the provision of informed consent.
Process of consent and assent for adults lacking capacity
Capacity was likely to be a major issue in this feasibility trial population; the presence of confusion
might reduce patients’ capacity to give consent. People with cognitive impairment in the last year of life
experience symptoms and care needs comparable to people with cancer,106 but have a high prevalence of
poor symptom management, notably pain management, and often experience aggressive treatment at the
end of life.107 The MCA105 requires that those lacking capacity are only included in research that is likely to
be of direct benefit to those taking part or to benefit the particular population under study. In this trial, ward
patients receiving the AMBER care bundle intervention may benefit directly from improved quality of care.
Another potential direct benefit for those taking part in the feasibility trial was that screening assessments
for delirium on admission to the ward might identify people with delirium at an earlier stage, allowing for
earlier treatment. Excluding those without capacity from this research would not be an ethical principle of
justice, as it would compromise the generalisability of findings by recruitment of an unrepresentative trial
sample and would potentially exclude this vulnerable group from the benefits of research evidence in
improving practice.
All participants were considered to have capacity unless it was established that they did not, and all
practicable steps were taken to enable individuals to decide for themselves if they wished to participate.
For example, with the advice and support of PPI members, the participant information sheet was designed
using accessible language. A potential participant’s level of capacity was discussed with the referring
clinician to identify participants with possible impaired capacity and to anticipate the likely consent
procedure. Capacity was established when meeting the individual using the MCA four-step process:105
1. The individual was able to understand the information about the trial.
2. The individual was able to retain the information (even for a short time).
3. The individual was able to use or weigh up that information.
4. The individual was able to communicate his or her decision (by any means).
Potential participants’ mental capacity was anticipated as ranging from ‘able to give informed consent’ to
‘lacking capacity to give informed consent’ (Figure 6). We have previously developed processes of consent
and assent that are tailored to an individual’s level of capacity that incorporate varying levels of capacity.
We anticipated that some participants might lose capacity during the course of this feasibility trial because
many of them might be close to death. Incorporating different processes of consent and assent is used in
end-of-life care research studies and also among those participants of advanced age.109–111 This feasibility
trial aimed to explore how it would be possible to enable individuals with varying levels of capacity to
decide for themselves if they wished to participate, and to incorporate a process of assent for adults
lacking capacity.
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Consent in the moment for participants with impaired capacity
For adults with impaired capacity but able to ‘understand, retain and weigh-up information in the moment’,
a process of consent in the moment was used with ongoing consent, whereby informed consent to
participate was reaffirmed prior to each data collection point.112 The approach of ‘consent in the moment’
has been developed and used in studies involving adults with dementia and/or cognitive impairment.112,113
If a participant’s capacity declines to a point whereby they are no longer able to give informed consent in
the moment, the researchers follow the procedure for adults lacking capacity detailed in Assent for adults
lacking capacity.
Advanced consent and assent for participants who lose capacity
An advanced consent was incorporated in anticipation that some participants might lose capacity and
may no longer have capacity to indicate their desire to withdraw from the trial. The process of advanced
consent was informed by previous studies with older people111 and in end-of-life care.114 Participants able
to give informed consent were asked to indicate, should they lose capacity in the future, if they would
wish to continue to be involved in the trial, and if they indicated ‘yes’ then they were to nominate a
‘personal consultee’ (e.g. NOK), or if not available a ‘nominated or professional consultee’ (e.g. social
worker). The named consultee was then approached if in the future the participant lost capacity to an
extent that they were no longer able to indicate their desire to withdraw from the trial and to complete
patient-reported outcome measures, instead requiring a proxy informant (e.g. informal or formal carer).
The procedure for assent for adults lacking capacity was followed to ascertain the named consultee’s
opinion on the individual’s continued participation (see the following section).
Non-CTIMP
Assess capacity: MCA
four-step criteria
Has capacity
Approach to take
consent
Impaired capacity:
able to understand,
retain and weigh-up
information in the
moment
Lacks capacity
Seek personal
consultee
Incorporate advanced
consent: participants
are asked to identify a
personal consultee or,
if not available, a
nominated consultee
Consent in the
moment with
ongoing consent
Personal consultee
available
Personal consultee
not available
Ask for advice from
personal consultee
Seek nominated
consultee
Ask for advice from
nominated consultee
Participant loses capacity
(e.g. nearness to death): named
consultee approached for opinion
on continued participation
FIGURE 6 Process of seeking consent. CTIMP, Clinical Trial of an Investigational Medicinal Product. Reproduced
with permission.108
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Assent for adults lacking capacity
When an adult lacks capacity, a ‘personal consultee’ was sought to give an opinion on whether or not,
in his/her knowledge of the potential participant, the participant would have wanted to participate in the
feasibility trial had they had capacity to indicate this, and that participation would not cause them undue
distress.105,111 A personal consultee could be the NOK, immediate carer or attorney with lasting power
of attorney. Identified consultees were given an information leaflet about the trial, a letter detailing why
they had been chosen as a consultee and their responsibilities as a consultee. The consultee documents
were informed by our previous research with older people,111 the MCA105 and MCA guidance,115 and PPI
involvement. If contact could not be made with a personal consultee within 1 week of initial identification,
a ‘nominated consultee’ was contacted.109,110 The ‘nominated consultee’ had a professional relationship
with the potential participant but could not be directly connected to the feasibility trial (i.e. not the
principal investigator).109 The nominated consultee was asked, based on their knowledge of the individual,
to give an opinion on whether or not it was in the individual’s best interest to participate in the feasibility
trial and that they would not be caused undue distress by participating. Participants’ general practitioners
were also informed of their involvement in the trial.
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Appendix 3 Research Ethics Committee approvals
for substantial amendments
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Appendix 4 Primary outcome measures
The Integrated Palliative care Outcome Scale
The IPOS is reproduced with the permission of Irene Higginson, Cicely Saunders Institute and King’s
College London as the Intellectual Property owners of the IPOS.
DOI: 10.3310/hta23550 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 55
© Irene Higginson, Cicely Saunders Institute and King’s College London.
123
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
124
‘HowRwe’ scale
Reproduced with permission from R-Outcomes Ltd (Bristol, UK; https://r-outcomes.com).
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Appendix 5 Patients who were discharged and
died within 100 days, by site and trial arm
TABLE 27 Patients who were discharged and died within 100 days, by site and trial arm
Descriptive variable
Trial arm and site, n (%)
Control Intervention
Con1 (N= 10) Con2 (N= 10) Int1 (N= 10) Int2 (N= 10)
Number of days survived
1–20 3 (30) 4 (40) 3 (30) 3 (30)
21–40 2 (20) 1 (10) 2 (20) 3 (30)
41–60 3 (30) 1 (10) 2 (20) 3 (30)
61–80 1 (10) 3 (30) 1 (10) 0 (0)
81–100 0 (0) 1 (10) 2 (20) 1 (10)
Unknown 1 (10) 0 (0) 0 (0) 0 (0)
Non-elective readmission within 30 days of discharge?
Yes 4 (40) 6 (60) 2 (20) 4 (40)
No 6 (60) 4 (40) 8 (80) 6 (60)
Place of death
Person’s own home 3 (30) 1 (10) 0 (0) 1 (10)
Hospital 2 (20) 6 (60) 1 (10) 2 (20)
Care home 0 (0) 0 (0) 2 (20) 2 (20)
Hospice 2 (20) 0 (0) 1 (10) 0 (0)
Unknown 3 (30) 3 (30) 6 (60) 5 (50)
Other 0 (0) 0 (0) 0 (0) 0 (0)
Place of death matched PPD?
Yes 3 (30) 1 (10) 1 (10) 2 (20)
No 2 (20) 0 (0) 1 (10) 0 (0)
Unknown 5 (50) 9 (90) 8 (80) 8 (80)
Quality of handover information
Poor 2 (20) 4 (40) 2 (20) 1 (10)
Average 4 (40) 2 (20) 1 (10) 6 (60)
Good 2 (20) 0 (0) 6 (60) 1 (10)
Very good 2 (20) 4 (40) 1 (10) 2 (20)
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Appendix 6 Pre- and post-implementation case
note reviews (intervention wards)
TABLE 28 Case note review at site Int1, pre and post implementation
Descriptive variable
Implementation, n (%)
Pre Post
Age group (years)
50–60 0 (0) 0 (0)
61–70 0 (0) 0 (0)
71–80 2 (10) 3 (15)
81–90 11 (55) 8 (40)
≥ 91 7 (35) 9 (45)
Primary diagnosis
Cardiology 4 (20) 2 (10)
Cancer 2 (10) 2 (10)
Acute respiratory 5 (25) 7 (35)
Dementia 2 (10) 2 (10)
Frailty 1 (5) 3 (15)
Stroke 0 (0) 1 (5)
Sepsis 1 (5) 3 (15)
Other 5 (32) 0 (0)
Uncertain recovery documented?
Yes 18 (90) 20 (100)
No 2 (10) 0 (0)
ACP in place?
Yes 7a (35) 20 (100)
No 13 (65) 0 (0)
Escalation plan documented?
Yes 18 (90) 20 (100)
No 2 (10) 0 (0)
DNAR/DNACPR status
Patient for CPR (decision documented) 0 (0) 0 (0)
Patient not to be resuscitated (decision documented) 20 (100) 20 (100)
No documented decision on resuscitation 0 (0) 0 (0)
Medical plan discussed and agreed with nursing staff?
Yes 19 (95) 20 (100)
No 1 (5) 0 (0)
continued
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TABLE 28 Case note review at site Int1, pre and post implementation (continued )
Descriptive variable
Implementation, n (%)
Pre Post
Patient/family discussion?
Yes 19 (95) 20 (100)
No 1 (5) 0 (0)
Daily follow-up?
Yes 19 (95) 20 (100)
No – should have received 1 (5) 0 (0)
No – not needed 0 (0) 0 (0)
Assessment of capacity?
Yes 10 (50) 17 (85)
No – it was not needed 9 (45) 3 (15)
No – it was needed 1 (5) 0 (0)
PPC
Person’s own home 2 (10) 2 (10)
Hospital 2 (10) 7 (35)
Care home 6 (30) 10 (50)
Hospice 1 (5) 0 (0)
Preference not documented 6 (30) 1 (5)
Other (include patients who are undecided) 3 (15) 0 (0)
PPD
Person’s own home 1 (5) 2 (10)
Hospital 2 (10) 4 (20)
Care home 1 (5) 7 (35)
Hospice 2 (10) 1 (5)
Preference not documented 3 (15) 5 (25)
Other (include patients who are undecided) 11 (55) 1 (5)
Patient and family wishes documented
Wishes documented 16 (80) 20 (100)
DNAR decision only 0 (0) 0 (0)
No wishes documented 4 (20) 0 (0)
Patient offered discussion but refused 0 (0) 0 (0)
Length of hospital stay (days)
Mean (SD) 12.6 (9.1) 25.9 (19.4)
Range 1–37 3–79
CPR, cardiopulmonary resuscitation; DNACPR, do not attempt cardiopulmonary resuscitation; DNAR, do not attempt
resuscitation.
a One acute respiratory, one cancer, five other.
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TABLE 29 Case note review at site Int1 for patients who were discharged and died within 100 days (N= 10)
Descriptive variable
Implementation, n (%)
Pre Post
Number of days survived
1–20 3 (30) 2 (20)
21–40 2 (20) 5 (50)
41–60 2 (20) 2 (20)
61–80 1 (10) 0 (0)
81–100 2 (20) 1 (10)
Unknown 0 (0) 0 (0)
Non-elective readmission within 30 days of discharge?
Yes 2 (20) 0 (0)
No 8 (80) 20 (100)
Place of death
Person’s own home 0 (0) 1 (10)
Hospital 1 (10) 0 (0)
Care home 2 (20) 8 (80)
Hospice 1 (10) 0 (0)
Unknown 6 (60) 1 (10)
Other 0 (0) 0 (0)
Place of death matched PPD?
Yes 1 (10) 6 (60)
No 1 (10) 2 (20)
Unknown 8 (80) 2 (20)
Quality of handover information
Poor 2 (20) 0 (0)
Average 1 (10) 1 (10)
Good 6 (60) 2 (20)
Very good 1 (10) 7 (70)
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TABLE 30 Case note review at site Int2, pre and post implementation
Descriptive variable
Implementation, n (%)
Pre (N= 20) Post (N= 18)
Age group (years)
40–60 3 (15) 2 (11)
61–70 6 (30) 4 (22)
71–80 6 (30) 5 (28)
81–90 5 (25) 6 (33)
≥ 91 0 (0) 1 (6)
Primary diagnosis
Cardiology 0 (0) 1 (6)
Cancer 6 (30) 3 (17)
Acute respiratory 2 (10) 8 (44)
Chronic respiratory 10 (50) 1 (6)
Stroke 1 (5) 0 (0)
Dementia 0 (0) 1 (6)
Sepsis 0 (0) 1 (6)
Other 1 (5) 3 (17)
Uncertain recovery documented?
Yes 12 (60) 18 (100)
No 8 (40) 0 (0)
ACP in place?
Yes 2a (10) 18 (100)
No 18 (90) 0 (0)
Escalation plan documented?
Yes 13 (65) 18 (100)
No 7 (35) 0 (0)
DNAR/DNACPR status
Patient for CPR (decision documented) 2 (10) 0 (0)
Patient not to be resuscitated (decision documented) 15 (75) 18 (100)
No documented decision on resuscitation 3 (15) 0 (0)
Medical plan discussed and agreed with nursing staff?
Yes 16 (80) 18 (100)
No 4 (20) 0 (0)
Patient/family discussion?
Yes 13 (65) 18 (100)
No 7 (35) 0 (0)
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TABLE 30 Case note review at site Int2, pre and post implementation (continued )
Descriptive variable
Implementation, n (%)
Pre (N= 20) Post (N= 18)
Daily follow-up?
Yes 12 (60) 18 (100)
No – should have received 8 (40) 0 (0)
No – not needed 0 (0) 0 (0)
Assessment of capacity?
Yes 7 (35) 11 (61)
No – it was not needed 12 (60) 7 (39)
No – it was needed 1 (5) 0 (0)
PPC
Person’s own home 10 (50) 5 (28)
Hospital 3 (15) 9 (50)
Care home 3 (15) 4 (22)
Hospice 1 (5) 0 (0)
Preference not documented 3 (15) 0 (0)
Other (include patients who are undecided) 0 (0) 0 (0)
PPD
Person’s own home 3 (15) 6 (33)
Hospital 0 (0) 5 (28)
Care home 3 (15) 4 (22)
Hospice 0 (0) 0 (0)
Preference not documented 12 (60) 3 (17)
Other (include patients who are undecided) 2 (10) 0 (0)
Patient and family wishes documented
Wishes documented 10 (50) 15 (83)
DNAR decision only 5 (25) 2 (11)
No wishes documented 4 (20) 1 (6)
Patient offered discussion but refused 1 (5) 0 (0)
Length of hospital stay (days)
Mean (SD) 16.7 (18.2) 19.8 (15.1)
Range 2–82 2–52
CPR, cardiopulmonary resuscitation; DNACPR, do not attempt cardiopulmonary resuscitation; DNAR, do not attempt
resuscitation.
a One acute respiratory, one chronic respiratory.
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TABLE 31 Case note review at site Int2 for patients who were discharged and died within 100 days
Descriptive variable
Implementation, n (%)
Pre (N= 10) Post (N= 8)
Number of days survived
1–20 3 (30) 5 (63)
21–40 3 (30) 2 (25)
41–60 3 (30) 0 (0)
61–80 0 (0) 1 (12)
81–100 1 (10) 0 (0)
Unknown 0 (0) 0 (0)
Non-elective readmission within 30 days of discharge?
Yes 4 (40) 2 (25)
No 6 (60) 6 (75)
Place of death
Person’s own home 1 (10) 2 (25)
Hospital 2 (20) 2 (25)
Care home 2 (20) 4 (50)
Hospice 0 (0) 0 (0)
Unknown 5 (50) 0 (0)
Other 0 (0) 0 (0)
Place of death matched PPD?
Yes 2 (20) 6 (75)
No 0 (0) 1 (12.5)
Unknown 8 (80) 1 (12.5)
Quality of handover information
Poor 1 (10) 1 (12.5)
Average 6 (60) 1 (12.5)
Good 1 (10) 2 (25)
Very good 2 (20) 4 (50)
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Appendix 7 Reasons for not participating
in qualitative interviews
TABLE 32 Reasons for not participating in qualitative interviews
Reasons
Trial arm, n (%)
Control Intervention
Number of participants who agreed to be approached by a researcher (N = 35) 20 (57.1) 15 (42.9)
Number of participants approached (N = 29) 16 (80.0) 13 (86.7)
Invalid contact details (N = 4) 2 (10.0) 2 (13.3)
Participant died prior to contact (N = 2) 2 (10.0) 0 (0.0)
Reasons for declining (N = 6)
Agreed but was too unwell on the day of the interview (spouse took part) 1 (16.7) 0 (0.0)
Main carer (will not have time) 1 (16.7) 0 (0.0)
Patient died a few days after the carer expressed interest 3 (49.9) 0 (0.0)
Does not want to relive the experiences 0 (0.0) 1 (16.7)
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Appendix 8 Descriptive analysis of participant
self- or proxy-reported symptoms
TABLE 33 Descriptive analysis of participant self- or proxy-reported symptoms (IPOS)
Item
Trial arm, mean (95% CI)
Control Intervention
Baseline
Pain 1.8 (1.3 to 2.3) (n = 32) 1.5 (1.3 to 1.9) (n = 27)
Shortness of breath 1.2 (0.7 to 1.6) (n = 34) 1.6 (1.2 to 2.0) (n = 28)
Weakness or lack of energy 2.9 (2.6 to 3.2) (n = 34) 3.2 (2.9 to 3.5) (n = 29)
Nausea (feeling like you are going to be sick) 1.0 (0.5 to 1.4) (n = 32) 0.6 (0.2 to 0.9) (n = 27)
Vomiting (being sick) 0.3 (< 0.1 to 0.6) (n = 36) 0.3 (< 0.1 to 0.6) (n = 28)
Poor appetite 2.4 (1.9 to 2.9) (n = 32) 2.4 (1.9 to 3.0) (n = 28)
Constipation 1.4 (0.9 to 1.8) (n = 34) 1.2 (0.6 to 1.8) (n = 23)
Sore or dry mouth 2.2 (1.7 to 2.6) (n = 35) 3.0 (1.6 to 2.4) (n = 27)
Drowsiness 2.0 (1.5 to 2.5) (n = 33) 2.5 (2.1 to 3.0) (n = 29)
Poor mobility 3.4 (3.1 to 3.7) (n = 33) 3.5 (3.2 to 3.8) (n = 28)
3–5 days
Pain 2.0 (1.2 to 2.8) (n = 17) 1.1 (0.6 to 1.7) (n = 14)
Shortness of breath 0.9 (0.3 to 1.5) (n = 17) 1.3 (0.7 to 1.9) (n = 14)
Weakness or lack of energy 2.7 (2.1 to 3.3) (n = 18) 2.8 (2.2 to 3.4) (n = 15)
Nausea (feeling like you are going to be sick) 1.0 (0.4 to 1.6) (n = 16) 0.3 (< 0.1 to 0.6) (n = 14)
Vomiting (being sick) 0.4 (< 0.1 to 0.8) (n = 19) N/A (n = 14)
Poor appetite 2.4 (1.7 to 3.2) (n = 16) 1.9 (1.0 to 2.8) (n = 14)
Constipation 1.6 (0.9 to 2.3) (n = 18) 1.2 (0.3 to 2.0) (n = 11)
Sore or dry mouth 2.1 (1.5 to 2.7) (n = 19) 1.5 (0.7 to 2.3) (n = 14)
Drowsiness 1.7 (1.0 to 2.3) (n = 15) 2.1 (1.3 to 2.8) (n = 16)
Poor mobility 3.2 (2.6 to 3.7) (n = 18) 3.1 (2.6 to 3.6) (n = 16)
10–15 days
Pain 2.0 (0.2 to 3.8) (n = 5) 1.9 (0.4 to 3.3) (n = 7)
Shortness of breath 1.0 (< 0.1 to 2.2) (n = 5) 1.4 (0.3 to 2.6) (n = 7)
Weakness or lack of energy 2.5 (0.9 to 4.1) (n = 4) 3.7 (3.3 to 4.2) (n = 7)
Nausea (feeling like you are going to be sick) 1.8 (0.4 to 3.2) (n = 5) 0.2 (< 0.1 to 0.6) (n = 6)
Vomiting (being sick) 0.2 (< 0.1 to 0.8) (n = 5) N/A (n = 6)
Poor appetite 2.0 (0.7 to 3.3) (n = 4) 2.3 (1.1 to 3.4) (n = 7)
Constipation 1.4 (0.3 to 2.5) (n = 5) 1.8 (0.6 to 3.1) (n = 6)
Sore or dry mouth 1.2 (0.2 to 2.2) (n = 5) 1.4 (0.5 to 2.3) (n = 7)
Drowsiness 0.8 (< 0.1 to 2.2) (n = 5) 2.0 (0.8 to 3.2) (n = 7)
Poor mobility 3.6 (2.9 to 4.3) (n = 5) 3.6 (3.1 to 4.1) (n = 7)
N/A, not applicable.
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Appendix 9 Level of missing data: Integrated
Palliative care Outcome Scale symptoms
TABLE 34 Level of missing data: IPOS symptoms
Item
Data, n (%)
Complete ‘Cannot assess’ ‘Don’t know’ Missing
Baseline (N = 65)
Pain 59 (90.8) 5 (7.7) 0 1 (1.5)
Shortness of breath 62 (95.4) 3 (4.6) 0 0
Weakness or lack of energy 63 (96.9) 1 (1.5) 0 1 (1.5)
Nausea (feeling like you are going to be sick) 59 (90.8) 4 (96.9) 0 2 (3.1)
Vomiting (being sick) 64 (98.5) 0 0 1 (1.5)
Poor appetite 60 (92.3) 5 (7.7) 0 0
Constipation 57 (87.7) 4 (6.2) 1 (1.5) 3 (4.6)
Sore or dry mouth 62 (95.4) 2 (98.5) 0 1 (1.5)
Drowsiness 62 (95.4) 3 (4.6) 0 0
Poor mobility 61 (93.9) 4 (6.2) 0 0
3–5 days (N = 36)
Pain 31 (86.1) 4 (11.1) 0 1 (2.8)
Shortness of breath 31 (86.1) 2 (91.7) 0 3 (8.3)
Weakness or lack of energy 33 (91.7) 2 (5.6) 0 1 (2.8)
Nausea (feeling like you are going to be sick) 30 (83.3) 4 (11.1) 0 2 (5.6)
Vomiting (being sick) 33 (91.7) 1 (2.8) 0 2 (5.6)
Poor appetite 30 (83.3) 5 (13.9) 0 1 (2.8)
Constipation 29 (80.6) 5 (13.9) 0 2 (5.6)
Sore or dry mouth 33 (91.7) 2 (5.6) 0 1 (2.8)
Drowsiness 31 (86.1) 5 (13.9) 0 0
Poor mobility 34 (94.4) 2 (5.6) 0 0
10–15 days (N = 12)
Pain 12 (100.0) 0 0 0
Shortness of breath 12 (100.0) 0 0 0
Weakness or lack of energy 11 (91.7) 0 1 (8.3) 0
Nausea (feeling like you are going to be sick) 11 (91.7) 0 0 1 (8.3)
Vomiting (being sick) 11 (91.7) 0 0 1 (8.3)
Poor appetite 11 (91.7) 1 (8.3) 0 0
Constipation 11 (91.7) 0 0 1 (8.3)
Sore or dry mouth 12 (100.0) 0 0 0
Drowsiness 12 (100.0) 0 0 0
Poor mobility 12 (100.0) 0 0 0
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Appendix 10 Descriptive analysis of participant
self-reported outcomes, by trial arm for all time points
TABLE 35 Descriptive analysis of participant self-reported outcomes, by trial arm for all time points
Data collection time point and outcome measure
Trial arm, mean (95% CI)
Control Intervention
Baseline
IPOS patient/family anxiety and communication subscale 13.1 (11.2 to 15.1) (n = 27) 13.4 (11.5 to 15.3) (n = 22)
howRwe 12.8 (11.4 to 14.2) (n = 17) 13.4 (10.9 to 15.9) (n = 7)
3–5 days
IPOS patient/family anxiety and communication subscale 13.4 (11.1 to 15.6) (n = 13) 14.3 (11.9 to 16.7) (n = 13)
howRwe 13.9 (11.8 to 16.0) (n = 8) 12.3 (10.9 to 13.8) (n = 3)
10–15 days
IPOS patient/family anxiety and communication subscale 12.0 (6.5 to 17.5) (n = 12) 13.9 (8.9 to 18.8) (n = 7)
howRwe 14.0 (9.0 to 19.0) (n = 3) 11.0 (n = 1)
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Appendix 11 Time spent to implement the
AMBER care bundle in the treatment sites
TABLE 36 Time spent to implement the AMBER care bundle in the treatment sites
Health-care professional
Activities (time in hours)
Individual Teama
Central research team
Research nurse (NHS band 7) 100% FTE for 3 months
Senior research associate 10
Site Int1 In situ Ex situ 14.5
Senior nurse (NHS bands 7 or 8) 2 4.7
Nurse (NHS bands 3–6) 7.7 6.4
Health-care assistant 7.3
Occupational therapist 0.3 1.3
Occupational therapist assistant 0.3
Physiotherapist 1 1.3
Physiotherapist assistant 0.7
Ward clerk 1 4.4
Consultant 4.3 3.8
Specialty registrar 4.7 3
Physician associate 0.7 2.3
Site Int2 5.3
Senior nurse (NHS bands 7 or 8) 13.5 7.3
Nurse (NHS bands 3–6) 8.3 18.7
Health-care assistant 0.5
Consultant 4.5 1.8
Specialty registrar 4 5
Foundation doctor 2.5 1.5
Clinical social worker 4.1
Ward staff or clerk 2.5 0.8
FTE, full-time equivalent.
a MDT meetings: 5 minutes per meeting were counted after the initial introduction stage at which 30–60 minutes were
allocated for AMBER. Participants of MDT meetings varied depending on the organisation of the hospital and/or wards
and the availability of HCPs.
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Appendix 12 Health-care and social care
utilisation and informal care provision at the
follow-up interview
TABLE 37 Health-care and social care utilisation and informal care provision at the follow-up interview
Type of care
Trial arm
Control Intervention
N User, n (%)
Utilisation,
mean (SD) N User, n (%)
Utilisation,
mean (SD)
Investigation/diagnostic tests
Blood test 5 5 (100) 16.25 (22.87) 7 7 (100) 8.00 (2.00)
X-ray 5 3 (60) 3.50 (2.12) 7 2 (29) 1.00 (0.00)
Echocardiogram 5 1 (20) 1.00 (N/A) 7 2 (29) 1.00 (0.00)
Electrocardiogram 5 0 (0) N/A (N/A) 7 3 (43) 2.00 (1.00)
Ultrasound 5 3 (60) 1.00 (0.00) 7 2 (29) 1.00 (0.00)
CT/CAT scan 5 3 (60) 1.00 (0.00) 7 3 (43) 1.00 (0.00)
Magnetic resonance image 5 0 (0) N/A (N/A) 7 1 (14) N/A (N/A)
Other 5 4 (80) 3.00 (N/A) 7 3 (43) 1.00 (N/A)
Informal care (hours)
Personal care 5 4 (80) 25.75 (10.90) 7 3 (43) 3.00 (1.41)
Help with medical
procedures
5 4 (80) 13.00 (2.65) 7 3 (43) 2.00 (1.41)
Help inside the home 5 3 (60) 2.00 (1.00) 7 4 (57) 2.50 (1.29)
Help outside the home 5 2 (40) 5.50 (2.12) 7 4 (57) 2.50 (1.00)
Time spent ‘on call’ 5 3 (60) 8.50 (9.19) 7 2 (29) 5.00 (0.00)
Other 5 0 (0) N/A (N/A) 7 2 (29) 2.50 (0.71)
EQ-5D index score 3 3 –0.01 (0.23) 7 7 –0.11 (0.36)
CAT, calibrated automated thrombography; CT, computerised tomography; N/A, not applicable.
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Appendix 13 Bereavement survey findings
TABLE 38 Bereavement survey findings
Survey questions
Trial arm, n (%)
Intervention (N= 8) Control (N= 7)
Awareness of prognosis
Was the patient aware they were going to die because of their illness?
Yes, she/he certainly knew 5 (62.5) 5 (71.4)
Yes, she/he probably knew 3 (37.5) 2 (28.6)
No, she/he probably did not know 0 0
No, she/he definitely did not know 0 0
Not sure if she/he knew or not 0 0
Did any health professional discuss with the patient the fact that she/he was likely to die because of the illness?
Yes 0 2 (28.6)
No 5 (62.5) 4 (57.1)
Don’t know 3 (37.5) 1 (14.3)
N/A 0 0
Not ticked 0 0
Communication and information sharing
Did you receive information about her/his condition that was clear and easy to understand?
Yes, most of the time 5 (62.5) 4 (57.1)
Sometimes 3 (37.5) 2 (28.6)
No, not at all 0 1 (14.3)
Not applicable 0 0
Don’t know 0 0
No answer 0 0
Do you remember receiving information on a day-to-day basis that helped you understand the reason for the care
she/he received?
Yes, most of the time 3 (37.5) 4 (57.1)
Sometimes 5 (62.5) 1 (14.3)
No, not at all 0 2 (28.6)
Not applicable 0 0
Don’t know 0 0
No answer 0 0
continued
DOI: 10.3310/hta23550 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 55
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Koffman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
147
TABLE 38 Bereavement survey findings (continued )
Survey questions
Trial arm, n (%)
Intervention (N= 8) Control (N= 7)
Did you receive consistent information about her/his condition?
Yes, most of the time 4 (50.0) 4 (57.1)
Sometimes 4 (50.0) 2 (28.6)
No, not at all 0 1 (14.3)
Not applicable 0 0
Don’t know 0 0
No answer 0 0
Involvement of palliative care
Did the patient see a palliative care or Macmillan Cancer Support team at that hospital?
Yes 2 (25.0) 6 (85.7)
No, this was not wanted 1 (12.5) 0
No, this was not needed 2 (25.0) 0
No, this was never offered 2 (25.0) 1 (14.3)
No, they offered to visit but never came 0 0
Don’t know 1 (12.5) 0
No, but not specified 0 0
N/A 0 0
Not ticked 0 0
Place of death
Patient preference – place where the patient would have preferred to die
In his/her own home 6 (75.0) 4 (57.1)
In the home of a relative or friend 0 0
In a hospice 0 0
Hospital 1 (12.5) 0
In a nursing home 1 (12.5) 0
Residential home 0 0
Elsewhere 0 0
No preference 0 1 (14.3)
Don’t know 0 2 (28.6)
Own home or hospice 0 0
Own home or home of a relative or friend 0 0
Hospice or nursing home 0 0
Own home or hospital 0 0
No answer 0 0
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TABLE 38 Bereavement survey findings (continued )
Survey questions
Trial arm, n (%)
Intervention (N= 8) Control (N= 7)
Place of death – place where the patient died
Own home 0 1 (14.3)
Home of relative or friend 0 0
Hospice 1 (12.5) 3 (42.9)
Hospital 5 (62.5) 3 (42.9)
Nursing home 2 (25.0) 0
Residential home 0 0
Elsewhere 0 0
Don’t know 0 0
No answer 0 0
N/A, not applicable.
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